

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/44210 A2

(51) International Patent Classification⁷: C07K 14/705

(21) International Application Number: PCT/US01/45336

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/250,587 1 December 2000 (01.12.2000) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; P.O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).

(72) Inventors: **GAUGHAN, Glen**; 30 Mansfield Drive #1503,
Northford, CT 06472 (US). **FEDER, John**; 277 Dutch-
town Zion Road, Belle Mead, NJ 08502 (US). **NELSON,**
Thomas; 12 Azalea Court, Lawrenceville, NJ 08648 (US).
MINTIER, Gabe; 318 Morrison Ave., Hightstown, NJ
08520 (US). **RAMANATHAN, Chandra**; 41 Alison AV-
enue, Wallingford, CT 06492 (US).

(74) Agents: **D'AMICO, Stephen et al.**; Bristol-Myers Squibb
Company, P.O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HUMAN NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING A NOVEL HUMAN ION CHANNEL EXPRESSED IN SPINAL CORD AND BRAIN

(57) Abstract: The present invention relates to novel human nucleic acid molecules encoding novel human cation channels, and proteins and polypeptides encoded by such nucleic acid molecules. More specifically, the nucleic acid molecules of the invention include novel human genes, e.g., hVR1d.1 and hVR1d.2, that encode proteins or polypeptides that are expressed in spinal cord and brain tissues and display sequence homology and structural homology to the vanilloid and TRP (transient receptor potential) families of cation channel proteins. The proteins and polypeptides of the invention directed to this novel human cation channel may be therapeutically valuable targets for drug delivery in the treatment of human diseases that involve calcium, sodium, potassium or other ionic homeostatic dysfunction, such as central nervous system (CNS) disorders, e.g., degenerative neurological disorders such as Alzheimer's disease or Parkinson's disease, or other disorders such as chronic pain, anxiety and depression, stroke, cardiac disorders, e.g., arrhythmia, diabetes, hypercalcemia, hypocalcemia, hypercalciuria, hypocalciuria, or ion disorders associated with immunological disorders, gastro-intestinal (GI) tract disorders or renal or liver disease.

BEST AVAILABLE COPY

NOVEL HUMAN NUCLEIC ACID MOLECULES
AND POLYPEPTIDES ENCODING A NOVEL
HUMAN ION CHANNEL EXPRESSED IN
SPINAL CORD AND BRAIN

This application claims benefit to provisional application U.S. Serial No. 60/250,587, filed December 1, 2000.

1. INTRODUCTION

The present invention relates to the isolation and identification of novel human nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, encoding novel human ion channels. More specifically, the nucleic acid molecules of the invention relate to a novel human gene, termed hVR1d, that encodes proteins or polypeptides that are expressed in spinal cord and brain tissues and display sequence homology and structural homology to the vanilloid and TRP (transient receptor potential) families of cation channel proteins. The proteins and polypeptides of the invention directed to this novel human cation channel may be therapeutically valuable targets for drug delivery in the treatment of human diseases that involve calcium, sodium, potassium or other ionic homeostatic dysfunction, such as central nervous system (CNS) disorders, e.g., degenerative neurological disorders such as Alzheimer's disease or Parkinson's disease, or other disorders such as chronic pain, anxiety and depression, stroke, cardiac disorders, e.g., arrhythmia, diabetes, hypercalcemia, hypocalcemia, hypercalciuria, hypocalciuria, or ion disorders associated with immunological disorders, gastro-intestinal (GI) tract disorders or renal or liver disease.

2. BACKGROUND OF THE INVENTION

Control of the internal ionic environment is an extremely important function of all living cells. Ion exchange with the external medium is regulated by a variety of means, the most important of which are various transporters and ion channels. Ion channels comprise a very large and diverse family of proteins which play an important role in cell homeostasis, hormone and neurotransmitter release, motility, neuronal action potential generation and propagation and other vital intra- and inter-cellular

functions. Thus, these channels are important targets for the development of
5 therapeutic compounds in the treatment of disease. A number of proteins have been
described as forming ion channels, including the vanilloid and TRP protein families.
These proteins have been shown to function as cation channels of varying degrees of
selectivity and with different, and in some cases unknown, mechanisms for channel
gating. For example, the TRP family of ion channels comprises a group of proteins
10 some of which are believed to form store-operated calcium (Ca^{2+}) channels, i.e., ion
channels that operate to allow the influx of extracellular Ca^{2+} into cells when the
intracellular stores of calcium are depleted (Zhu et al., 1996, Cell 85: 661-671). It is
believed that TRP ion channels are expressed, in some form, in most, if not all, animal
tissues (Zhu et al., supra at 661). In addition, another protein, termed trp-like or trpl,
15 has been disclosed (Phillips et al., 1992, Neuron 8: 631-642; Gillo et al., 1996, PNAS
USA 93: 14146-14151) and it has been suggested that there may be a cooperative
interaction between TRP and TRPL proteins, perhaps these proteins contributing
channel subunits to form a multimeric Ca^{2+} channel (Gillo et al., supra).

The capsaicin receptor, also known as VR1 or vanilloid receptor subtype 1,
20 has been isolated from rats and characterized as a Ca^{2+} -permeable non-selective ion
channel that is structurally related to the TRP family of ion channels (Caterina et al.,
1997, Nature 389: 816-824). The rat VR1 cDNA contains an open reading frame of
2,514 nucleotides encoding a 838-amino acid protein. Hydrophilicity studies have
indicated that VR1 contains six transmembrane domains with a short hydrophobic
25 stretch between transmembrane regions 5 and 6 which may represent the ion
permeation path. In addition, VR1 is disclosed as containing three ankyrin repeat
domains at the N-terminal end of the protein (Caterina et al., supra at 820). It has
been noted that VR1 resembles the trp and trpl proteins in topological organization,
the presence of multiple N-terminal ankyrin repeats and in amino acid sequence
30 homology within and adjacent to the sixth transmembrane domain (Caterina et al.,
supra at 820-821). However, outside of these regions of homology, there is actually
very little sequence homology between VR1 and the TRP-related proteins. Moreover,
studies have indicated that VR1 is not a store-operated Ca^{2+} channel as are some of
the TRP proteins and the expression of this protein is restricted to sensory neurons
35 (Caterina et al., supra at 821 and Figure 6 at 820; Mezey, E. et al., 2000, Proc. Natl.
Acad. Sci. USA 97: 3655-3660).

Human VR1 (also known in the art as "hVR1" or "OTRPC1") has been disclosed in PCT Patent Application WO 99/37675 and PCT Patent Application WO 00/29577, which disclose nucleotide and amino acid sequences for human VR1 as well as another subtype, human VR2 (also known in the art as "hVR2", "VANILREP2", "VRRP", "VLR" or "OTRPC2"). In addition, PCT Patent Application WO 99/37765 discloses nucleotide and amino acid sequences for VANILREP2 and polymorphic variants thereof. The VANILREP2 protein sequence set forth in PCT application WO 99/37765 appears to be essentially the same as hVR2 disclosed in PCT application WO 99/37675. See also PCT Application WO 99/46377, which corresponds to EP 953638 A1, PCT application WO 00/22121, and GB patent application 2346882 A, which also disclose the nucleotide and amino acid sequences for hVR2.

Additional members of the vanilloid family of cation channels have also been identified. For example, a homologue of VR1, termed SIC, was cloned from the rat kidney. This protein was identified as a stretch-inactivating channel (SIC), i.e., it is inactivated by membrane stretch, and as being expressed mainly in the kidney and liver. SIC was further described as sharing the same transmembrane and pore alignments with VR1 but having different electrophysiological properties (Suzuki et al., March 1999, J. Biol. Chem. 274 (No. 10): 6330-6335). Recent reports, however, indicate that SIC may be a chimera of VR1 and a newly-identified VR subtype, OTRPC4 (see, e.g., Strotmann et al., October 2000, Nature Cell Biology 2: 695-702 and Liedtke W. et al., 2000, Cell 103: 525-535). Moreover, it has been noted in the art that, despite structural homologies between members of the vanilloid family, respective proteins within the family may possess significant differences, e.g., in conductance or permeability to various ions (Suzuki et al., supra at 6335).

Another cation channel protein that has been identified as sharing a relatively low sequence homology (<30%) with the vanilloid family is ECaC (epithelial calcium channel). This protein was initially cloned from rabbit kidney cells and found to be expressed in the proximal small intestine, the kidney and the placenta of the rabbit. This protein was disclosed as resembling the VR1 and TRP family of receptors in predicted topological organization and the presence of multiple NH₂-terminal ankyrin repeats. In addition, amino acid sequence homologies between ECaC, VR1 and the TRP-related proteins were noted within and adjacent to the sixth transmembrane segment, including the predicted region for the ion permeation path (Hoenderop et al.,

March 1999, J. Biol. Chem. 274 (No. 13): 8375-8378). However, it was also noted
5 that, despite these structural and sequence homologies, there is actually a low
sequence homology between these proteins outside of the sixth transmembrane
segment, "suggesting a distant evolutionary relationship among these channels."
(Hoenderop et al., supra at 8377).

More recently, the human homologue of ECaC, hECaC, has been identified
10 and disclosed as having a <30% sequence homology with other Ca^{2+} channels and as
being highly expressed in kidney, small intestine, and pancreas (see Muller, et al.,
2000, Genomics 67: 48-53).

Yet another Ca^{2+} transport protein, CaT1, has been identified from rat
duodenum, which protein is structurally related to the ECaC, VR1, and TRP ion
15 channels. However, CaT1 is not stimulated by capsaicin or calcium store depletion,
as would be expected with VR1 and the TRP receptors, respectively, thus suggesting
that CaT1 is not a subtype of the VR1 or TRP ion channels (Peng et al., August 1999,
J. Biol. Chem. 274 (No. 32): 22739-22746). More recently, a homologue of CaT1,
termed CaT2, has been identified in the rat (Peng et al., September 2000, J. Biol.
20 Chem. 275 (36): 28186-28194).

Finally, it should be noted that, while the proteins described above have clear
structural and sequence homologies (compare Zhu et al., supra, Fig. 6D at 668,
Caterina et al., supra, Fig. 5b at 819, and Hoenderop et al., Fig. 1B at 8376), they
nevertheless display varying patterns of tissue expression, electrophysiological
25 properties and functions (e.g., selective vs. non-selective), such that it is
acknowledged in the art that these molecules, while distantly related from an
evolutionary standpoint, are a diverse group of proteins with significantly different
and distinct properties and functions (Suzuki et al., supra at 6335; Hoenderop et al.,
supra at 8377; and Caterina et al., supra at 822). For a review of the various members
30 of this complex family of proteins, see Harteneck et al., 2000, Trends Neurosci. 23:
159-166.

3. SUMMARY OF THE INVENTION

The present invention relates to the isolation and identification of novel
35 nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid
molecules, or degenerate variants thereof, that participate in the formation or function
of novel human ion channels. More specifically, the nucleic acid molecules of the

invention are directed to a novel human gene, termed "hVR1d", that encodes proteins
5 or polypeptides involved in the formation or function of a novel human cation
channel. The novel hVR1d proteins of the invention display some sequence
homology and structural homology to the TRP and vanilloid family of cation channels
but represent distinct human channel proteins with distinct distribution patterns, e.g.,
tissue expression. The hVR1d proteins of the invention are highly expressed in spinal
10 cord and brain tissues.

According to one embodiment of the invention, a novel human hVR1d cDNA
and the amino acid sequence of its derived expressed protein is disclosed. This cDNA
has been isolated in two splice forms, hVR1d.1 and hVR1d.2, which differ in the
absence (hVR1d.1) or presence (hVR1d.2) of a short nucleotide segment at the 3' end
15 of the molecule. The encoded proteins corresponding to these hVR1d cDNAs show a
modest level of homology to the human vanilloid receptor family of ion channels.

The compositions of this invention include nucleic acid molecules (also
termed herein as "nucleic acids"), e.g., the hVR1d.1 and hVR1d.2 nucleic acid
molecules, including recombinant DNA molecules, cloned genes or degenerate
20 variants thereof, especially naturally occurring variants, that encode novel hVR1d.1
and hVR1d.2 gene products, and antibodies directed against such gene products or
conserved variants or fragments thereof.

In particular, the compositions of the present invention include nucleic acid
molecules (also referred to herein as "hVR1d nucleic acid molecules or nucleic
25 acids") that comprise the following sequences: (a) the nucleotide sequences of the
human hVR1d.1 and hVR1d.2 splice variants as depicted in FIGS. 1A and 1B,
respectively, as well as allelic variants and homologs thereof; (b) nucleotide
sequences that encode the hVR1d.1 or hVR1d.2 gene product amino acid sequences
as depicted in FIGS. 2A and 2B, respectively; (c) nucleotide sequences that encode
30 portions of the hVR1d.1 or hVR1d.2 gene products corresponding to functional
domains and individual exons; (d) nucleotide sequences comprising the novel
hVR1d.1 or hVR1d.2 nucleic acid sequences disclosed herein, or portions thereof, that
encode mutants of the corresponding gene product in which all or a part of one or
more of the domains is deleted or altered; (e) nucleotide sequences that encode fusion
35 proteins comprising the hVR1d.1 or hVR1d.2 gene product, or one or more of its
domains, fused to a heterologous polypeptide; (f) nucleotide sequences within the
hVR1d.1 or hVR1d.2 gene, as well as chromosome sequences flanking those genes,

that can be utilized as part of the methods of the present invention for the diagnosis or
5 treatment of human disease; and (g) nucleotide sequences that hybridize to the above-
described sequences under highly or moderately stringent conditions. The nucleic
acids of the invention include, but are not limited to, cDNA and genomic DNA
molecules of the hVR1d.1 or hVR1d.2 genes:

The present invention also encompasses gene products of the nucleic acid
10 molecules listed above; i.e., proteins and/or polypeptides that are encoded by the
above-disclosed hVR1d nucleic acid molecules, e.g., the hVR1d.1 and hVR1d.2
nucleic acid molecules, and are expressed in recombinant host systems. In a preferred
embodiment, the hVR1 proteins of the invention include the proteins encoded by the
amino acid sequences of hVR1d.1 and hVR1d.2 as depicted in FIGS. 2A (SEQ ID
15 NO:2) and 2B (SEQ ID NO:4), respectively, or functionally equivalent fragments or
derivatives thereof. These proteins can be produced by recombinant means or by
chemical synthesis methods known in the art.

Antagonists and agonists of the hVR1d genes and/or gene products disclosed
herein are also included in the present invention. Such antagonists and agonists will
20 include, for example, small molecules, large molecules, and antibodies directed
against the hVR1d.1 or hVR1d.2 proteins and polypeptides of the invention.
Antagonists and agonists of the invention also include nucleotide sequences, such as
antisense and ribozyme molecules, and gene or regulatory sequence replacement
constructs, that can be used to inhibit or enhance expression of the disclosed hVR1d
25 nucleic acid molecules.

The present invention further encompasses cloning vectors, including
expression vectors, that contain the nucleic acid molecules of the invention and can be
used to express those nucleic acid molecules in host organisms. The present invention
also relates to host cells engineered to contain and/or express the nucleic acid
30 molecules of the invention. Further, host organisms that have been transformed with
these nucleic acid molecules are also encompassed in the present invention, e.g.,
transgenic animals, particularly transgenic non-human animals, and particularly
transgenic non-human mammals.

The present invention also relates to methods and compositions for the
35 diagnosis of human disease involving cation, e.g., Ca^{2+} , sodium or potassium channel,
dysfunction or lack of other ionic homeostasis including but not limited to CNS
disorders, e.g., degenerative neurological diseases such as Alzheimer's or Parkinson's

disease, or other disorders such as chronic pain, anxiety and depression, cardiac disorders, e.g., arrhythmia, or other disorders such as diabetes, hypercalcemia, hypercalciuria, or ion disorders associated with immunological disorders, GI tract disorders or renal or liver disease. Such methods comprise, for example, measuring expression of the hVR1d gene in a patient sample, or detecting a mutation in the gene in the genome of a mammal, including a human, suspected of exhibiting ion channel dysfunction. The nucleic acid molecules of the invention can also be used as diagnostic hybridization probes or as primers for diagnostic PCR analysis to identify hVR1d gene mutations, allelic variations, or regulatory defects, such as defects in the expression of the gene. Such diagnostic PCR analyses can be used to diagnose individuals with disorders associated with a particular hVR1d gene mutation, allelic variation, or regulatory defect. Such diagnostic PCR analyses can also be used to identify individuals susceptible to ion channel disorders.

Methods and compositions, including pharmaceutical compositions, for the treatment of ion channel disorders are also included in the invention. Such methods and compositions are capable of modulating the level of hVR1d, e.g., hVR1d1.1 or hVR1d.2, gene expression and/or the level of activity of the respective gene product or polypeptide. Such methods include, for example, modulating the expression of the hVR1d gene and/or the activity of the hVR1d gene product for the treatment of a disorder that is mediated by a defect in some other gene.

Such methods also include screening methods for the identification of compounds that modulate the expression of the nucleic acids and/or the activity of the polypeptides of the invention, e.g., assays that measure hVR1d mRNA and/or gene product levels, or assays that measure levels of hVR1d activity, such as the ability of the gene products to allow Ca^{2+} influx into cells.

For example, cellular and non-cellular assays are known that can be used to identify compounds that interact with the hVR1d gene and/or gene product, e.g., modulate the activity of the gene and/or bind to the gene product. Such cell-based assays of the invention utilize cells, cell lines, or engineered cells or cell lines that express the gene product.

In one embodiment, such methods comprise contacting a compound to a cell that expresses a hVR1d gene, measuring the level of gene expression, gene product expression, or gene product activity, and comparing this level to the level of the hVR1d gene expression, gene product expression, or gene product activity produced

by the cell in the absence of the compound, such that if the level obtained in the
5 presence of the compound differs from that obtained in its absence, a compound that
modulates the expression of the hVR1d gene and/or the synthesis or activity of the
gene product has been identified.

In an alternative embodiment, such methods comprise administering a
compound to a host organism, e.g., a transgenic animal that expresses a hVR1d
10 transgene or a mutant hVR1d transgene, and measuring the level of hVR1d gene
expression, gene product expression, or gene product activity. The measured level is
compared to the level of hVR1d gene expression, gene product expression, or gene
product activity in a host that is not exposed to the compound, such that if the level
obtained when the host is exposed to the compound differs from that obtained when
15 the host is not exposed to the compound, a compound that modulates the expression
of the hVR1d gene and/or the synthesis or activity of hVR1d gene products has been
identified.

The compounds identified by these methods include therapeutic compounds
that can be used as pharmaceutical compositions to reduce or eliminate the symptoms
20 of ion channel disorders such as CNS disorders, e.g., degenerative neurological
diseases such as Alzheimer's or Parkinson's disease, or other disorders such as
chronic pain, anxiety and depression, cardiac disorders, e.g., arrhythmia, or other
disorders such as diabetes, hypercalcemia, hypercalciuria, or ion disorders associated
with immunological disorders, GI tract disorders or renal or liver disease.

25 The present invention also relates to an isolated nucleic acid comprising a
nucleic acid sequence that encodes a polypeptide having the amino acid sequence of
FIG. 2A (SEQ ID NO:2) or FIG. 2B (SEQ ID NO:4), or the complement of the
nucleic acid of said sequence(s).

The present invention also relates to an isolated nucleic acid comprising a
30 nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic
acid molecule of FIG 1A (SEQ ID NO:1) or FIG 1B (SEQ ID NO:3) and encoding a
hVR1d polypeptide having an activity of a naturally-occurring hVR1d protein.

The present invention also relates to an isolated nucleic acid comprising the
nucleic acid sequence of FIG. 1A (SEQ ID NO:1).

35 The present invention also relates to an isolated nucleic acid comprising the
nucleic acid sequence of FIG. 1B (SEQ ID NO:3).

The present invention also relates to an isolated nucleic acid of FIG 1A (SEQ
5 ID NO:1) or FIG 1B (SEQ ID NO:3), wherein the nucleic acid is genomic or cDNA.

The present invention also relates to an isolated nucleic acid of FIG 1A (SEQ
ID NO:1) or FIG 1B (SEQ ID NO:3), which is RNA.

The present invention also relates to an isolated nucleic acid of FIG 1A (SEQ
ID NO:1) or FIG 1B (SEQ ID NO:3), further comprising a label.

10 The present invention also relates to an isolated nucleic acid wherein to any
nucleic acid described herein that encodes an hVR1d protein or polypeptide is linked
in frame to a nucleic acid sequence that encodes a heterologous protein or peptide.

The present invention also relates to a nucleic acid comprising a nucleic acid
sequence encoding (a) a deletion mutant of hVR1d.1; (b) a deletion mutant of
15 hVR1d.2; or (c) the complement of the nucleic acid sequences of (a) or (b).

The invention further relates to an isolated nucleic acid molecule of SEQ ID
NO:1, and/or 3, wherein the nucleotide sequence comprises sequential nucleotide
deletions from either the C-terminus or the N-terminus.

The invention further relates to an isolated polypeptide molecule of SEQ ID
20 NO:2, and/or 4, wherein the polypeptide sequence comprises sequential amino acid
deletions from either the C-terminus or the N-terminus.

The invention further relates to a nucleic acid comprising a nucleic acid
sequence encoding (a) an addition mutant of hVR1d.1; (b) an addition mutant of
hVR1d.2; or (c) the complement of the nucleotide sequences of (a) or (b).

25 The invention further relates to a nucleic acid comprising a nucleic acid
sequence encoding (a) a substitution mutant of hVR1d.1; (b) a substitution mutant of
hVR1d.2; or (c) the complement of the nucleic acid sequences of (a) or (b).

The invention further relates to a recombinant vector comprising a nucleic acid
of the present invention.

30 The invention further relates to an expression vector comprising a nucleic acid
of the present invention operatively associated with a regulatory nucleotide sequence
containing transcriptional and translational regulatory information that controls
expression of the nucleic acid in a host cell.

The invention further relates to an expression vector comprising a nucleic acid
35 of the present invention operatively associated with a regulatory nucleotide sequence
containing transcriptional and translational regulatory information that controls
expression of the nucleic acid in a host cell.

The invention further relates to a delivery complex comprising an expression
5 vector described herein and a targeting means.

The invention further relates to a genetically engineered host cell containing a
nucleic acid of the present invention

The invention further relates to an genetically engineered host cell containing a
nucleic acid described herein operatively associated with a regulatory nucleotide
10 sequence containing transcriptional and translational regulatory information that
controls expression of the nucleic acid sequence in a host cell.

The invention further relates to an genetically engineered host cell containing a
nucleic acid described herein operatively associated with a regulatory nucleotide
sequence containing transcriptional and translational regulatory information that
15 controls expression of the nucleic acid sequence in a host cell.

The invention further relates to a method of making an hVR1d polypeptide
comprising the steps of (a) culturing a host cell in an appropriate culture medium to
produce an hVR1d polypeptide; and (b) isolating the hVR1d polypeptide.

The invention further relates to a method of making an hVR1d polypeptide
20 comprising the steps of: (a) culturing a genetically engineered host cell containing a
nucleic acid described herein operatively associated with a regulatory nucleotide
sequence containing transcriptional and translational regulatory information that
controls expression of the nucleic acid sequence in a host cell in an appropriate culture
medium to produce an hVR1d polypeptide; and (b) isolating the hVR1d polypeptide.

25 The invention further relates to a method of making an hVR1d polypeptide,
wherein the hVR1d polypeptide is hVR1d1.1 or hVR1d.2 or a functionally equivalent
derivative thereof.

The invention further relates to a method of antibody preparation which is
specifically reactive with an epitope of an hVR1d polypeptide.

30 The invention further relates to a method of making a transgenic animal
comprising a nucleic acid of the present invention.

The invention further relates to a substantially pure polypeptide encoded by a
nucleic acid of the present invention.

The invention further relates to a substantially pure polypeptide encoded by
35 the nucleic acid sequence provided in the deposited clone.

The invention further relates to a substantially pure human hVR1d polypeptide
as depicted in FIGS. 2A (SEQ ID NO: 2) or 2B (SEQ ID NO: 4).

The invention further relates to a substantially pure polypeptide which is at least 90% identical to the polypeptide as set forth in FIGS. 2A (SEQ ID NO: 2) or 2B (SEQ ID NO: 4).

The invention further relates to a fusion protein comprising a polypeptide of the present invention and a second heterologous polypeptide.

The invention further relates to a pharmaceutical preparation comprising a therapeutically effective amount of the polypeptide of the present invention and a pharmaceutically acceptable carrier.

The invention further relates to a test kit for detecting and/or quantitating a wild type or mutant hVR1d nucleic acid molecule in a sample, comprising the steps of contacting the sample with a nucleic acid of the present invention; and detecting and/or quantitating the label as an indication of the presence or absence and/or amount of a wild type or mutant hVR1d nucleic acid.

The invention further relates to a test kit for detecting and/or quantitating a wild type or mutant hVR1d polypeptide in a sample, comprising the steps of contacting the sample with an antibody of the present invention; and detecting and/or quantitating a polypeptide-antibody complex as an indication of the presence or absence and/or amount of a wild type or mutant hVR1d nucleic acid.

The invention further relates to a method for identifying compounds that modulate hVR1d activity comprising: (a) contacting a test compound to a cell that expresses a hVR1d gene; (b) measuring the level of hVR1d gene expression in the cell; and (c) comparing the level obtained in (b) with the hVR1d gene expression obtained in the absence of the compound; such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound that modulates hVR1d activity is identified.

The invention further relates to a method for identifying compounds that modulate hVR1d activity comprising: (a) contacting a test compound to a cell that contains a hVR1d polypeptide; (b) measuring the level of hVR1d polypeptide or activity in the cell; and (c) comparing the level obtained in (b) with the level of hVR1d polypeptide or activity obtained in the absence of the compound; such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound that modulates hVR1d activity is identified.

The invention further relates to a method for identifying compounds that regulate ion channel-related disorders, comprising: (a) contacting a test

compound with a cell which expresses a nucleic acid of the present invention and (b)
5 determining whether the test compound modulates hVR1d activity.

The invention further relates to a method for identifying compounds that regulate ion channel-related disorders comprising: (a) contacting a test compound with a nucleic acid of the present invention; and (b) determining whether the test compound interacts with the nucleic acid of the present invention.

10 The invention further relates to a method for identifying compounds that regulate ion channel-related disorders, comprising: (a) contacting a test compound with a cell or cell lysate containing a reporter gene operatively associated with a hVR1d regulatory element; and (b) detecting expression of the reporter gene product.

15 The invention further relates to a method for identifying compounds that regulate ion channel-related disorders comprising: (a) contacting a test compound with a cell or cell lysate containing hVR1d transcripts; and (b) detecting the translation of the hVR1d transcript.

The invention further relates to a method for modulating ion channel-related disorders in a subject, comprising administering to the subject a therapeutically
20 effective amount of a hVR1d polypeptide.

The invention further relates to a method for modulating ion channel-related disorders in a subject, wherein the hVR1d polypeptide is hVR1d.1 or hVR1d.2, or a functionally equivalent derivative thereof.

25 The invention further relates to a method for modulating ion channel-related disorders in a subject, wherein the hVR1d polypeptide is hVR1d.1 or hVR1d.2, or a functionally equivalent derivative thereof wherein the subject is a human.

The invention further relates to a method of gene therapy, comprising administering to a subject an effective amount of a delivery complex of the present
30 invention.

The invention further relates to a method for the treatment of ion channel-related disorders, comprising modulating the activity of a hVR1d polypeptide.

The invention further relates to a method for the treatment of ion channel-related disorders, comprising modulating the activity of a hVR1d polypeptide,
35 wherein the hVR1d polypeptide is hVR1d.1 or hVR1d.2, or a functionally equivalent derivative thereof.

The invention further relates to a method for the treatment of ion channel-
5 related disorders, comprising modulating the activity of a hVR1d polypeptide,
wherein the hVR1d polypeptide is hVR1d.1 or hVR1d.2, or a functionally equivalent
derivative thereof, wherein the method comprises administering an effective amount
of a compound that agonizes or antagonizes the activity of the hVR1d polypeptide.

The invention further relates to a method for the treatment of ion channel-
10 related disorders, comprising administering an effective amount of a compound that
decreases expression of a hVR1d gene.

The invention further relates to a method for the treatment of ion channel-
related disorders, comprising administering an effective amount of a compound that
decreases expression of a hVR1d gene in which the compound is an oligonucleotide
15 encoding an antisense or ribozyme molecule that targets hVR1d transcripts and
inhibits translation.

The invention further relates to a method for the treatment of ion channel-
related disorders, comprising administering an effective amount of a compound that
decreases expression of a hVR1d gene in which the compound is an oligonucleotide
20 encoding an antisense or ribozyme molecule that targets hVR1d transcripts and
inhibits translation, in which the compound is an oligonucleotide that forms a triple
helix with the promoter of the hVR1d gene and inhibits transcription.

The invention further relates to a method for the treatment of ion channel-
related disorders, comprising administering an effective amount of a compound that
25 increases expression of a hVR1d gene.

The invention further relates to a pharmaceutical formulation for the treatment
of ion channel-related disorders, comprising a compound that activates or inhibits
hVR1d activity, mixed with a pharmaceutically acceptable carrier.

The invention further relates to a method of identifying a compound that
30 modulates the biological activity of hVR1d, comprising the steps of, (a) combining a
candidate modulator compound with hVR1d having the sequence set forth in one or more
of SEQ ID NO:2 or SEQ ID NO:4; and measuring an effect of the candidate modulator
compound on the activity of hVR1d.

35 The invention further relates to a method of identifying a compound that
modulates the biological activity of an ion channel, comprising the steps of, (a)
combining a candidate modulator compound with a host cell expressing hVR1d having
the sequence as set forth in SEQ ID NO:2 or SEQ ID NO:4; and , (b) measuring an effect

of the candidate modulator compound on the activity of the expressed hVR1d.

5 The invention further relates to a method of identifying a compound that modulates the biological activity of hVR1d, comprising the steps of, (a) combining a candidate modulator compound with a host cell containing a vector described herein, wherein hVR1d is expressed by the cell; and, (b) measuring an effect of the candidate modulator compound on the activity of the expressed hVR1d.

10 The invention further relates to a method of screening for a compound that is capable of modulating the biological activity of hVR1d, comprising the steps of: (a) providing a host cell described herein; (b) determining the biological activity of hVR1d in the absence of a modulator compound; (c) contacting the cell with the modulator
15 compound; and (d) determining the biological activity of hVR1d in the presence of the modulator compound; wherein a difference between the activity of hVR1d in the presence of the modulator compound and in the absence of the modulator compound indicates a modulating effect of the compound.

20 The invention further relates to a compound that modulates the biological activity of human hVR1d as identified by the methods described herein.

4. DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B. Human hVR1d.1 and hVR1d.2 nucleic acid sequences, respectively. The putative start codon is bolded and the stop codon is underlined.

25 FIGS. 2A and 2B. Human hVR1d.1 and hVR1d.2 amino acid sequences, respectively, with the six transmembrane domains in boldface, the ankyrin domains underscored and the pore loop region boxed.

FIG. 3. Alignment of amino acid sequences for hVR1d.2 with the reported vanilloid receptors hVR1, hVR2, OTRPC4, and hECaC (using GCG pileup program).

30 FIG. 4. Tissue expression profile of hVR1d.

FIG. 5. Tissue expression profile of the hVR1d splice variant, hVR1d.

FIG. 6. Tissue expression profile of the hVR1d splice variant, hVR1d.2, in brain subregions.

35

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the isolation and identification of novel nucleic acid molecules, as well as novel proteins and polypeptides, for the formation

or function of novel human ion channels. More specifically, the invention relates to a novel human gene, hVR1d, that includes two different splice variants, hVR1d.1 and hVR1d.2, that encode corresponding hVR1d.1 and hVR1d.2 proteins or biologically active derivatives or fragments thereof, involved in the formation or function of cation channels. All references to hVR1d shall also be construed to apply to hVR1d.1 and hVR1d.2 unless explicitly stated otherwise herein.

The hVR1d nucleic acid molecules of the present invention include isolated naturally-occurring or recombinantly-produced human hVR1d.1 and hVR1d.2 nucleic acid molecules, e.g., DNA molecules, cloned genes or degenerate variants thereof. The compositions of the invention also include isolated, naturally-occurring or recombinantly-produced human hVR1d.1 and hVR1d.2 proteins or polypeptides.

More specifically, disclosed herein are the DNA sequences of two splice variants of the hVR1d gene of the invention. These variants are referred to herein as hVR1d.1 and hVR1d.2 (see FIGS. 1A and 1B). The hVR1d.2 DNA sequence contains an additional 25 base pairs at the 3' end of the molecule as compared to the hVR1d.1 DNA sequence. The corresponding hVR1d.1 and hVR1d.2 proteins are identical in amino acid sequence until amino acid residue 715, at which point hVR1d.1 contains a six amino acid C terminal sequence that differs from the 31 amino acid C terminal sequence of the hVR1d.2 protein (see FIGS. 2A and 2B).

The predicted molecular weight of the hVR1d.1 (Figure 2A) polypeptide was determined to be about 81.3kDa. The predicted molecular weight of the hVR1d.2 (Figure 2B) polypeptide was determined to be about 84.3kDa.

Polynucleotides corresponding to the encoding region of the hVR1d.1 are from nucleotide 1 to nucleotide 2160 of SEQ ID NO:1 (Figure 2A). Polynucleotides corresponding to the encoding region of the hVR1d.2 are from nucleotide 1 to nucleotide 2235 of SEQ ID NO:1 (Figure 2B).

In preferred embodiments, the present invention encompasses a polynucleotide lacking the initiating start codon, in addition to, the resulting encoded polypeptide of hVR1d.1. Specifically, the present invention encompasses the polynucleotide corresponding to nucleotides 4 thru 2160 of SEQ ID NO:1, and the polypeptide corresponding to amino acids 2 thru 720 of SEQ ID NO:2. Also encompassed are recombinant vectors comprising said encoding sequence, and host cells comprising said vector.

In preferred embodiments, the present invention encompasses a polynucleotide
5 lacking the initiating start codon, in addition to, the resulting encoded polypeptide of
hVR1d.2. Specifically, the present invention encompasses the polynucleotide
corresponding to nucleotides 4 thru 2235 of SEQ ID NO:3, and the polypeptide
corresponding to amino acids 2 thru 745 of SEQ ID NO:4. Also encompassed are
10 recombinant vectors comprising said encoding sequence, and host cells comprising
said vector.

The proteins corresponding to the hVR1d cDNAs of FIG. 1 show a modest
level of homology to the human vanilloid receptor family of ion channels, e.g., an
approximately 41-47% identity and 49-57% similarity to the reported VR1, VR2 and
15 OTRPC4 proteins and an approximately 30-33% identity and 41-42% similarity to the
reported EcaC and CaT1 and CaT2 proteins.

The hVR1d DNA sequences and encoded proteins of this invention also differ
from the reported vanilloid family of ion channels in their patterns of tissue
expression. For example, the hVR1d proteins of the invention are highly expressed in
20 the spinal cord and brain tissues, such as the corpus callosum (CC), caudate nucleus
(CN), and amygdala (A) of the brain (see FIG. 4).

The hVR1d proteins of the invention are predicted to contain six
transmembrane domains as well as multiple consensus ankyrin domains (in the case of
hVR1d, three ankyrin domains) in the N-terminal section of the protein, characteristic
25 structural features of the TRP-vanilloid family of channels (see FIGS. 2A and 2B).

Specifically, the hVR1d.1 polypeptide was predicted to comprise six transmembrane
domains (TM1 to TM6) located from about amino acid 395 to about amino acid 415
(TM1; SEQ ID NO:9); from about amino acid 439 to about amino acid 463 (TM2; SEQ
ID NO:10); from about amino acid 479 to about amino acid 499 (TM3; SEQ ID NO:11);
30 from about amino acid 502 to about amino acid 520 (TM4; SEQ ID NO:12); from about
amino acid 545 to about amino acid 564 (TM5; SEQ ID NO:13); and/or from about
amino acid 607 to about amino acid 625 (TM6; SEQ ID NO:14) of SEQ ID NO:2 (Figure
2A). In this context, the term "about" may be construed to mean 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10 amino acids beyond the N-Terminus and/or C-terminus of the above referenced
35 transmembrane domain polypeptides.

In preferred embodiments, the following transmembrane domain polypeptides are
encompassed by the present invention: MFFLSFCFYFFYNITLTLVSY (SEQ ID NO:9),

LLGRMFVLIWAMCISVKEGIAIFLL (SEQ ID NO:10), FVFFIQAVLVILSVFLYLFA Y
5 (SEQ ID NO:11), YLACLVLAMALGWANMLYY (SEQ ID NO:12),
FLFVYIAFLLGFGVALASLI (SEQ ID NO:13), and/or ILFLLLITYVILTFVLLL (SEQ
ID NO:14). Polynucleotides encoding these polypeptides are also provided. The present
invention also encompasses the use of these hVR1d.1 transmembrane domain
polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

10 The present invention also encompasses the polypeptide sequences that intervene
between each of the predicted hVR1d.1 transmembrane domains. Since these regions are
solvent accessible either hVR1d.1 or intracellularly, they are particularly useful for
designing antibodies specific to each region. Such antibodies may be useful as
15 antagonists or agonists of the hVR1d.1 full-length polypeptide and may modulate its
activity.

In preferred embodiments, the following inter-transmembrane domain
polypeptides are encompassed by the present invention:
YRPREEEAIPHPLALTHKMGWLQ (SEQ ID NO:15), RPSDLQSILSDAWFH (SEQ
20 ID NO:16), TRGFQSMGMYSVMIQKVILHDVLKFLFVYIAFLLGFGVAL (SEQ ID
NO:17), and/or EKCPKDNKDCSSYGFSDAVLELFKLTIGLGDLNIQQNSKYP (SEQ
ID NO:18). Polynucleotides encoding these polypeptides are also provided. The present
invention also encompasses the use of these hVR1d.1 intertransmembrane domain
polypeptides as immunogenic and/or antigenic epitopes as described elsewhere herein.

25 Specifically, the hVR1d.2 polypeptide was also predicted to comprise six
transmembrane domains (TM1 to TM6) located from about amino acid 395 to about
amino acid 415 (TM1; SEQ ID NO:9); from about amino acid 439 to about amino acid
463 (TM2; SEQ ID NO:10); from about amino acid 479 to about amino acid 499 (TM3;
30 SEQ ID NO:11); from about amino acid 502 to about amino acid 520 (TM4; SEQ ID
NO:12); from about amino acid 545 to about amino acid 564 (TM5; SEQ ID NO:13);
and/or from about amino acid 607 to about amino acid 625 (TM6; SEQ ID NO:14) of
SEQ ID NO:4 (Figure 2B). In this context, the term "about" may be construed to mean
1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids beyond the N-Terminus and/or C-terminus of
35 the above referenced transmembrane domain polypeptides.

The present invention encompasses the use of the polypeptide corresponding to
5 the ankyrin domain and the pore loop region delineated in Figures 2A and 2B as
immunogenic and/or antigenic epitopes as described elsewhere herein.

Using known methods of protein engineering and recombinant DNA technology,
variants may be generated to improve or alter the characteristics of the polypeptides of
the present invention. For instance, one or more amino acids can be deleted from the N-
10 terminus or C-terminus of the protein without substantial loss of biological function. The
authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF
proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal
amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher
15 activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein
(Dobeli et al., J. Biotechnology 7:199-216 (1988)).

Moreover, ample evidence demonstrates that variants often retain a biological
activity similar to that of the naturally occurring protein. For example, Gayle and
coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational
20 analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500
individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire
length of the molecule. Multiple mutations were examined at every possible amino acid
position. The investigators found that "[m]ost of the molecule could be altered with little
25 effect on either [binding or biological activity]." In fact, only 23 unique amino acid
sequences, out of more than 3,500 nucleotide sequences examined, produced a protein
that significantly differed in activity from wild-type. Furthermore, even if deleting
one or more amino acids from the N-terminus or C-terminus of a polypeptide results in
modification or loss of one or more biological functions, other biological activities may
30 still be retained. For example, the ability of a deletion variant to induce and/or to bind
antibodies which recognize the protein will likely be retained when less than the majority
of the residues of the protein are removed from the N-terminus or C-terminus. Whether
a particular polypeptide lacking N- or C-terminal residues of a protein retains such
immunogenic activities can readily be determined by routine methods described herein
35 and otherwise known in the art.

Alternatively, such N-terminus or C-terminus deletions of a polypeptide of the
present invention may, in fact, result in a significant increase in one or more of the

biological activities of the polypeptide(s). For example, biological activity of many polypeptides are governed by the presence of regulatory domains at either one or both termini. Such regulatory domains effectively inhibit the biological activity of such polypeptides in lieu of an activation event (e.g., binding to a cognate ligand or receptor, phosphorylation, proteolytic processing, etc.). Thus, by eliminating the regulatory domain of a polypeptide, the polypeptide may effectively be rendered biologically active in the absence of an activation event.

In preferred embodiments, the following N-terminal hVR1d.1 deletion polypeptides are encompassed by the present invention: M1-R720, S2-R720, F3-R720, I4-R720, C5-R720, R6-R720, P7-R720, R8-R720, G9-R720, G10-R720, G11-R720, R12-R720, L13-R720, E14-R720, T15-R720, D16-R720, S17-R720, R18-R720, V19-R720, A20-R720, A21-R720, G22-R720, G23-R720, W24-R720, T25-R720, A26-R720, G27-R720, S28-R720, H29-R720, T30-R720, V31-R720, G32-R720, K33-R720, E34-R720, Q35-R720, K36-R720, A37-R720, S38-R720, D39-R720, T40-R720, S41-R720, P42-R720, M43-R720, G44-R720, H45-R720, R46-R720, E47-R720, Q48-R720, G49-R720, A50-R720, S51-R720, I52-R720, G53-R720, D54-R720, G55-R720, G56-R720, E57-R720, T58-R720, A59-R720, G60-R720, E61-R720, G62-R720, G63-R720, E64-R720, R65-R720, P66-R720, S67-R720, V68-R720, R69-R720, S70-R720, G71-R720, S72-R720, G73-R720, D74-R720, V75-R720, E76-R720, Q77-R720, G78-R720, L79-R720, G80-R720, V81-R720, C82-R720, G83-R720, C84-R720, S85-R720, N86-R720, H87-R720, T88-R720, L89-R720, W90-R720, A91-R720, G92-R720, R93-R720, A94-R720, K95-R720, G96-R720, S97-R720, R98-R720, G99-R720, P100-R720, P101-R720, V102-R720, T103-R720, P104-R720, P105-R720, M106-R720, A107-R720, L108-R720, P109-R720, A110-R720, D111-R720, F112-R720, L113-R720, M114-R720, H115-R720, K116-R720, L117-R720, T118-R720, A119-R720, S120-R720, D121-R720, T122-R720, G123-R720, K124-R720, T125-R720, C126-R720, L127-R720, M128-R720, K129-R720, A130-R720, L131-R720, L132-R720, N133-R720, I134-R720, N135-R720, P136-R720, N137-R720, T138-R720, K139-R720, E140-R720, I141-R720, V142-R720, R143-R720, I144-R720, L145-R720, L146-R720, A147-R720, F148-R720, A149-R720, E150-R720, E151-R720, N152-R720, D153-R720, I154-R720, L155-R720, G156-R720, R157-R720, F158-R720, I159-R720, N160-R720, A161-R720, E162-R720, Y163-R720, T164-R720, E165-R720, E166-R720, A167-R720, Y168-R720, E169-R720, G170-R720, Q171-R720, T172-R720, A173-R720,

L174-R720, N175-R720, I176-R720, A177-R720, I178-R720, E179-R720, R180-
5 R720, R181-R720, Q182-R720, G183-R720, D184-R720, I185-R720, A186-R720,
A187-R720, L188-R720, L189-R720, I190-R720, A191-R720, A192-R720, G193-
R720, A194-R720, D195-R720, V196-R720, N197-R720, A198-R720, H199-R720,
A200-R720, K201-R720, G202-R720, A203-R720, F204-R720, F205-R720, N206-
R720, P207-R720, K208-R720, Y209-R720, Q210-R720, H211-R720, E212-R720,
10 G213-R720, F214-R720, Y215-R720, F216-R720, G217-R720, E218-R720, T219-
R720, P220-R720, L221-R720, A222-R720, L223-R720, A224-R720, A225-R720,
C226-R720, T227-R720, N228-R720, Q229-R720, P230-R720, E231-R720, I232-
R720, V233-R720, Q234-R720, L235-R720, L236-R720, M237-R720, E238-R720,
H239-R720, E240-R720, Q241-R720, T242-R720, D243-R720, I244-R720, T245-
15 R720, S246-R720, R247-R720, D248-R720, S249-R720, R250-R720, G251-R720,
N252-R720, N253-R720, I254-R720, L255-R720, H256-R720, A257-R720, L258-
R720, V259-R720, T260-R720, V261-R720, A262-R720, E263-R720, D264-R720,
F265-R720, K266-R720, T267-R720, Q268-R720, N269-R720, D270-R720, F271-
R720, V272-R720, K273-R720, R274-R720, M275-R720, Y276-R720, D277-R720,
20 M278-R720, I279-R720, L280-R720, L281-R720, R282-R720, S283-R720, G284-
R720, N285-R720, W286-R720, E287-R720, L288-R720, E289-R720, T290-R720,
T291-R720, R292-R720, N293-R720, N294-R720, D295-R720, G296-R720, L297-
R720, T298-R720, P299-R720, L300-R720, Q301-R720, L302-R720, A303-R720,
A304-R720, K305-R720, M306-R720, G307-R720, K308-R720, A309-R720, E310-
25 R720, I311-R720, L312-R720, K313-R720, Y314-R720, I315-R720, L316-R720,
S317-R720, R318-R720, E319-R720, I320-R720, K321-R720, E322-R720, K323-
R720, R324-R720, L325-R720, R326-R720, S327-R720, L328-R720, S329-R720,
R330-R720, K331-R720, F332-R720, T333-R720, D334-R720, W335-R720, A336-
R720, Y337-R720, G338-R720, P339-R720, V340-R720, S341-R720, S342-R720,
30 S343-R720, L344-R720, Y345-R720, D346-R720, L347-R720, T348-R720, N349-
R720, V350-R720, D351-R720, T352-R720, T353-R720, T354-R720, D355-R720,
N356-R720, S357-R720, V358-R720, L359-R720, E360-R720, I361-R720, T362-
R720, V363-R720, Y364-R720, N365-R720, T366-R720, N367-R720, I368-R720,
D369-R720, N370-R720, R371-R720, H372-R720, E373-R720, M374-R720, L375-
35 R720, T376-R720, L377-R720, E378-R720, P379-R720, L380-R720, H381-R720,
T382-R720, L383-R720, L384-R720, H385-R720, M386-R720, K387-R720, W388-
R720, K389-R720, K390-R720, F391-R720, A392-R720, K393-R720, H394-R720,

M395-R720, F396-R720, F397-R720, L398-R720, S399-R720, F400-R720, C401-
5 R720, F402-R720, Y403-R720, F404-R720, F405-R720, Y406-R720, N407-R720,
I408-R720, T409-R720, L410-R720, T411-R720, L412-R720, V413-R720, S414-
R720, Y415-R720, Y416-R720, R417-R720, P418-R720, R419-R720, E420-R720,
E421-R720, E422-R720, A423-R720, I424-R720, P425-R720, H426-R720, P427-
R720, L428-R720, A429-R720, L430-R720, T431-R720, H432-R720, K433-R720,
10 M434-R720, G435-R720, W436-R720, L437-R720, Q438-R720, L439-R720, L440-
R720, G441-R720, R442-R720, M443-R720, F444-R720, V445-R720, L446-R720,
I447-R720, W448-R720, A449-R720, M450-R720, C451-R720, I452-R720, S453-
R720, V454-R720, K455-R720, E456-R720, G457-R720, I458-R720, A459-R720,
I460-R720, F461-R720, L462-R720, L463-R720, R464-R720, P465-R720, S466-
15 R720, D467-R720, L468-R720, Q469-R720, S470-R720, I471-R720, L472-R720,
S473-R720, D474-R720, A475-R720, W476-R720, F477-R720, H478-R720, F479-
R720, V480-R720, F481-R720, F482-R720, I483-R720, Q484-R720, A485-R720,
V486-R720, L487-R720, V488-R720, I489-R720, L490-R720, S491-R720, V492-
R720, F493-R720, L494-R720, Y495-R720, L496-R720, F497-R720, A498-R720,
20 Y499-R720, K500-R720, E501-R720, Y502-R720, L503-R720, A504-R720, C505-
R720, L506-R720, V507-R720, L508-R720, A509-R720, M510-R720, A511-R720,
L512-R720, G513-R720, W514-R720, A515-R720, N516-R720, M517-R720, L518-
R720, Y519-R720, Y520-R720, T521-R720, R522-R720, G523-R720, F524-R720,
Q525-R720, S526-R720, M527-R720, G528-R720, M529-R720, Y530-R720, S531-
25 R720, V532-R720, M533-R720, I534-R720, Q535-R720, K536-R720, V537-R720,
I538-R720, L539-R720, H540-R720, D541-R720, V542-R720, L543-R720, K544-
R720, F545-R720, L546-R720, F547-R720, V548-R720, Y549-R720, I550-R720,
A551-R720, F552-R720, L553-R720, L554-R720, G555-R720, F556-R720, G557-
R720, V558-R720, A559-R720, L560-R720, A561-R720, S562-R720, L563-R720,
30 I564-R720, E565-R720, K566-R720, C567-R720, P568-R720, K569-R720, D570-
R720, N571-R720, K572-R720, D573-R720, C574-R720, S575-R720, S576-R720,
Y577-R720, G578-R720, S579-R720, F580-R720, S581-R720, D582-R720, A583-
R720, V584-R720, L585-R720, E586-R720, L587-R720, F588-R720, K589-R720,
L590-R720, T591-R720, I592-R720, G593-R720, L594-R720, G595-R720, D596-
35 R720, L597-R720, N598-R720, I599-R720, Q600-R720, Q601-R720, N602-R720,
S603-R720, K604-R720, Y605-R720, P606-R720, I607-R720, L608-R720, F609-
R720, L610-R720, F611-R720, L612-R720, L613-R720, I614-R720, T615-R720,

Y616-R720, V617-R720, I618-R720, L619-R720, T620-R720, F621-R720, V622-
5 R720, L623-R720, L624-R720, L625-R720, N626-R720, M627-R720, L628-R720,
I629-R720, A630-R720, L631-R720, M632-R720, G633-R720, E634-R720, T635-
R720, V636-R720, E637-R720, N638-R720, V639-R720, S640-R720, K641-R720,
E642-R720, S643-R720, E644-R720, R645-R720, I646-R720, W647-R720, R648-
R720, L649-R720, Q650-R720, R651-R720, A652-R720, R653-R720, T654-R720,
10 I655-R720, L656-R720, E657-R720, F658-R720, E659-R720, K660-R720, M661-
R720, L662-R720, P663-R720, E664-R720, W665-R720, L666-R720, R667-R720,
S668-R720, R669-R720, F670-R720, R671-R720, M672-R720, G673-R720, E674-
R720, L675-R720, C676-R720, K677-R720, V678-R720, A679-R720, E680-R720,
D681-R720, D682-R720, F683-R720, R684-R720, L685-R720, C686-R720, L687-
15 R720, R688-R720, I689-R720, N690-R720, E691-R720, V692-R720, K693-R720,
W694-R720, T695-R720, E696-R720, W697-R720, K698-R720, T699-R720, H700-
R720, V701-R720, S702-R720, F703-R720, L704-R720, N705-R720, E706-R720,
D707-R720, P708-R720, G709-R720, P710-R720, V711-R720, R712-R720, R713-
R720, and/or T714-R720 of SEQ ID NO:2. Polynucleotide sequences encoding these
20 polypeptides are also provided. The present invention also encompasses the use of
these N-terminal hVR1d.1 deletion polypeptides as immunogenic and/or antigenic
epitopes as described elsewhere herein.

In preferred embodiments, the following C-terminal hVR1d.1 deletion
polypeptides are encompassed by the present invention: M1-R720, M1-V719, M1-
25 A718, M1-V717, M1-T716, M1-G715, M1-T714, M1-R713, M1-R712, M1-V711,
M1-P710, M1-G709, M1-P708, M1-D707, M1-E706, M1-N705, M1-L704, M1-F703,
M1-S702, M1-V701, M1-H700, M1-T699, M1-K698, M1-W697, M1-E696, M1-
T695, M1-W694, M1-K693, M1-V692, M1-E691, M1-N690, M1-I689, M1-R688,
M1-L687, M1-C686, M1-L685, M1-R684, M1-F683, M1-D682, M1-D681, M1-
30 E680, M1-A679, M1-V678, M1-K677, M1-C676, M1-L675, M1-E674, M1-G673,
M1-M672, M1-R671, M1-F670, M1-R669, M1-S668, M1-R667, M1-L666, M1-
W665, M1-E664, M1-P663, M1-L662, M1-M661, M1-K660, M1-E659, M1-F658,
M1-E657, M1-L656, M1-I655, M1-T654, M1-R653, M1-A652, M1-R651, M1-Q650,
M1-L649, M1-R648, M1-W647, M1-I646, M1-R645, M1-E644, M1-S643, M1-E642,
35 M1-K641, M1-S640, M1-V639, M1-N638, M1-E637, M1-V636, M1-T635, M1-
E634, M1-G633, M1-M632, M1-L631, M1-A630, M1-I629, M1-L628, M1-M627,
M1-N626, M1-L625, M1-L624, M1-L623, M1-V622, M1-F621, M1-T620, M1-L619,

M1-I618, M1-V617, M1-Y616, M1-T615, M1-I614, M1-L613, M1-L612, M1-F611,
5 M1-L610, M1-F609, M1-L608, M1-I607, M1-P606, M1-Y605, M1-K604, M1-S603,
M1-N602, M1-Q601, M1-Q600, M1-I599, M1-N598, M1-L597, M1-D596, M1-
G595, M1-L594, M1-G593, M1-I592, M1-T591, M1-L590, M1-K589, M1-F588, M1-
L587, M1-E586, M1-L585, M1-V584, M1-A583, M1-D582, M1-S581, M1-F580,
M1-S579, M1-G578, M1-Y577, M1-S576, M1-S575, M1-C574, M1-D573, M1-
10 K572, M1-N571, M1-D570, M1-K569, M1-P568, M1-C567, M1-K566, M1-E565,
M1-I564, M1-L563, M1-S562, M1-A561, M1-L560, M1-A559, M1-V558, M1-G557,
M1-F556, M1-G555, M1-L554, M1-L553, M1-F552, M1-A551, M1-I550, M1-Y549,
M1-V548, M1-F547, M1-L546, M1-F545, M1-K544, M1-L543, M1-V542, M1-
D541, M1-H540, M1-L539, M1-I538, M1-V537, M1-K536, M1-Q535, M1-I534, M1-
15 M533, M1-V532, M1-S531, M1-Y530, M1-M529, M1-G528, M1-M527, M1-S526,
M1-Q525, M1-F524, M1-G523, M1-R522, M1-T521, M1-Y520, M1-Y519, M1-
L518, M1-M517, M1-N516, M1-A515, M1-W514, M1-G513, M1-L512, M1-A511,
M1-M510, M1-A509, M1-L508, M1-V507, M1-L506, M1-C505, M1-A504, M1-
L503, M1-Y502, M1-E501, M1-K500, M1-Y499, M1-A498, M1-F497, M1-L496,
20 M1-Y495, M1-L494, M1-F493, M1-V492, M1-S491, M1-L490, M1-I489, M1-V488,
M1-L487, M1-V486, M1-A485, M1-Q484, M1-I483, M1-F482, M1-F481, M1-V480,
M1-F479, M1-H478, M1-F477, M1-W476, M1-A475, M1-D474, M1-S473, M1-
L472, M1-I471, M1-S470, M1-Q469, M1-L468, M1-D467, M1-S466, M1-P465, M1-
R464, M1-L463, M1-L462, M1-F461, M1-I460, M1-A459, M1-I458, M1-G457, M1-
25 E456, M1-K455, M1-V454, M1-S453, M1-I452, M1-C451, M1-M450, M1-A449,
M1-W448, M1-I447, M1-L446, M1-V445, M1-F444, M1-M443, M1-R442, M1-
G441, M1-L440, M1-L439, M1-Q438, M1-L437, M1-W436, M1-G435, M1-M434,
M1-K433, M1-H432, M1-T431, M1-L430, M1-A429, M1-L428, M1-P427, M1-
H426, M1-P425, M1-I424, M1-A423, M1-E422, M1-E421, M1-E420, M1-R419, M1-
30 P418, M1-R417, M1-Y416, M1-Y415, M1-S414, M1-V413, M1-L412, M1-T411,
M1-L410, M1-T409, M1-I408, M1-N407, M1-Y406, M1-F405, M1-F404, M1-Y403,
M1-F402, M1-C401, M1-F400, M1-S399, M1-L398, M1-F397, M1-F396, M1-M395,
M1-H394, M1-K393, M1-A392, M1-F391, M1-K390, M1-K389, M1-W388, M1-
K387, M1-M386, M1-H385, M1-L384, M1-L383, M1-T382, M1-H381, M1-L380,
35 M1-P379, M1-E378, M1-L377, M1-T376, M1-L375, M1-M374, M1-E373, M1-
H372, M1-R371, M1-N370, M1-D369, M1-I368, M1-N367, M1-T366, M1-N365,
M1-Y364, M1-V363, M1-T362, M1-I361, M1-E360, M1-L359, M1-V358, M1-S357,

M1-N356, M1-D355, M1-T354, M1-T353, M1-T352, M1-D351, M1-V350, M1-
5 N349, M1-T348, M1-L347, M1-D346, M1-Y345, M1-L344, M1-S343, M1-S342,
M1-S341, M1-V340, M1-P339, M1-G338, M1-Y337, M1-A336, M1-W335, M1-
D334, M1-T333, M1-F332, M1-K331, M1-R330, M1-S329, M1-L328, M1-S327,
M1-R326, M1-L325, M1-R324, M1-K323, M1-E322, M1-K321, M1-I320, M1-E319,
M1-R318, M1-S317, M1-L316, M1-I315, M1-Y314, M1-K313, M1-L312, M1-I311,
10 M1-E310, M1-A309, M1-K308, M1-G307, M1-M306, M1-K305, M1-A304, M1-
A303, M1-L302, M1-Q301, M1-L300, M1-P299, M1-T298, M1-L297, M1-G296,
M1-D295, M1-N294, M1-N293, M1-R292, M1-T291, M1-T290, M1-E289, M1-
L288, M1-E287, M1-W286, M1-N285, M1-G284, M1-S283, M1-R282, M1-L281,
M1-L280, M1-I279, M1-M278, M1-D277, M1-Y276, M1-M275, M1-R274, M1-
15 K273, M1-V272, M1-F271, M1-D270, M1-N269, M1-Q268, M1-T267, M1-K266,
M1-F265, M1-D264, M1-E263, M1-A262, M1-V261, M1-T260, M1-V259, M1-
L258, M1-A257, M1-H256, M1-L255, M1-I254, M1-N253, M1-N252, M1-G251,
M1-R250, M1-S249, M1-D248, M1-R247, M1-S246, M1-T245, M1-I244, M1-D243,
M1-T242, M1-Q241, M1-E240, M1-H239, M1-E238, M1-M237, M1-L236, M1-
20 L235, M1-Q234, M1-V233, M1-I232, M1-E231, M1-P230, M1-Q229, M1-N228,
M1-T227, M1-C226, M1-A225, M1-A224, M1-L223, M1-A222, M1-L221, M1-
P220, M1-T219, M1-E218, M1-G217, M1-F216, M1-Y215, M1-F214, M1-G213,
M1-E212, M1-H211, M1-Q210, M1-Y209, M1-K208, M1-P207, M1-N206, M1-
F205, M1-F204, M1-A203, M1-G202, M1-K201, M1-A200, M1-H199, M1-A198,
25 M1-N197, M1-V196, M1-D195, M1-A194, M1-G193, M1-A192, M1-A191, M1-
I190, M1-L189, M1-L188, M1-A187, M1-A186, M1-I185, M1-D184, M1-G183, M1-
Q182, M1-R181, M1-R180, M1-E179, M1-I178, M1-A177, M1-I176, M1-N175, M1-
L174, M1-A173, M1-T172, M1-Q171, M1-G170, M1-E169, M1-Y168, M1-A167,
M1-E166, M1-E165, M1-T164, M1-Y163, M1-E162, M1-A161, M1-N160, M1-I159,
30 M1-F158, M1-R157, M1-G156, M1-L155, M1-I154, M1-D153, M1-N152, M1-E151,
M1-E150, M1-A149, M1-F148, M1-A147, M1-L146, M1-L145, M1-I144, M1-R143,
M1-V142, M1-I141, M1-E140, M1-K139, M1-T138, M1-N137, M1-P136, M1-N135,
M1-I134, M1-N133, M1-L132, M1-L131, M1-A130, M1-K129, M1-M128, M1-
L127, M1-C126, M1-T125, M1-K124, M1-G123, M1-T122, M1-D121, M1-S120,
35 M1-A119, M1-T118, M1-L117, M1-K116, M1-H115, M1-M114, M1-L113, M1-
F112, M1-D111, M1-A110, M1-P109, M1-L108, M1-A107, M1-M106, M1-P105,
M1-P104, M1-T103, M1-V102, M1-P101, M1-P100, M1-G99, M1-R98, M1-S97,

M1-G96, M1-K95, M1-A94, M1-R93, M1-G92, M1-A91, M1-W90, M1-L89, M1-
5 T88, M1-H87, M1-N86, M1-S85, M1-C84, M1-G83, M1-C82, M1-V81, M1-G80,
M1-L79, M1-G78, M1-Q77, M1-E76, M1-V75, M1-D74, M1-G73, M1-S72, M1-
G71, M1-S70, M1-R69, M1-V68, M1-S67, M1-P66, M1-R65, M1-E64, M1-G63,
M1-G62, M1-E61, M1-G60, M1-A59, M1-T58, M1-E57, M1-G56, M1-G55, M1-
10 D54, M1-G53, M1-I52, M1-S51, M1-A50, M1-G49, M1-Q48, M1-E47, M1-R46,
M1-H45, M1-G44, M1-M43, M1-P42, M1-S41, M1-T40, M1-D39, M1-S38, M1-
A37, M1-K36, M1-Q35, M1-E34, M1-K33, M1-G32, M1-V31, M1-T30, M1-H29,
M1-S28, M1-G27, M1-A26, M1-T25, M1-W24, M1-G23, M1-G22, M1-A21, M1-
A20, M1-V19, M1-R18, M1-S17, M1-D16, M1-T15, M1-E14, M1-L13, M1-R12,
M1-G11, M1-G10, M1-G9, M1-R8, and/or M1-P7 of SEQ ID NO:2. Polynucleotide
15 sequences encoding these polypeptides are also provided. The present invention also
encompasses the use of these C-terminal hVR1d.1 deletion polypeptides as
immunogenic and/or antigenic epitopes as described elsewhere herein.

In preferred embodiments, the following N-terminal hVR1d.2 deletion
polypeptides are encompassed by the present invention: M1-V745, S2-V745, F3-
20 V745, I4-V745, C5-V745, R6-V745, P7-V745, R8-V745, G9-V745, G10-V745, G11-
V745, R12-V745, L13-V745, E14-V745, T15-V745, D16-V745, S17-V745, R18-
V745, V19-V745, A20-V745, A21-V745, G22-V745, G23-V745, W24-V745, T25-
V745, A26-V745, G27-V745, S28-V745, H29-V745, T30-V745, V31-V745, G32-
V745, K33-V745, E34-V745, Q35-V745, K36-V745, A37-V745, S38-V745, D39-
25 V745, T40-V745, S41-V745, P42-V745, M43-V745, G44-V745, H45-V745, R46-
V745, E47-V745, Q48-V745, G49-V745, A50-V745, S51-V745, I52-V745, G53-
V745, D54-V745, G55-V745, G56-V745, E57-V745, T58-V745, A59-V745, G60-
V745, E61-V745, G62-V745, G63-V745, E64-V745, R65-V745, P66-V745, S67-
V745, V68-V745, R69-V745, S70-V745, G71-V745, S72-V745, G73-V745, D74-
30 V745, V75-V745, E76-V745, Q77-V745, G78-V745, L79-V745, G80-V745, V81-
V745, C82-V745, G83-V745, C84-V745, S85-V745, N86-V745, H87-V745, T88-
V745, L89-V745, W90-V745, A91-V745, G92-V745, R93-V745, A94-V745, K95-
V745, G96-V745, S97-V745, R98-V745, G99-V745, P100-V745, P101-V745, V102-
V745, T103-V745, P104-V745, P105-V745, M106-V745, A107-V745, L108-V745,
35 P109-V745, A110-V745, D111-V745, F112-V745, L113-V745, M114-V745, H115-
V745, K116-V745, L117-V745, T118-V745, A119-V745, S120-V745, D121-V745,
T122-V745, G123-V745, K124-V745, T125-V745, C126-V745, L127-V745, M128-

V745, K129-V745, A130-V745, L131-V745, L132-V745, N133-V745, I134-V745,
5 N135-V745, P136-V745, N137-V745, T138-V745, K139-V745, E140-V745, I141-
V745, V142-V745, R143-V745, I144-V745, L145-V745, L146-V745, A147-V745,
F148-V745, A149-V745, E150-V745, E151-V745, N152-V745, D153-V745, I154-
V745, L155-V745, G156-V745, R157-V745, F158-V745, I159-V745, N160-V745,
A161-V745, E162-V745, Y163-V745, T164-V745, E165-V745, E166-V745, A167-
10 V745, Y168-V745, E169-V745, G170-V745, Q171-V745, T172-V745, A173-V745,
L174-V745, N175-V745, I176-V745, A177-V745, I178-V745, E179-V745, R180-
V745, R181-V745, Q182-V745, G183-V745, D184-V745, I185-V745, A186-V745,
A187-V745, L188-V745, L189-V745, I190-V745, A191-V745, A192-V745, G193-
V745, A194-V745, D195-V745, V196-V745, N197-V745, A198-V745, H199-V745,
15 A200-V745, K201-V745, G202-V745, A203-V745, F204-V745, F205-V745, N206-
V745, P207-V745, K208-V745, Y209-V745, Q210-V745, H211-V745, E212-V745,
G213-V745, F214-V745, Y215-V745, F216-V745, G217-V745, E218-V745, T219-
V745, P220-V745, L221-V745, A222-V745, L223-V745, A224-V745, A225-V745,
C226-V745, T227-V745, N228-V745, Q229-V745, P230-V745, E231-V745, I232-
20 V745, V233-V745, Q234-V745, L235-V745, L236-V745, M237-V745, E238-V745,
H239-V745, E240-V745, Q241-V745, T242-V745, D243-V745, I244-V745, T245-
V745, S246-V745, R247-V745, D248-V745, S249-V745, R250-V745, G251-V745,
N252-V745, N253-V745, I254-V745, L255-V745, H256-V745, A257-V745, L258-
V745, V259-V745, T260-V745, V261-V745, A262-V745, E263-V745, D264-V745,
25 F265-V745, K266-V745, T267-V745, Q268-V745, N269-V745, D270-V745, F271-
V745, V272-V745, K273-V745, R274-V745, M275-V745, Y276-V745, D277-V745,
M278-V745, I279-V745, L280-V745, L281-V745, R282-V745, S283-V745, G284-
V745, N285-V745, W286-V745, E287-V745, L288-V745, E289-V745, T290-V745,
T291-V745, R292-V745, N293-V745, N294-V745, D295-V745, G296-V745, L297-
30 V745, T298-V745, P299-V745, L300-V745, Q301-V745, L302-V745, A303-V745,
A304-V745, K305-V745, M306-V745, G307-V745, K308-V745, A309-V745, E310-
V745, I311-V745, L312-V745, K313-V745, Y314-V745, I315-V745, L316-V745,
S317-V745, R318-V745, E319-V745, I320-V745, K321-V745, E322-V745, K323-
V745, R324-V745, L325-V745, R326-V745, S327-V745, L328-V745, S329-V745,
35 R330-V745, K331-V745, F332-V745, T333-V745, D334-V745, W335-V745, A336-
V745, Y337-V745, G338-V745, P339-V745, V340-V745, S341-V745, S342-V745,
S343-V745, L344-V745, Y345-V745, D346-V745, L347-V745, T348-V745, N349-

V745, V350-V745, D351-V745, T352-V745, T353-V745, T354-V745, D355-V745,
5 N356-V745, S357-V745, V358-V745, L359-V745, E360-V745, I361-V745, T362-
V745, V363-V745, Y364-V745, N365-V745, T366-V745, N367-V745, I368-V745,
D369-V745, N370-V745, R371-V745, H372-V745, E373-V745, M374-V745, L375-
V745, T376-V745, L377-V745, E378-V745, P379-V745, L380-V745, H381-V745,
T382-V745, L383-V745, L384-V745, H385-V745, M386-V745, K387-V745, W388-
10 V745, K389-V745, K390-V745, F391-V745, A392-V745, K393-V745, H394-V745,
M395-V745, F396-V745, F397-V745, L398-V745, S399-V745, F400-V745, C401-
V745, F402-V745, Y403-V745, F404-V745, F405-V745, Y406-V745, N407-V745,
I408-V745, T409-V745, L410-V745, T411-V745, L412-V745, V413-V745, S414-
V745, Y415-V745, Y416-V745, R417-V745, P418-V745, R419-V745, E420-V745,
15 E421-V745, E422-V745, A423-V745, I424-V745, P425-V745, H426-V745, P427-
V745, L428-V745, A429-V745, L430-V745, T431-V745, H432-V745, K433-V745,
M434-V745, G435-V745, W436-V745, L437-V745, Q438-V745, L439-V745, L440-
V745, G441-V745, R442-V745, M443-V745, F444-V745, V445-V745, L446-V745,
I447-V745, W448-V745, A449-V745, M450-V745, C451-V745, I452-V745, S453-
20 V745, V454-V745, K455-V745, E456-V745, G457-V745, I458-V745, A459-V745,
I460-V745, F461-V745, L462-V745, L463-V745, R464-V745, P465-V745, S466-
V745, D467-V745, L468-V745, Q469-V745, S470-V745, I471-V745, L472-V745,
S473-V745, D474-V745, A475-V745, W476-V745, F477-V745, H478-V745, F479-
V745, V480-V745, F481-V745, F482-V745, I483-V745, Q484-V745, A485-V745,
25 V486-V745, L487-V745, V488-V745, I489-V745, L490-V745, S491-V745, V492-
V745, F493-V745, L494-V745, Y495-V745, L496-V745, F497-V745, A498-V745,
Y499-V745, K500-V745, E501-V745, Y502-V745, L503-V745, A504-V745, C505-
V745, L506-V745, V507-V745, L508-V745, A509-V745, M510-V745, A511-V745,
L512-V745, G513-V745, W514-V745, A515-V745, N516-V745, M517-V745, L518-
30 V745, Y519-V745, Y520-V745, T521-V745, R522-V745, G523-V745, F524-V745,
Q525-V745, S526-V745, M527-V745, G528-V745, M529-V745, Y530-V745, S531-
V745, V532-V745, M533-V745, I534-V745, Q535-V745, K536-V745, V537-V745,
I538-V745, L539-V745, H540-V745, D541-V745, V542-V745, L543-V745, K544-
V745, F545-V745, L546-V745, F547-V745, V548-V745, Y549-V745, I550-V745,
35 A551-V745, F552-V745, L553-V745, L554-V745, G555-V745, F556-V745, G557-
V745, V558-V745, A559-V745, L560-V745, A561-V745, S562-V745, L563-V745,
I564-V745, E565-V745, K566-V745, C567-V745, P568-V745, K569-V745, D570-

V745, N571-V745, K572-V745, D573-V745, C574-V745, S575-V745, S576-V745,
5 Y577-V745, G578-V745, S579-V745, F580-V745, S581-V745, D582-V745, A583-
V745, V584-V745, L585-V745, E586-V745, L587-V745, F588-V745, K589-V745,
L590-V745, T591-V745, I592-V745, G593-V745, L594-V745, G595-V745, D596-
V745, L597-V745, N598-V745, I599-V745, Q600-V745, Q601-V745, N602-V745,
S603-V745, K604-V745, Y605-V745, P606-V745, I607-V745, L608-V745, F609-
10 V745, L610-V745, F611-V745, L612-V745, L613-V745, I614-V745, T615-V745,
Y616-V745, V617-V745, I618-V745, L619-V745, T620-V745, F621-V745, V622-
V745, L623-V745, L624-V745, L625-V745, N626-V745, M627-V745, L628-V745,
I629-V745, A630-V745, L631-V745, M632-V745, G633-V745, E634-V745, T635-
V745, V636-V745, E637-V745, N638-V745, V639-V745, S640-V745, K641-V745,
15 E642-V745, S643-V745, E644-V745, R645-V745, I646-V745, W647-V745, R648-
V745, L649-V745, Q650-V745, R651-V745, A652-V745, R653-V745, T654-V745,
I655-V745, L656-V745, E657-V745, F658-V745, E659-V745, K660-V745, M661-
V745, L662-V745, P663-V745, E664-V745, W665-V745, L666-V745, R667-V745,
S668-V745, R669-V745, F670-V745, R671-V745, M672-V745, G673-V745, E674-
20 V745, L675-V745, C676-V745, K677-V745, V678-V745, A679-V745, E680-V745;
D681-V745, D682-V745, F683-V745, R684-V745, L685-V745, C686-V745, L687-
V745, R688-V745, I689-V745, N690-V745, E691-V745, V692-V745, K693-V745,
W694-V745, T695-V745, E696-V745, W697-V745, K698-V745, T699-V745, H700-
V745, V701-V745, S702-V745, F703-V745, L704-V745, N705-V745, E706-V745,
25 D707-V745, P708-V745, G709-V745, P710-V745, V711-V745, R712-V745, R713-
V745, T714-V745, D715-V745, F716-V745, N717-V745, K718-V745, I719-V745,
Q720-V745, D721-V745, S722-V745, S723-V745, R724-V745, N725-V745, N726-
V745, S727-V745, K728-V745, T729-V745, T730-V745, L731-V745, N732-V745,
A733-V745, F734-V745, E735-V745, E736-V745, V737-V745, E738-V745, and/or
30 E739-V745 of SEQ ID NO:4. Polynucleotide sequences encoding these polypeptides
are also provided. The present invention also encompasses the use of these N-
terminal hVR1d.2 deletion polypeptides as immunogenic and/or antigenic epitopes as
described elsewhere herein.

In preferred embodiments, the following C-terminal hVR1d.2 deletion
35 polypeptides are encompassed by the present invention: M1-V745, M1-S744, M1-
T743, M1-E742, M1-P741, M1-F740, M1-E739, M1-E738, M1-V737, M1-E736,
M1-E735, M1-F734, M1-A733, M1-N732, M1-L731, M1-T730, M1-T729, M1-

K728, M1-S727, M1-N726, M1-N725, M1-R724, M1-S723, M1-S722, M1-D721,
5 M1-Q720, M1-I719, M1-K718, M1-N717, M1-F716, M1-D715, M1-T714, M1-R713,
M1-R712, M1-V711, M1-P710, M1-G709, M1-P708, M1-D707, M1-E706, M1-
N705, M1-L704, M1-F703, M1-S702, M1-V701, M1-H700, M1-T699, M1-K698,
M1-W697, M1-E696, M1-T695, M1-W694, M1-K693, M1-V692, M1-E691, M1-
N690, M1-I689, M1-R688, M1-L687, M1-C686, M1-L685, M1-R684, M1-F683, M1-
10 D682, M1-D681, M1-E680, M1-A679, M1-V678, M1-K677, M1-C676, M1-L675,
M1-E674, M1-G673, M1-M672, M1-R671, M1-F670, M1-R669, M1-S668, M1-
R667, M1-L666, M1-W665, M1-E664, M1-P663, M1-L662, M1-M661, M1-K660,
M1-E659, M1-F658, M1-E657, M1-L656, M1-I655, M1-T654, M1-R653, M1-A652,
M1-R651, M1-Q650, M1-L649, M1-R648, M1-W647, M1-I646, M1-R645, M1-
15 E644, M1-S643, M1-E642, M1-K641, M1-S640, M1-V639, M1-N638, M1-E637,
M1-V636, M1-T635, M1-E634, M1-G633, M1-M632, M1-L631, M1-A630, M1-
I629, M1-L628, M1-M627, M1-N626, M1-L625, M1-L624, M1-L623, M1-V622,
M1-F621, M1-T620, M1-L619, M1-I618, M1-V617, M1-Y616, M1-T615, M1-I614,
M1-L613, M1-L612, M1-F611, M1-L610, M1-F609, M1-L608, M1-I607, M1-P606,
20 M1-Y605, M1-K604, M1-S603, M1-N602, M1-Q601, M1-Q600, M1-I599, M1-
N598, M1-L597, M1-D596, M1-G595, M1-L594, M1-G593, M1-I592, M1-T591,
M1-L590, M1-K589, M1-F588, M1-L587, M1-E586, M1-L585, M1-V584, M1-A583,
M1-D582, M1-S581, M1-F580, M1-S579, M1-G578, M1-Y577, M1-S576, M1-S575,
M1-C574, M1-D573, M1-K572, M1-N571, M1-D570, M1-K569, M1-P568, M1-
25 C567, M1-K566, M1-E565, M1-I564, M1-L563, M1-S562, M1-A561, M1-L560, M1-
A559, M1-V558, M1-G557, M1-F556, M1-G555, M1-L554, M1-L553, M1-F552,
M1-A551, M1-I550, M1-Y549, M1-V548, M1-F547, M1-L546, M1-F545, M1-K544,
M1-L543, M1-V542, M1-D541, M1-H540, M1-L539, M1-I538, M1-V537, M1-K536,
M1-Q535, M1-I534, M1-M533, M1-V532, M1-S531, M1-Y530, M1-M529, M1-
30 G528, M1-M527, M1-S526, M1-Q525, M1-F524, M1-G523, M1-R522, M1-T521,
M1-Y520, M1-Y519, M1-L518, M1-M517, M1-N516, M1-A515, M1-W514, M1-
G513, M1-L512, M1-A511, M1-M510, M1-A509, M1-L508, M1-V507, M1-L506,
M1-C505, M1-A504, M1-L503, M1-Y502, M1-E501, M1-K500, M1-Y499, M1-
A498, M1-F497, M1-L496, M1-Y495, M1-L494, M1-F493, M1-V492, M1-S491,
35 M1-L490, M1-I489, M1-V488, M1-L487, M1-V486, M1-A485, M1-Q484, M1-I483,
M1-F482, M1-F481, M1-V480, M1-F479, M1-H478, M1-F477, M1-W476, M1-
A475, M1-D474, M1-S473, M1-L472, M1-I471, M1-S470, M1-Q469, M1-L468, M1-

D467, M1-S466, M1-P465, M1-R464, M1-L463, M1-L462, M1-F461, M1-I460, M1-
5 A459, M1-I458, M1-G457, M1-E456, M1-K455, M1-V454, M1-S453, M1-I452, M1-
C451, M1-M450, M1-A449, M1-W448, M1-I447, M1-L446, M1-V445, M1-F444,
M1-M443, M1-R442, M1-G441, M1-L440, M1-L439, M1-Q438, M1-L437, M1-
W436, M1-G435, M1-M434, M1-K433, M1-H432, M1-T431, M1-L430, M1-A429,
M1-L428, M1-P427, M1-H426, M1-P425, M1-I424, M1-A423, M1-E422, M1-E421,
10 M1-E420, M1-R419, M1-P418, M1-R417, M1-Y416, M1-Y415, M1-S414, M1-
V413, M1-L412, M1-T411, M1-L410, M1-T409, M1-I408, M1-N407, M1-Y406,
M1-F405, M1-F404, M1-Y403, M1-F402, M1-C401, M1-F400, M1-S399, M1-L398,
M1-F397, M1-F396, M1-M395, M1-H394, M1-K393, M1-A392, M1-F391, M1-
K390, M1-K389, M1-W388, M1-K387, M1-M386, M1-H385, M1-L384, M1-L383,
15 M1-T382, M1-H381, M1-L380, M1-P379, M1-E378, M1-L377, M1-T376, M1-L375,
M1-M374, M1-E373, M1-H372, M1-R371, M1-N370, M1-D369, M1-I368, M1-
N367, M1-T366, M1-N365, M1-Y364, M1-V363, M1-T362, M1-I361, M1-E360,
M1-L359, M1-V358, M1-S357, M1-N356, M1-D355, M1-T354, M1-T353, M1-
T352, M1-D351, M1-V350, M1-N349, M1-T348, M1-L347, M1-D346, M1-Y345,
20 M1-L344, M1-S343, M1-S342, M1-S341, M1-V340, M1-P339, M1-G338, M1-Y337,
M1-A336, M1-W335, M1-D334, M1-T333, M1-F332, M1-K331, M1-R330, M1-
S329, M1-L328, M1-S327, M1-R326, M1-L325, M1-R324, M1-K323, M1-E322,
M1-K321, M1-I320, M1-E319, M1-R318, M1-S317, M1-L316, M1-I315, M1-Y314,
M1-K313, M1-L312, M1-I311, M1-E310, M1-A309, M1-K308, M1-G307, M1-
25 M306, M1-K305, M1-A304, M1-A303, M1-L302, M1-Q301, M1-L300, M1-P299,
M1-T298, M1-L297, M1-G296, M1-D295, M1-N294, M1-N293, M1-R292, M1-
T291, M1-T290, M1-E289, M1-L288, M1-E287, M1-W286, M1-N285, M1-G284,
M1-S283, M1-R282, M1-L281, M1-L280, M1-I279, M1-M278, M1-D277, M1-Y276,
M1-M275, M1-R274, M1-K273, M1-V272, M1-F271, M1-D270, M1-N269, M1-
30 Q268, M1-T267, M1-K266, M1-F265, M1-D264, M1-E263, M1-A262, M1-V261,
M1-T260, M1-V259, M1-L258, M1-A257, M1-H256, M1-L255, M1-I254, M1-N253,
M1-N252, M1-G251, M1-R250, M1-S249, M1-D248, M1-R247, M1-S246, M1-
T245, M1-I244, M1-D243, M1-T242, M1-Q241, M1-E240, M1-H239, M1-E238,
M1-M237, M1-L236, M1-L235, M1-Q234, M1-V233, M1-I232, M1-E231, M1-P230,
35 M1-Q229, M1-N228, M1-T227, M1-C226, M1-A225, M1-A224, M1-L223, M1-
A222, M1-L221, M1-P220, M1-T219, M1-E218, M1-G217, M1-F216, M1-Y215,
M1-F214, M1-G213, M1-E212, M1-H211, M1-Q210, M1-Y209, M1-K208, M1-

P207, M1-N206, M1-F205, M1-F204, M1-A203, M1-G202, M1-K201, M1-A200,
 5 M1-H199, M1-A198, M1-N197, M1-V196, M1-D195, M1-A194, M1-G193, M1-
 A192, M1-A191, M1-I190, M1-L189, M1-L188, M1-A187, M1-A186, M1-I185, M1-
 D184, M1-G183, M1-Q182, M1-R181, M1-R180, M1-E179, M1-I178, M1-A177,
 M1-I176, M1-N175, M1-L174, M1-A173, M1-T172, M1-Q171, M1-G170, M1-E169,
 M1-Y168, M1-A167, M1-E166, M1-E165, M1-T164, M1-Y163, M1-E162, M1-
 10 A161, M1-N160, M1-I159, M1-F158, M1-R157, M1-G156, M1-L155, M1-I154, M1-
 D153, M1-N152, M1-E151, M1-E150, M1-A149, M1-F148, M1-A147, M1-L146,
 M1-L145, M1-I144, M1-R143, M1-V142, M1-I141, M1-E140, M1-K139, M1-T138,
 M1-N137, M1-P136, M1-N135, M1-I134, M1-N133, M1-L132, M1-L131, M1-A130,
 M1-K129, M1-M128, M1-L127, M1-C126, M1-T125, M1-K124, M1-G123, M1-
 15 T122, M1-D121, M1-S120, M1-A119, M1-T118, M1-L117, M1-K116, M1-H115,
 M1-M114, M1-L113, M1-F112, M1-D111, M1-A110, M1-P109, M1-L108, M1-
 A107, M1-M106, M1-P105, M1-P104, M1-T103, M1-V102, M1-P101, M1-P100,
 M1-G99, M1-R98, M1-S97, M1-G96, M1-K95, M1-A94, M1-R93, M1-G92, M1-
 A91, M1-W90, M1-L89, M1-T88, M1-H87, M1-N86, M1-S85, M1-C84, M1-G83,
 20 M1-C82, M1-V81, M1-G80, M1-L79, M1-G78, M1-Q77, M1-E76, M1-V75, M1-
 D74, M1-G73, M1-S72, M1-G71, M1-S70, M1-R69, M1-V68, M1-S67, M1-P66,
 M1-R65, M1-E64, M1-G63, M1-G62, M1-E61, M1-G60, M1-A59, M1-T58, M1-
 E57, M1-G56, M1-G55, M1-D54, M1-G53, M1-I52, M1-S51, M1-A50, M1-G49,
 M1-Q48, M1-E47, M1-R46, M1-H45, M1-G44, M1-M43, M1-P42, M1-S41, M1-
 25 T40, M1-D39, M1-S38, M1-A37, M1-K36, M1-Q35, M1-E34, M1-K33, M1-G32,
 M1-V31, M1-T30, M1-H29, M1-S28, M1-G27, M1-A26, M1-T25, M1-W24, M1-
 G23, M1-G22, M1-A21, M1-A20, M1-V19, M1-R18, M1-S17, M1-D16, M1-T15,
 M1-E14, M1-L13, M1-R12, M1-G11, M1-G10, M1-G9, M1-R8, and/or M1-P7 of
 SEQ ID NO:4. Polynucleotide sequences encoding these polypeptides are also
 30 provided. The present invention also encompasses the use of these C-terminal
 hVR1d.2 deletion polypeptides as immunogenic and/or antigenic epitopes as
 described elsewhere herein.

In addition, the present invention provides the hVR1d clone corresponding to
 SEQ ID NO:1, deposited at the American Type Culture Collection (ATCC), 10801
 35 University Boulevard, Manassas, VA 20110-2209 on _____ and under
 ATCC Accession No. _____ according to the terms of the Budapest Treaty.

Other embodiments of the invention include antibodies directed to the hVR1d proteins and polypeptides of the invention, and methods and compositions for the diagnosis and treatment of human diseases related to ion channel dysfunction as described below.

5.1. THE hVR1d NUCLEIC ACID MOLECULES OF THE INVENTION

The hVR1d nucleic acids of the invention, e.g., hVR1d.1 and hVR1d.2, are novel human nucleic acid molecules that encode proteins or polypeptides involved in the formation and/or function of novel human ion channels. Although these novel nucleic acids and proteins display some sequence and structural homology to the TRP and vanilloid families of cation channel proteins as well as other cation channel proteins known in the art, it is also known in the art that proteins displaying such homologies have significant differences in function, such as conductance and permeability, as well as differences in tissue expression. As such, it is acknowledged in the art that nucleic acid molecules and the proteins encoded by those molecules sharing these homologies can still represent diverse, distinct and unique nucleic acids and proteins, respectively.

The hVR1d nucleic acid molecules of the invention are those that comprise the following sequences: (a) the DNA sequence of hVR1d.1 or hVR1d.2 as shown in FIGS. 1A or 1B, respectively; (b) any nucleic acid sequence that encodes the amino acid sequence of hVR1d.1 or hVR1d.2 as shown in FIGS. 2A or 2B, respectively; (c) any nucleic acid sequence that hybridizes to the complement of nucleic acid sequences that encode the amino acid sequences of FIGS. 2A or 2B under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (see, e.g., Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) or (d) any nucleic acid sequence that hybridizes to the complement of nucleic acid sequences that encode the amino acid sequences of FIGS. 2A or 2B under less stringent conditions, such as moderately stringent conditions, e.g., washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, supra), and which encodes a gene product functionally equivalent to a hVR1d gene product encoded by the sequences depicted in FIGS. 2A or 2B. "Functionally equivalent" as used herein refers to any protein capable of exhibiting a substantially similar in vivo or in vitro

activity as the hVR1d gene products encoded by the hVR1d nucleic acid molecules
5 described herein, e.g., ion channel formation or function.

As used herein, the term "hVR1d nucleic acid molecule" or "hVR1d nucleic acid" may also refer to fragments and/or degenerate variants of nucleic acid sequences (a) through (d), including naturally occurring variants or mutant alleles thereof. Such fragments include, for example, nucleic acid sequences that encode portions of the
10 hVR1d protein that correspond to functional domains of the protein. One embodiment of such a hVR1d nucleic acid fragment comprises a nucleic acid containing a contiguous open reading frame, without introns, that encodes the fifth and sixth transmembrane segments of the hVR1d protein, including the predicted pore loop.

15 Additionally, the hVR1d nucleic acid molecules of the invention include isolated nucleic acids, preferably DNA molecules, that hybridize under highly stringent or moderately stringent hybridization conditions to at least about 6, preferably at least about 12, and more preferably at least about 18, consecutive nucleotides of the nucleic acid sequences of (a) through (d), identified supra.

20 The hVR1d nucleic acid molecules of the invention also include nucleic acids, preferably DNA molecules, that hybridize to, and are therefore complements of, the nucleic acid sequences of (a) through (d), supra. Such hybridization conditions may be highly stringent or moderately stringent, as described above. In those instances in which the nucleic acid molecules are deoxyoligonucleotides ("oligos"), highly
25 stringent conditions may include, e.g., washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). The nucleic acid molecules of the invention may encode or act as hVR1d antisense molecules useful, for example, in hVR1d gene regulation or as antisense primers in amplification reactions of hVR1d
30 nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for hVR1d gene regulation. Still further, such molecules may be used as components of diagnostic methods whereby, for example, the presence of a particular hVR1d allele or alternatively-spliced hVR1d transcript responsible for causing or predisposing one to a disorder involving ion
35 channel dysfunction may be detected.

Moreover, due to the degeneracy of the genetic code, other DNA sequences that encode substantially the amino acid sequences of hVR1d1.1 or hVR1d.2 may be

used in the practice of the present invention for the cloning and expression of hVR1d polypeptides. Such DNA sequences include those that are capable of hybridizing to the hVR1d nucleic acids of this invention under stringent (high or moderate) conditions, or that would be capable of hybridizing under stringent conditions but for the degeneracy of the genetic code.

Typically, the hVR1d nucleic acids of the invention should exhibit at least about 80% overall sequence homology at the nucleotide level, more preferably at least about 85-90% overall homology and most preferably at least about 95% overall homology to the nucleic acid sequences of FIGS. 1A or 1B (as determined by the CLUSTAL W algorithm using default parameters (Thompson, J.D., et al., Nucleic Acids Research, 2(22):4673-4680, (1994)).

Altered hVR1d nucleic acid sequences that may be used in accordance with the invention include deletions, additions or substitutions of different nucleotide residues resulting in a modified nucleic acid molecule, i.e., mutated or truncated, that encodes the same or a functionally equivalent gene product as those described supra. The gene product itself may contain deletions, additions or substitutions of amino acid residues within the hVR1d protein sequence, which result in a silent change, thus producing a functionally equivalent hVR1d polypeptide. Such amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipatic nature of the residues involved. For example, negatively-charged amino acids include aspartic acid and glutamic acid; positively-charged amino acids include lysine, arginine and histidine; amino acids with uncharged polar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, tyrosine. A functionally equivalent hVR1d polypeptide can include a polypeptide which displays the same type of biological activity (e.g., cation channel) as the native hVR1d protein, but not necessarily to the same extent.

The nucleic acid molecules or sequences of the invention may be engineered in order to alter the hVR1d coding sequence for a variety of ends including but not limited to alterations that modify processing and expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, phosphorylation, etc. For example, in certain expression systems such as yeast, host cells may over-glycosylate the gene product. When using such expression

systems, it may be preferable to alter the hVR1d coding sequence to eliminate any
5 N-linked glycosylation sites.

In another embodiment, a hVR1d nucleic acid of the invention, e.g., a modified hVR1d nucleic acid, may be ligated to a heterologous protein-encoding sequence to encode a fusion protein. According to a preferred embodiment, a hVR1d nucleic acid of the invention that encodes a polypeptide with an activity of a hVR1d
10 protein, or a fragment thereof, is linked, uninterrupted by stop codons and in frame, to a nucleotide sequence that encodes a heterologous protein or peptide. The fusion protein may be engineered to contain a cleavage site located between the hVR1d sequence and the heterologous protein sequence, so that the hVR1d protein can be cleaved away from the heterologous moiety. Nucleic acid sequences encoding fusion
15 proteins of the invention may include full length hVR1d coding sequences, sequences encoding truncated hVR1d, sequences encoding mutated hVR1d or sequences encoding peptide fragments of hVR1d.

The hVR1d nucleic acid molecules of the invention can also be used as hybridization probes for obtaining hVR1d cDNAs or genomic hVR1d DNA. In
20 addition, the nucleic acids of the invention can be used as primers in PCR amplification methods to isolate hVR1d cDNAs and genomic DNA, e.g., from other species.

The hVR1d gene sequences of the invention may also be used to isolate mutant hVR1d gene alleles. Such mutant alleles may be isolated from individuals either
25 known or proposed to have a genotype related to ion channel dysfunction. Mutant alleles and mutant allele gene products may then be utilized in the screening, therapeutic and diagnostic systems described in Section 5.4., *infra*. Additionally, such hVR1d gene sequences can be used to detect hVR1d gene regulatory (e.g., promoter) defects which can affect ion channel function.

30 A cDNA of a mutant hVR1d gene may be isolated, for example, by using PCR, a technique which is well known to those of skill in the art (see, e.g., U.S. Patent No. 4,683,202). The first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying the mutant hVR1d allele, and by extending the
35 new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, cloned

into a suitable vector, and subjected to DNA sequence analysis through methods well known in the art. By comparing the DNA sequence of the mutant hVR1d allele to that of the normal hVR1d allele, the mutation(s) responsible for the loss or alteration of function of the mutant hVR1d gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry the mutant hVR1d allele, or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express the mutant hVR1d allele. The normal hVR1d gene or any suitable fragment thereof may then be labeled and used as a probe to identify the corresponding mutant hVR1d allele in such libraries. Clones containing the mutant hVR1d gene sequences may then be purified and subjected to sequence analysis according to methods well known in the art.

According to another embodiment, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant hVR1d allele in an individual suspected of or known to carry such a mutant allele. Gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal hVR1d gene product, as described in Section 5.3, *supra*. For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Anti-bodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.

In cases where a hVR1d mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frameshift mutation), a polyclonal set of anti-hVR1d gene product antibodies are likely to cross-react with the mutant hVR1d gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

In an alternate embodiment of the invention, the coding sequence of hVR1d can be synthesized in whole or in part, using chemical methods well known in the art, based on the nucleic acid and/or amino acid sequences of the hVR1d genes and proteins disclosed herein. See, for example, Caruthers et al., 1980, Nuc. Acids Res. Symp. Ser. 7: 215-233; Crea and Horn, 1980, Nuc. Acids Res. 9(10): 2331; Matteucci and Caruthers, 1980, Tetrahedron Letters 21: 719; and Chow and Kempe, 1981, Nuc. Acids Res. 9(12): 2807-2817. The invention also encompasses (a) DNA vectors that

contain any of the foregoing hVR1d nucleic acids and/or their complements; (b) DNA
5 expression vectors that contain any of the foregoing hVR1d coding sequences
operatively associated with a regulatory element that directs the expression of the
coding sequences; and (c) genetically engineered host cells that contain any of the
foregoing hVR1d coding sequences operatively associated with a regulatory element
that directs the expression of the coding sequences in the host cell. As used herein,
10 regulatory elements include, but are not limited to inducible and non-inducible
promoters, enhancers, operators and other elements known to those skilled in the art
that drive and regulate expression. Such regulatory elements include but are not
limited to the cytomegalovirus hCMV immediate early gene, the early or late
promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the
15 TRC system, the major operator and promoter regions of phage A, the control regions
of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid
phosphatase, and the promoters of the yeast α -mating factors.

The invention still further includes nucleic acid analogs, including but not
limited to, peptide nucleic acid analogues, equivalent to the nucleic acid molecules
20 described herein. "Equivalent" as used in this context refers to nucleic acid analogs
that have the same primary base sequence as the nucleic acid molecules described
above. Nucleic acid analogs and methods for the synthesis of nucleic acid analogs are
well known to those of skill in the art. See, e.g., Egholm, M. et al., 1993, Nature
365:566-568; and Perry-O'Keefe, H. et al., 1996, Proc. Natl. Acad. USA 93:14670-
25 14675.

5.2. hVR1d PROTEINS AND POLYPEPTIDES

The hVR1d nucleic acid molecules of the invention may be used to generate
recombinant DNA molecules that direct the expression in appropriate host cells of
30 hVR1d polypeptides, including the full-length hVR1d proteins, e.g., hVR1d.1 or
hVR1d.2, functionally active or equivalent hVR1d proteins and polypeptides, e.g.,
mutated, truncated or deleted forms of hVR1d, peptide fragments of hVR1d, or
hVR1d fusion proteins. A functionally equivalent hVR1d polypeptide can include a
polypeptide which displays the same type of biological activity (e.g., cation channel
35 formation and/or function) as the native hVR1d protein, but not necessarily to the
same extent.

In a preferred embodiment, the proteins and polypeptides of the invention include the hVR1d.1 and hVR1d.2 amino acid sequences depicted in FIGS. 2A and 2B, respectively. These sequences include six transmembrane domains and an overall topology that is conserved in the TRP-vanilloid family of ion channels. In addition, the amino acid sequences of FIGS. 2A and 2B contain three ankyrin domains in the N-terminal segment of the protein preceding the first transmembrane domain.

The hVR1 proteins and polypeptides of the invention include peptide fragments of hVR1d.1 or hVR1d.2, e.g., peptides corresponding to one or more domains of the protein, mutated, truncated or deleted forms of the proteins and polypeptides, as well as hVR1d fusion proteins, all of which derivatives of hVR1d can be obtained by techniques well known in the art, given the hVR1d nucleic acid and amino acid sequences disclosed herein. As noted in Section 5.1, supra, the proteins and polypeptides of the invention may contain deletions, additions or substitutions of amino acid residues within the hVR1d protein sequence, which result in a silent change, thus producing a functionally equivalent hVR1d polypeptide. Such amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, negatively-charged amino acids include aspartic acid and glutamic acid; positively-charged amino acids include lysine, arginine and histidine; amino acids with uncharged polar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, tyrosine.

Modified or altered forms of the hVR1d proteins and polypeptides of the invention can be obtained using either random mutagenesis techniques or site-directed mutagenesis techniques well known in the art or by chemical methods, e.g., protein synthesis techniques (see Section 5.1, supra). Mutant hVR1d proteins or polypeptides can be engineered so that regions important for function are maintained, while variable residues are altered, e.g., by deletion or insertion of an amino acid residue(s) or by the substitution of one or more different amino acid residues. For example, conservative alterations at the variable positions of a polypeptide can be engineered to produce a mutant hVR1d polypeptide that retains the function of hVR1d. Non-conservative alterations of variable regions can be engineered to alter hVR1d function, if desired. Alternatively, in those cases where modification of function

(either to increase or decrease function) is desired, deletion or non-conservative
5 alterations of conserved regions of the polypeptide may be engineered.

Fusion proteins containing hVR1d amino acid sequences can also be obtained by techniques known in the art, including genetic engineering and chemical protein synthesis techniques. According to a preferred embodiment, the fusion proteins of the invention are encoded by an isolated nucleic acid molecule comprising an hVR1d
10 nucleic acid of the invention that encodes a polypeptide with an activity of a hVR1d protein, or a fragment thereof, linked in frame and uninterrupted by stop codons to a nucleotide sequence that encodes a heterologous protein or peptide.

The fusion proteins of the invention include those that contain the full length hVR1d amino acid sequence, an hVR1d peptide sequence, e.g., encoding one or more
15 functional domains, a mutant hVR1d amino acid sequence or a truncated hVR1d amino acid sequence linked to an unrelated protein or polypeptide sequence. Such fusion proteins include but are not limited to IgFc fusions which stabilize the hVR1d fusion protein and may prolong half-life of the protein in vivo or fusions to an enzyme, fluorescent protein or luminescent protein that provides a marker function.

20 According to a preferred embodiment of the invention, the hVR1d proteins and polypeptides, and derivatives thereof, of the invention are produced using genetic engineering techniques. Thus, in order to express a biologically active hVR1d polypeptide by recombinant technology, a nucleic acid molecule coding for the polypeptide, or a functional equivalent thereof as described in Section 5.1, supra, is
25 inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. More specifically, the hVR1d nucleic acid is operatively associated with a regulatory nucleotide sequence containing transcriptional and/or translational regulatory information that controls expression of the hVR1d nucleic acid in the host
30 cell. The hVR1d gene products so produced, as well as host cells or cell lines transfected or transformed with recombinant hVR1d expression vectors, can be used for a variety of purposes. These include but are not limited to generating antibodies (i.e., monoclonal or polyclonal) that bind to the hVR1d protein or polypeptide, including those that competitively inhibit binding and thus can "neutralize" hVR1d
35 activity, and the screening and selection of hVR1d analogs or ligands.

Methods that are well known to those skilled in the art are used to construct expression vectors containing the hVR1d coding sequences of the invention and

appropriate transcriptional and translational control elements and/or signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y. See also Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.

A variety of host-expression vector systems may be used to express the hVR1d coding sequences of this invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the corresponding hVR1d gene products in situ and/or function in vivo. These hosts include but are not limited to microorganisms such as bacteria (e.g., E.coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the hVR1d coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the hVR1d coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the hVR1d coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the hVR1d coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., the metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter or vaccinia virus 7.5K promoter).

The expression elements of these systems can vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcriptional and translational elements, including constitutive and inducible promoters, may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage λ , plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedrin promoter may be used; when

cloning in plant cell systems, promoters derived from the genome of plant cells (e.g.,
5 heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter
for the chlorophyll a/b binding protein) or from plant viruses (e.g., the 35S RNA
promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in
mammalian cell systems, promoters derived from the genome of mammalian cells
(e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late
10 promoter; the vaccinia virus 7.5K promoter) may be used; when generating cell lines
that contain multiple copies of the hVR1d DNA, SV40-, BPV- and EBV-based
vectors may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be advantageously
selected depending upon the use intended for the hVR1d polypeptide expressed. For
15 example, when large quantities of an hVR1d polypeptide are to be produced, e.g., for
the generation of antibodies or the production of the hVR1d gene product, vectors
which direct the expression of high levels of fusion protein products that are readily
purified may be desirable. Such vectors include but are not limited to the E. coli
expression vector pUR278 (Ruther et al., 1983, EMBO J. 2: 1791), in which the
20 hVR1d coding sequence may be ligated into the vector in frame with the lacZ coding
region so that a hybrid hVR1d/lacZ protein is produced; pIN vectors (Inouye &
Inouye, 1985, Nucleic Acids Res. 13: 3101-3109; Van Heeke & Schuster, 1989, J.
Biol. Chem. 264: 5503-5509); and the like. pGEX vectors may also be used to
express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
25 In general, such fusion proteins are soluble and can easily be purified from lysed cells
by affinity chromatography, e.g., adsorption to glutathione-agarose beads followed by
elution in the presence of free glutathione. The pGEX vectors are designed to include
thrombin or factor Xa protease cleavage sites so that the cloned polypeptide of interest
can be released from the GST moiety. See also Booth et al., 1988, Immunol. Lett. 19:
30 65-70; and Gardella et al., 1990, J. Biol. Chem. 265: 15854-15859; Pritchett et al.,
1989, Biotechniques 7: 580.

In yeast, a number of vectors containing constitutive or inducible promoters
may be used. For a review, see Current Protocols in Molecular Biology, Vol. 2, 1988,
Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et al.,
35 1987, Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds.
Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp. 516-544; Glover, 1986,
DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous

Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular Biology of the Yeast *Saccharomyces*, 1982, Cold Spring Harbor Press, Vols. I and II.

In an insect system, Autographa californica nuclear polyhidrosis virus (AcNPV) can be used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The hVR1d coding sequence may be cloned into non-essential regions (for example, the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedrin promoter). Successful insertion of the hVR1d coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses can then be used to infect Spodoptera frugiperda cells in which the inserted gene is expressed (see e.g., Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the hVR1d coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing hVR1d in infected hosts (see, e.g., Logan & Shenk, 1984, Proc. Natl. Acad. Sci. (USA) 81: 3655-3659). Alternatively, the vaccinia 7.5K promoter may be used (see, e.g., Mackett et al., 1982, Proc. Natl. Acad. Sci. (USA) 79: 7415-7419; Mackett et al., 1984, J. Virol. 49: 857-864; Panicali et al., 1982, Proc. Natl. Acad. Sci. 79: 4927-4931).

Specific initiation signals may also be required for efficient translation of inserted hVR1d coding sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where the entire hVR1d gene, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the hVR1d coding sequence is inserted, exogenous translational control signals, including the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the

hVR1d coding sequence to ensure translation of the entire insert. These exogenous
5 translational control signals and initiation codons can be of a variety of origins, both
natural and synthetic. The efficiency of expression may be enhanced by the inclusion
of appropriate transcription enhancer elements, transcription terminators, etc. (see,
e.g., Bittner et al., 1987, *Methods in Enzymol.* 153:516-544).

In addition, a host cell strain may be chosen which modulates the expression
10 of the inserted sequences, or modifies and processes the gene product in the specific
fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,
cleavage) of protein products may be important for the function of the protein.
Different host cells have characteristic and specific mechanisms for the post-transla-
tional processing and modification of proteins. Appropriate cells lines or host systems
15 can be chosen to ensure the correct modification and processing of the foreign protein
expressed. To this end, eukaryotic host cells which possess the cellular machinery for
proper processing of the primary transcript, glycosylation, and phosphorylation of the
gene product may be used. Such mammalian host cells include but are not limited to
CHO, VERO, BHK, HeLa, COS, MDCK, 293, WI38, etc.

20 For long-term, high-yield production of recombinant proteins, stable
expression is preferred. For example, cell lines which stably express the hVR1d
polypeptides of this invention may be engineered. Thus, rather than using expression
vectors which contain viral origins of replication, host cells can be transformed with
hVR1d nucleic acid molecules, e.g., DNA, controlled by appropriate expression
25 control elements (e.g., promoter, enhancer, sequences, transcription terminators,
polyadenylation sites, etc.), and a selectable marker. Following the introduction of
foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched
media, and then are switched to a selective media. The selectable marker in the
recombinant plasmid confers resistance to the selection and allows cells to stably
30 integrate the plasmid into their chromosomes and grow to form foci which in turn can
be cloned and expanded into cell lines. This method may advantageously be used to
engineer cell lines which express hVR1d polypeptides on the cell surface. Such
engineered cell lines are particularly useful in screening for hVR1d analogs or ligands.

In instances where the mammalian cell is a human cell, among the expression
35 systems by which the hVR1d nucleic acid sequences of the invention can be expressed
are human artificial chromosome (HAC) systems (see, e.g., Harrington et al., 1997,
Nature Genetics 15: 345-355).

hVR1d gene products can also be expressed in transgenic animals such as mice, rats, rabbits, guinea pigs, pigs, micro-pigs, sheep, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees. The term "transgenic" as used herein refers to animals expressing hVR1d nucleic acid sequences from a different species (e.g., mice expressing human hVR1d nucleic acid sequences), as well as animals that have been genetically engineered to overexpress endogenous (i.e., same species) hVR1d nucleic acid sequences or animals that have been genetically engineered to no longer express endogenous hVR1d nucleic acid sequences (i.e., "knock-out" animals), and their progeny.

Transgenic animals according to this invention may be produced using techniques well known in the art, including but not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., 1985, Proc. Natl. Acad. Sci., USA 82: 6148-6152); gene targeting in embryonic stem cells (Thompson et al., 1989, Cell 56: 313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. 3: 1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57: 717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115: 171-229.

In addition, any technique known in the art may be used to produce transgenic animal clones containing a hVR1d transgene, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal or adult cells induced to quiescence (Campbell et al., 1996, Nature 380: 64-66; Wilmut et al., 1997, Nature 385: 810-813).

Host cells which contain the hVR1d coding sequence and which express a biologically active gene product may be identified by at least four general approaches; (a) DNA-DNA or DNA-RNA hybridization; (b) the presence or absence of "marker" gene functions; (c) assessing the level of transcription as measured by the expression of hVR1d mRNA transcripts in the host cell; and (d) detection of the gene product as measured by immunoassay or by its biological activity.

In the first approach, the presence of the hVR1d coding sequence inserted in the expression vector can be detected by DNA-DNA or DNA-RNA hybridization using probes comprising nucleotide sequences that are homologous to the hVR1d coding sequence, respectively, or portions or derivatives thereof.

In the second approach, the recombinant expression vector/host system can be
5 identified and selected based upon the presence or absence of certain "marker" gene
functions. For example, if the hVR1d coding sequence is inserted within a marker
gene sequence of the vector, recombinants containing the hVR1d coding sequence can
be identified by the absence of the marker gene function. Alternatively, a marker gene
can be placed in tandem with the hVR1d sequence under the control of the same or
10 different promoter used to control the expression of the hVR1d coding sequence.
Expression of the marker in response to induction or selection indicates expression of
the hVR1d coding sequence.

Selectable markers include resistance to antibiotics, resistance to methotrexate,
transformation phenotype, and occlusion body formation in baculovirus. In addition,
15 thymidine kinase activity (Wigler et al., 1977, Cell 11: 223) hypoxanthine-guanine
phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA
48: 2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22: 817)
genes can be employed in tk⁻, hgprt⁻ or aprt⁻ cells, respectively. Also, antimetabolite
resistance can be used as the basis of selection for dhfr, which confers resistance to
20 methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77: 3567; O'Hare et al.,
1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt, which confers resistance to
mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78: 2072);
neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al.,
1981, J. Mol. Biol. 150: 1); and hygro, which confers resistance to hygromycin
25 (Santerre et al., 1984, Gene 30: 147). Additional selectable genes have been
described, namely trpB, which allows cells to utilize indole in place of tryptophan;
hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan,
1988, Proc. Natl. Acad. Sci. USA 85: 8047); and ODC (ornithine decarboxylase)
which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-
30 DL-ornithine, DFMO (McConlogue, 1987, in Current Communications in Molecular
Biology, Cold Spring Harbor Laboratory ed.).

In the third approach, transcriptional activity for the hVR1d coding region can
be assessed by hybridization assays. For example, RNA can be isolated and analyzed
by Northern blot using a probe homologous to the hVR1d coding sequence or
35 particular portions thereof. Alternatively, total nucleic acids of the host cell may be
extracted and assayed for hybridization to such probes.

In the fourth approach, the expression of the hVR1d protein product can be assessed immunologically, for example by Western blots, immunoassays such as radioimmuno-precipitation, enzyme-linked immunoassays and the like. The ultimate test of the success of the expression system, however, involves the detection of biologically active hVR1d gene product. A number of assays can be used to detect hVR1d activity including but not limited to binding assays and biological assays for hVR1d activity.

Once a clone that produces high levels of a biologically active hVR1d polypeptide is identified, the clone may be expanded and used to produce large amounts of the polypeptide which may be purified using techniques well known in the art, including but not limited to, immunoaffinity purification using antibodies, immunoprecipitation or chromatographic methods including high performance liquid chromatography (HPLC).

Where the hVR1d coding sequence is engineered to encode a cleavable fusion protein, purification may be readily accomplished using affinity purification techniques. For example, a collagenase cleavage recognition consensus sequence may be engineered between the carboxy terminus of hVR1d and protein A. The resulting fusion protein may be readily purified using an IgG column that binds the protein A moiety. Unfused hVR1d may be readily released from the column by treatment with collagenase. Another example would be the use of pGEX vectors that express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). The fusion protein may be engineered with either thrombin or factor Xa cleavage sites between the cloned gene and the GST moiety. The fusion protein may be easily purified from cell extracts by adsorption to glutathione agarose beads followed by elution in the presence of glutathione. In fact, any cleavage site or enzyme cleavage substrate may be engineered between the hVR1d gene product sequence and a second peptide or protein that has a binding partner which could be used for purification, e.g., any antigen for which an immunoaffinity column can be prepared.

In addition, hVR1d fusion proteins may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused

to an amino-terminal tag consisting of six histidine residues. Extracts from cells
5 infected with recombinant vaccinia virus are loaded onto Ni^{2+} -nitriloacetic acid-
agarose columns and histidine-tagged proteins are selectively eluted with imidazole-
containing buffers.

Alternatively, the hVR1d proteins and polypeptides of the invention can be
produced using chemical methods to synthesize the hVR1d amino acid sequences in
10 whole or in part. For example, peptides can be synthesized by solid phase techniques,
cleaved from the resin, and purified by preparative high performance liquid
chromatography (see, e.g., Creighton, 1983, Proteins Structures And Molecular
Principles, W.H. Freeman and Co., N.Y., pp. 50-60). The composition of the
synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the
15 Edman degradation procedure; see Creighton, 1983, Proteins, Structures and
Molecular Principles, W.H. Freeman and Co., N.Y., pp. 34-49).

The hVR1d proteins, polypeptides and peptide fragments, mutated, truncated
or deleted forms of hVR1d and/or hVR1d fusion proteins can be prepared for various
uses, including but not limited to, the generation of antibodies, as reagents in
20 diagnostic assays, the identification of other cellular gene products involved in ion
transport, as reagents in assays for screening for compounds for use in the treatment of
ion channel disorders.

5.3. ANTIBODIES TO hVR1d POLYPEPTIDES

25 The present invention also includes antibodies directed to the hVR1d
polypeptides of this invention and methods for the production of those antibodies,
including antibodies that specifically recognize one or more hVR1d epitopes or
epitopes of conserved variants or peptide fragments of hVR1d.

Such antibodies may include, but are not limited to, polyclonal antibodies,
30 monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain
antibodies, Fab fragments, F(ab')_2 fragments, fragments produced by a Fab expression
library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the
above. Such antibodies may be used, for example, in the detection of a hVR1d
protein or polypeptide in a biological sample and may, therefore, be utilized as part of
35 a diagnostic or prognostic technique whereby patients may be tested for abnormal
levels of hVR1d and/or for the presence of abnormal forms of the protein. Such
antibodies may also be utilized in conjunction with, for example, compound screening

protocols for the evaluation of the effect of test compounds on hVR1d levels and/or
5 activity. Additionally, such antibodies can be used in conjunction with the gene
therapy techniques described in Section 5.4, *infra*, to, for example, evaluate normal
and/or genetically-engineered hVR1d-expressing cells prior to their introduction into
the patient.

For the production of antibodies against hVR1d, various host animals may be
10 immunized by injection with the protein or a portion thereof. Such host animals
include rabbits, mice, rats, and baboons. Various adjuvants may be used to increase
the immunological response, depending on the host species, including but not limited
to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide,
surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides,
15 oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful
human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium
parvum.

Polyclonal antibodies are heterogeneous populations of antibody molecules
derived from the sera of animals immunized with an antigen, such as a hVR1d
20 polypeptide, or an antigenic functional derivative thereof. For the production of
polyclonal antibodies, host animals such as those described above, may be immunized
by injection with the hVR1d polypeptide supplemented with adjuvants as also
described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a
25 particular antigen, may be obtained by any technique which provides for the
production of antibody molecules by continuous cell lines in culture. These include,
but are not limited to, the hybridoma technique of Kohler and Milstein (1975, Nature
256: 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique
(Kosbor et al., 1983, Immunology Today 4: 72; Cole et al., 1983, Proc. Natl. Acad.
30 Sci. USA 80: 2026-2030), and the EBV-hybridoma technique (Cole et al., 1985,
Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such
antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD
and any subclass thereof. The hybridomas producing the monoclonal antibodies of
this invention may be cultivated *in vitro* or *in vivo*.

35 In addition, techniques developed for the production of chimeric antibodies
(Morrison et al., 1984, Proc. Natl. Acad. Sci., 81: 6851-6855; Neuberger et al., 1984,
Nature 312: 604-608; Takeda et al., 1985, Nature 314: 452-454) by splicing the genes

from a mouse antibody molecule of appropriate antigen specificity together with genes
5 from a human antibody molecule of appropriate biological activity can be used. A
chimeric antibody is a molecule in which different portions are derived from different
animal species, such as those having a variable region derived from a murine mAb
and a human immunoglobulin constant region (see, e.g., Cabilly et al., U.S. Patent No.
4,816,567; and Boss et al., U.S. Patent No. 4,816,397.)

10 In addition, techniques have been developed for the production of humanized
antibodies (see, e.g., Queen, U.S. Patent No. 5,585,089). Humanized antibodies are
antibody molecules from non-human species having one or more CDRs from the non-
human species and a framework region from a human immunoglobulin molecule.

Alternatively, techniques described for the production of single chain
15 antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242: 423-426; Huston et al.,
1988, Proc. Natl. Acad. Sci. USA 85: 5879-5883; and Ward et al., 1989, Nature 334:
544-546) can be used in the production of single chain antibodies against hVR1d.
Single chain antibodies are formed by linking the heavy and light chain fragments of
the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

20 Furthermore, antibody fragments which recognize specific epitopes of hVR1d
may be produced by techniques well known in the art. For example, such fragments
include but are not limited to, F(ab')₂ fragments which can be produced by pepsin
digestion of the antibody molecule and Fab fragments which can be generated by
reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression
25 libraries may be constructed (Huse et al., 1989, Science 246: 1275-1281) to allow
rapid and easy identification of monoclonal Fab fragments with the desired specificity.

5.4. USES OF THE hVR1d NUCLEIC ACID MOLECULES, PROTEINS AND POLYPEPTIDES, AND ANTIBODIES 30 OF THE INVENTION

As discussed supra, the hVR1d nucleic acid molecules of this invention
encode proteins that are involved in the formation and/or function of ion channels,
more particularly, cation channels. Given the importance of cations such as calcium,
sodium or potassium in many cellular processes, the hVR1d nucleic acid molecules
35 and proteins and polypeptides of this invention are useful for the diagnosis and
treatment of a variety of human disease conditions which involve ion, more
particularly, cation, channel dysfunction. For example, calcium plays a role in the

release of neurotransmitters, hormones and other circulating factors, the expression of numerous regulatory genes as well as the cellular process of apoptosis or cell death. Potassium provides for neuroprotection and also affects insulin secretion. Sodium is involved in the regulation of normal neuronal action potential generation and propagation. Sodium channel blockers such as lidocaine are important analgesics. Therefore, cation channel dysfunction may play a role in many human diseases and disorders such as CNS disorders, e.g., degenerative neurological disorders such as Alzheimer's disease or Parkinson's disease, as well as other neurological disorders such chronic pain, anxiety and depression. Other diseases and disorders that can be affected by ion channel dysfunction include cardiac disorders, e.g., arrhythmia, diabetes, hypercalcemia, hypercalciuria, or ion channel dysfunction that is associated with immunological disorders, GI tract disorders or renal or liver disease. As such, proteins that are involved in either the formation or function of these ion channels (and the nucleic acids that encode those proteins) are useful for the diagnosis and treatment of many human diseases.

Among the uses for the nucleic acid molecules, proteins and polypeptides of the invention are the prognostic and diagnostic evaluation of human disorders involving ion/cation channel dysfunction, and the identification of subjects with a predisposition to such disorders, as described below. Other uses include methods for the treatment of such ion/cation channel dysfunction disorders, for the modulation of hVR1d gene-mediated activity, and for the modulation of hVR1d-mediated effector functions.

In addition, the nucleic acid molecules and proteins and polypeptides of the invention can be used in assays for the identification of compounds which modulate the expression of the hVR1d genes of the invention and/or the activity of the hVR1d gene products. Such compounds can include, for example, other cellular products or small molecule compounds that are involved in cation homeostasis or activity.

5.4.1. DIAGNOSIS AND PROGNOSIS OF ION-RELATED DISORDERS

Methods of the invention for the diagnosis and prognosis of human diseases involving ion, e.g., cation, dysfunction may utilize reagents such as the hVR1d nucleic acid molecules and sequences described in Sections 5.1, supra, or antibodies directed against hVR1d proteins or polypeptides, including peptide fragments thereof, as described in Section 5.3., supra. Specifically, such reagents may be used, for

example, for: (1) the detection of the presence of hVR1d gene mutations, or the
5 detection of either over- or under-expression of hVR1d gene mRNA relative to the
non-cation dysfunctional state or the qualitative or quantitative detection of
alternatively-spliced forms of hVR1d transcripts which may correlate with certain ion
homeostasis disorders or susceptibility toward such disorders; and (2) the detection of
either an over- or an under-abundance of hVR1d gene product relative to the non-
10 cation dysfunctional state or the presence of a modified (e.g., less than full length)
hVR1d gene product which correlates with a cation dysfunctional state or a
progression toward such a state.

The methods described herein may be performed, for example, by utilizing
pre-packaged diagnostic test kits comprising at least one specific hVR1d gene nucleic
15 acid or anti-hVR1d gene antibody reagent described herein, which may be
conveniently used, e.g., in clinical settings, to screen and diagnose patients exhibiting
ion/cation channel/homeostasis abnormalities and to screen and identify those
individuals exhibiting a predisposition to such abnormalities.

For the detection of hVR1d mutations, any nucleated cell can be used as a
20 starting source for genomic nucleic acid. For the detection of hVR1d transcripts or
hVR1d gene products, any cell type or tissue in which the hVR1d gene is expressed
may be utilized.

Nucleic acid-based detection techniques are described in Section 5.4.1.1.,
infra, whereas peptide-based detection techniques are described in Section 5.4.1.2.,
25 infra.

5.4.1.1. DETECTION OF hVR1d GENE NUCLEIC ACID MOLECULES

Mutations or polymorphisms within the hVR1d gene can be detected by
utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as
30 the starting point for such assay techniques, and may be isolated according to standard
nucleic acid preparation procedures which are well known to those of skill in the art.

Genomic DNA may be used in hybridization or amplification assays of
biological samples to detect abnormalities involving hVR1d gene structure, including
point mutations, insertions, deletions and chromosomal rearrangements. Such assays
35 may include, but are not limited to, direct sequencing (Wong, C. et al., 1987, Nature
330:384-386), single stranded conformational polymorphism analyses (SSCP; Orita,
M. et al., 1989, Proc. Natl. Acad. Sci. USA 86:2766-2770), heteroduplex analysis

(Keen, T.J. et al., 1991, Genomics 11:199-205; Perry, D.J. & Carrell, R.W., 1992),
5 denaturing gradient gel electrophoresis (DGGE; Myers, R.M. et al., 1985, Nucl. Acids
Res. 13:3131-3145), chemical mismatch cleavage (Cotton, R.G. et al., 1988, Proc.
Natl. Acad. Sci. USA 85:4397-4401) and oligonucleotide hybridization (Wallace,
R.B. et al., 1981, Nucl. Acids Res. 9:879-894; Lipshutz, R.J. et al., 1995,
Biotechniques 19:442-447).

10 Diagnostic methods for the detection of hVR1d gene-specific nucleic acid
molecules, in patient samples or other appropriate cell sources, may involve the
amplification of specific gene sequences, e.g., by PCR, followed by the analysis of the
amplified molecules using techniques well known to those of skill in the art, such as,
for example, those listed above. Utilizing analysis techniques such as these, the
15 amplified sequences can be compared to those which would be expected if the nucleic
acid being amplified contained only normal copies of the hVR1d gene in order to
determine whether a hVR1d gene mutation exists.

Further, well-known genotyping techniques can be performed to type
polymorphisms that are in close proximity to mutations in the hVR1d gene itself.
20 These polymorphisms can be used to identify individuals in families likely to carry
mutations. If a polymorphism exhibits linkage disequilibrium with mutations in the
hVR1d gene, it can also be used to identify individuals in the general population likely
to carry mutations. Polymorphisms that can be used in this way include restriction
fragment length polymorphisms (RFLPs), which involve sequence variations in
25 restriction enzyme target sequences, single-base polymorphisms and simple sequence
repeat polymorphisms (SSLPs).

For example, Weber (U.S. Pat. No. 5,075,217) describes a DNA marker based
on length polymorphisms in blocks of (dC-dA)_n-(dG-dT)_n short tandem repeats. The
average separation of (dC-dA)_n-(dG-dT)_n blocks is estimated to be 30,000-60,000 bp.
30 Markers which are so closely spaced exhibit a high frequency co-inheritance, and are
extremely useful in the identification of genetic mutations, such as, for example,
mutations within the hVR1d gene, and the diagnosis of diseases and disorders related
to hVR1d mutations.

Also, Caskey et al. (U.S. Pat. No. 5,364,759) describe a DNA profiling assay
35 for detecting short tri- and tetra- nucleotide repeat sequences. The process includes
extracting the DNA of interest, such as the hVR1d gene, amplifying the extracted

DNA, and labelling the repeat sequences to form a genotypic map of the individual's
5 DNA.

A hVR1d probe could additionally be used to directly identify RFLPs. Additionally, a hVR1d probe or primers derived from the hVR1d sequences of the invention could be used to isolate genomic clones such as YACs, BACs, PACs, cosmids, phage or plasmids. The DNA contained in these clones can be screened for
10 single-base polymorphisms or simple sequence length polymorphisms (SSLPs) using standard hybridization or sequencing procedures.

Alternative diagnostic methods for the detection of hVR1d gene-specific mutations or polymorphisms can include hybridization techniques which involve for example, contacting and incubating nucleic acids including recombinant DNA
15 molecules, cloned genes or degenerate variants thereof, obtained from a sample, e.g., derived from a patient sample or other appropriate cellular source, with one or more labeled nucleic acid reagents including the hVR1d nucleic acid molecules of the invention including recombinant DNA molecules, cloned genes or degenerate variants thereof, as described in Section 5.1 supra, under conditions favorable for the specific
20 annealing of these reagents to their complementary sequences within the hVR1d gene. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:hVR1d molecule hybrid. The presence of nucleic acids which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic
25 acid from the cell type or tissue of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this case, after incubation, non-annealed, labeled nucleic acid molecules of the invention as described in Section 5.1 are easily removed. Detection of the remaining, annealed, labeled hVR1d nucleic acid reagents is accomplished
30 using standard techniques well-known to those in the art. The hVR1d gene sequences to which the nucleic acid molecules of the invention have annealed can be compared to the annealing pattern expected from a normal hVR1d gene sequence in order to determine whether a hVR1d gene mutation is present.

Quantitative and qualitative aspects of hVR1d gene expression can also be
35 assayed. For example, RNA from a cell type or tissue known, or suspected, to express the hVR1d gene may be isolated and tested utilizing hybridization or PCR techniques as described supra. The isolated cells can be derived from cell culture or from a

patient. The analysis of cells taken from culture may be a necessary step in the
5 assessment of cells to be used as part of a cell-based gene therapy technique or,
alternatively, to test the effect of compounds on the expression of the hVR1d gene.
Such analyses may reveal both quantitative and qualitative aspects of the expression
pattern of the hVR1d gene, including activation or inactivation of hVR1d gene
expression and presence of alternatively spliced hVR1d transcripts.

10 In one embodiment of such a detection scheme, a cDNA molecule is
synthesized from an RNA molecule of interest (e.g., by reverse transcription of the
RNA molecule into cDNA). All or part of the resulting cDNA is then used as the
template for a nucleic acid amplification reaction, such as a PCR amplification
reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents
15 (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this
method are chosen from among the hVR1d nucleic acid molecules of the invention as
described in Section 5.1, supra. The preferred lengths of such nucleic acid reagents
are at least 9-30 nucleotides.

For detection of the amplified product, the nucleic acid amplification may be
20 performed using radioactively or non-radioactively labeled nucleotides. Alternatively,
enough amplified product may be made such that the product may be visualized by
standard ethidium bromide staining or by utilizing any other suitable nucleic acid
staining protocol or e.g., quantitative PCR.

Such RT-PCR techniques can be utilized to detect differences in hVR1d
25 transcript size which may be due to normal or abnormal alternative splicing.
Additionally, such techniques can be utilized to detect quantitative differences
between levels of full length and/or alternatively-spliced hVR1d transcripts detected
in normal individuals relative to those individuals exhibiting ion dysfunction disorders
or exhibiting a predisposition to toward such disorders.

30 In the case where detection of specific alternatively-spliced species is desired,
appropriate primers and/or hybridization probes can be used, such that, in the absence
of such sequence, no amplification would occur. Alternatively, primer pairs may be
chosen utilizing the sequences depicted in FIGS. 1A or 1B to choose primers which
will yield fragments of differing size depending on whether a particular exon is
35 present or absent from the hVR1d transcript being utilized.

As an alternative to amplification techniques, standard Northern analyses can
be performed if a sufficient quantity of the appropriate cells can be obtained.

Utilizing such techniques, quantitative as well as size-related differences between
5 hVR1d transcripts can also be detected.

Additionally, it is possible to perform hVR1d gene expression assays in situ,
i.e., directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from
biopsies or resections, such that no nucleic acid purification is necessary. The nucleic
acid molecules of the invention as described in Section 5.1 may be used as probes
10 and/or primers for such in situ procedures (see, for example, Nuovo, G.J., 1992, "PCR
In Situ Hybridization: Protocols And Applications", Raven Press, NY).

5.4.1.2. DETECTION OF hVR1d GENE PRODUCTS

Antibodies directed against wild type or mutant hVR1d gene products or
15 conserved variants or peptide fragments thereof as described supra may also be used
for the diagnosis and prognosis of ion or cation-related disorders. Such diagnostic
methods may be used to detect abnormalities in the level of hVR1d gene expression or
abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location
of hVR1d gene products. Antibodies, or fragments of antibodies, may be used to
20 screen potentially therapeutic compounds in vitro to determine their effects on hVR1d
gene expression and hVR1d peptide production. The compounds which have
beneficial effects on ion and cation-related disorders can be identified and a
therapeutically effective dose determined.

In vitro immunoassays may be used, for example, to assess the efficacy of cell-
25 based gene therapy for ion or cation-related disorders. For example, antibodies
directed against hVR1d peptides may be used in vitro to determine the level of hVR1d
gene expression achieved in cells genetically engineered to produce hVR1d peptides.
Such analysis will allow for a determination of the number of transformed cells
necessary to achieve therapeutic efficacy in vivo, as well as optimization of the gene
30 replacement protocol.

The tissue or cell type to be analyzed will generally include those which are
known, or suspected, to express the hVR1d gene. The protein isolation methods
employed may, for example, be such as those described in Harlow, E. and Lane, D.,
1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press,
35 Cold Spring Harbor, New York. The isolated cells can be derived from cell culture or
from a patient. The analysis of cells taken from culture may be a necessary step in the

assessment of cells to be used as part of a cell-based gene therapy technique or,
5 alternatively, to test the effect of compounds on the expression of the hVR1d gene.

Preferred diagnostic methods for the detection of hVR1d gene products or conserved variants or peptide fragments thereof, may involve, for example, immunoassays wherein the hVR1d gene products or conserved variants, including gene products which are the result of alternatively-spliced transcripts, or peptide
10 fragments are detected by their interaction with an anti-hVR1d gene product-specific antibody. For example, antibodies, or fragments of antibodies, such as those described in Section 5.3 supra, may be used to quantitatively or qualitatively detect the presence of hVR1d gene products or conserved variants or peptide fragments thereof. The antibodies (or fragments thereof) may, additionally, be employed
15 histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of hVR1d gene products or conserved variants or peptide fragments thereof. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled hVR1d antibody of the present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or
20 fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the hVR1d gene product, or conserved variants or peptide fragments, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order
25 to achieve such in situ detection.

Immunoassays for hVR1d gene products or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of
30 identifying hVR1d gene products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is
35 capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled hVR1d gene specific antibody. The solid phase support may then be washed with the

buffer a second time to remove unbound antibody. The amount of bound label on
5 solid support may then be detected by conventional means.

By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be
10 either soluble to some extent or insoluble. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.
15 Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of anti-hVR1d gene product antibody may be determined according to well known methods. Those skilled in the art will be able
20 to determine operative and optimal assay conditions for each determination by employing routine experimentation.

One of the ways in which the hVR1d gene peptide-specific antibody can be detectably labeled is by linking the antibody to an enzyme in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978,
25 Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller, A. et al., 1978, J. Clin. Pathol. 31:507-520; Butler, J.E., 1981, Meth. Enzymol. 73:482-523; Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL.; Ishikawa, E. et al., (eds.), 1981, Enzyme Immunoassay, Kaku Shoin, Tokyo). The enzyme which is bound to the antibody will react with an
30 appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase,
35 alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and

acetylcholinesterase. The detection can be accomplished by colorimetric methods
5 which employ a chromogenic substrate for the enzyme. Detection may also be
accomplished by visual comparison of the extent of enzymatic reaction of a substrate
in comparison with similarly prepared standards.

Detection may also be accomplished using any of a variety of other
immunoassays. For example, by radioactively labeling the antibodies or antibody
10 fragments, it is possible to detect hVR1d gene peptides through the use of a
radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of
Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques,
The Endocrine Society, March, 1986. The radioactive isotope can be detected by such
means as the use of a gamma counter or a scintillation counter or by autoradiography.

15 It is also possible to label the antibody with a fluorescent compound. When
the fluorescently labeled antibody is exposed to light of the proper wave length, its
presence can then be detected due to fluorescence. Among the most commonly used
fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine,
phycoerythrin, phycocyanin, allophycocyanin, α -phthaldehyde and fluorescamine.

20 The antibody can also be detectably labeled using fluorescence emitting metals
such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the
antibody using such metal chelating groups as diethylenetriaminepentacetic acid
(DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a
25 chemiluminescent compound. The presence of the chemiluminescent-tagged antibody
is then determined by detecting the presence of luminescence that arises during the
course of a chemical reaction. Examples of particularly useful chemiluminescent
labeling compounds are luminol, isoluminol, therrromatic acridinium ester, imidazole,
acridinium salt and oxalate ester.

30 Likewise, a bioluminescent compound may be used to label the antibody of the
present invention. Bioluminescence is a type of chemiluminescence found in
biological systems in which a catalytic protein increases the efficiency of the
chemiluminescent reaction. The presence of a bioluminescent protein is determined
by detecting the presence of luminescence. Important bioluminescent compounds for
35 purposes of labeling are luciferin, luciferase and aequorin.

5.4.2. SCREENING ASSAYS FOR COMPOUNDS THAT MODULATE hVR1d ACTIVITY

5 Screening assays can be used to identify compounds that modulate hVR1d activity. These compounds can include, but are not limited to, peptides, small organic or inorganic molecules or macromolecules such as nucleic acid molecules or proteins, and may be utilized, e.g., in the control of ion and cation-related disorders, in the modulation of cellular processes such as the release of neurotransmitters or other
10 cellular regulatory factors, cell activation or regulation, cell death and changes in cell membrane properties. These compounds may also be useful, e.g., in elaborating the biological functions of hVR1d gene products, i.e., hVR1 proteins and polypeptides, modulating those biological functions and for ameliorating symptoms of ion or cation-related disorders.

15 The compositions of the invention include pharmaceutical compositions comprising one or more of these compounds. Such pharmaceutical compositions can be formulated as discussed in Section 5.5, *infra*.

More specifically, these compounds can include compounds that bind to hVR1d gene products, compounds that bind to other proteins that interact with a
20 hVR1d gene product and/or interfere with the interaction of the hVR1d gene product with other proteins, and compounds that modulate the activity of the hVR1d gene, i.e., modulate the level of hVR1d gene expression and/or modulate the level of hVR1d gene product or protein activity.

For example, assays may be utilized that identify compounds that bind to
25 hVR1d gene regulatory sequences, e.g., promoter sequences (see e.g., Platt, K.A., 1994, J. Biol. Chem. 269:28558-28562), which compounds may modulate the level of hVR1d gene expression. In addition, functional assays can be used to screen for compounds that modulate hVR1d gene product activity. In such assays, compounds are screened for agonistic or antagonistic activity with respect to a biological activity
30 or function of the hVR1d protein or polypeptide, such as changes in the intracellular levels of an ion or cation, changes in regulatory factor release, or other activities or functions of the hVR1d proteins and polypeptides of the invention.

According to a preferred embodiment, a Ca^{2+} flux assay can be utilized to monitor calcium uptake in hVR1d-expressing host cells. The host cells are pre-loaded
35 with a Ca^{2+} -sensitive fluorescently-labeled dye (e.g., Fluo-4, Fluo-3, Indo-1 or Fura-2), i.e., the intracellular calcium is fluorescently labelled with the dye, and the effect of the compound, e.g., on the intracellular levels of the labeled-calcium determined and compared to the intracellular levels of control cells, e.g., lacking exposure to the

compound of interest. Compounds that have an agonistic, i.e., stimulatory, modulatory effect on hVR1d activity are those that, when contacted with the hVR1d-expressing cells, produce an increase in intracellular calcium relative to the control cells, whereas those compounds having an antagonistic modulatory effect on hVR1d activity will be those that produce a decrease in intracellular calcium.

Functional assays for monitoring the effects of compounds on the levels or flux of other ions can be similarly performed; for example, the levels of potassium can be monitored using rubidium influx.

Screening assays may also be designed to identify compounds capable of binding to the hVR1d gene product of the invention. Such compounds may be useful, e.g., in modulating the activity of wild type and/or mutant hVR1d gene products, in elaborating the biological function of the hVR1d gene product, and in screens for identifying compounds that disrupt normal hVR1d gene product interactions, or may in themselves disrupt such interactions.

The principle of such screening assays to identify compounds that bind to the hVR1d gene product involves preparing a reaction mixture of the hVR1d gene product and the test compound under conditions and for a time sufficient to allow the two components to interact with, i.e., bind to, and thus form a complex, which can represent a transient complex, which can be removed and/or detected in the reaction mixture. For example, one assay involves anchoring a hVR1d gene product or the test substance onto a solid phase and detecting hVR1d gene product/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the hVR1d gene product may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.

The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously non-immobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using

an immobilized antibody specific for hVR1d gene product or the test compound to
5 anchor any complexes formed in solution, and a labeled antibody specific for the other
component of the possible complex to detect anchored complexes.

Compounds that modulate hVR1d gene product activity can also include
compounds that bind to proteins that interact with the hVR1d gene product. These
modulatory compounds can be identified by first identifying those proteins that
10 interact with the hVR1d gene product, e.g., by standard techniques known in the art
for detecting protein-protein interactions, such as co-immunoprecipitation,
crosslinking and co-purification through gradients or chromatographic columns.
Utilizing procedures such as these allows for the isolation of proteins that interact
with hVR1d gene products or polypeptides of the invention as described supra.

15 Once isolated, such a protein can be identified and can, in turn, be used, in
conjunction with standard techniques, to identify additional proteins with which it
interacts. For example, at least a portion of the amino acid sequence of the protein
that interacts with the hVR1d gene product can be ascertained using techniques well
known to those of skill in the art, such as via the Edman degradation technique (see,
20 e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles", W.H. Freeman
& Co., N.Y., pp.34-49). The amino acid sequence thus obtained may be used as a
guide for the generation of oligonucleotide mixtures that can be used to screen for
gene sequences encoding such proteins. Screening may be accomplished, for
example, by standard hybridization or PCR techniques. Techniques for the generation
25 of oligonucleotide mixtures and screening are well-known (see, e.g., Ausubel, supra,
and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds.
Academic Press, Inc., New York).

Additionally, methods may be employed that result in the simultaneous
identification of genes which encode proteins interacting with hVR1d gene products
30 or polypeptides. These methods include, for example, probing expression libraries
with labeled hVR1d protein or polypeptide, using hVR1d protein or polypeptide in a
manner similar to the well known technique of antibody probing of λ gt11 libraries.
One method that detects protein interactions in vivo is the two-hybrid system. A
version of this system is described by Chien et al., 1991, Proc. Natl. Acad. Sci. USA,
35 88:9578-9582 and is commercially available from Clontech (Palo Alto, CA).

In addition, compounds that disrupt hVR1d interactions with its interacting or
binding partners, as determined immediately above, may be useful in regulating the

activity of the hVR1d gene product, including mutant hVR1d proteins and
5 polypeptide. Such compounds may include, but are not limited to, molecules such as peptides, and the like, which may bind to the hVR1d gene product as described above.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the hVR1d gene product and its interacting partner or partners involves preparing a reaction mixture containing the hVR1d gene
10 product, and the interacting partner under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of hVR1d gene product and its
15 interacting partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the hVR1d gene product and the interacting partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the hVR1d gene product
20 and the interacting partner. Additionally, complex formation within reaction mixtures containing the test compound and a normal hVR1d gene product may also be compared to complex formation within reaction mixtures containing the test compound and a mutant hVR1d gene product. This comparison may be important in those cases wherein it is desirable to identify compounds that disrupt interactions of
25 mutant but not normal hVR1d proteins.

The assay for compounds that interfere with the interaction of hVR1d gene products and interacting partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the hVR1d gene product or the binding partner onto a solid phase and detecting complexes
30 anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the hVR1d gene products and the interacting partners, e.g., by
35 competition, can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the hVR1d gene product and interacting partner. Alternatively,

test compounds that disrupt preformed complexes, e.g., compounds with higher
5 binding constants that displace one of the components from the complex, can be
tested by adding the test compound to the reaction mixture after complexes have been
formed. The various formats are described briefly below.

In a heterogeneous assay system, either the hVR1d gene product or the
interacting partner, is anchored onto a solid surface, while the non-anchored species is
10 labeled, either directly or indirectly. In practice, microtiter plates are conveniently
utilized. The anchored species may be immobilized by non-covalent or covalent
attachments. Non-covalent attachment may be accomplished simply by coating the
solid surface with a solution of the hVR1d gene product or interacting partner and
drying. Alternatively, an immobilized antibody specific for the species to be anchored
15 may be used to anchor the species to the solid surface. The surfaces may be prepared
in advance and stored.

In order to conduct the assay, the partner of the immobilized species is
exposed to the coated surface with or without the test compound. After the reaction is
complete, unreacted components are removed (e.g., by washing) and any complexes
20 formed will remain immobilized on the solid surface. The detection of complexes
anchored on the solid surface can be accomplished in a number of ways. Where the
non-immobilized species is pre-labeled, the detection of label immobilized on the
surface indicates that complexes were formed. Where the non-immobilized species is
not pre-labeled, an indirect label can be used to detect complexes anchored on the
25 surface; e.g., using a labeled antibody specific for the initially non-immobilized
species (the antibody, in turn, may be directly labeled or indirectly labeled with a
labeled anti-Ig antibody). Depending upon the order of addition of reaction
components, test compounds which inhibit complex formation or which disrupt
preformed complexes can be detected.

30 Alternatively, the reaction can be conducted in a liquid phase in the presence
or absence of the test compound, the reaction products separated from unreacted
components, and complexes detected; e.g., using an immobilized antibody specific for
one of the interacting components to anchor any complexes formed in solution, and a
labeled antibody specific for the other partner to detect anchored complexes. Again,
35 depending upon the order of addition of reactants to the liquid phase, test compounds
that inhibit complex formation or that disrupt preformed complexes can be identified.

In an alternate embodiment, a preformed complex of the hVR1d gene protein
5 and the interacting partner is prepared in which either the hVR1d gene product or its
interacting partners is labeled, but the signal generated by the label is quenched due to
complex formation (see, e.g., U.S. Patent No. 4,109,496 by Rubenstein which utilizes
this approach for immunoassays). The addition of a test substance that competes with
and displaces one of the species from the preformed complex will result in the
10 generation of a signal above background. In this way, test substances that disrupt
hVR1d gene protein/interacting partner interaction can be identified.

In another embodiment of the invention, these same techniques can be
employed using peptide fragments that correspond to the binding domains of the
hVR1d protein and/or the interacting partner, in place of one or both of the full length
15 proteins. Any number of methods routinely practiced in the art can be used to identify
and isolate the binding sites. These methods include, but are not limited to,
mutagenesis of the gene encoding one of the proteins and screening for disruption of
binding in a co-immunoprecipitation assay. Compensating mutations in the gene
encoding the second species in the complex can then be selected. Sequence analysis
20 of the genes encoding the respective proteins will reveal the mutations that correspond
to the region of the protein involved in interacting, e.g., binding. Alternatively, one
protein can be anchored to a solid surface using methods described in this Section
above, and allowed to interact with, e.g., bind, to its labeled interacting partner, which
has been treated with a proteolytic enzyme, such as trypsin. After washing, a short,
25 labeled peptide comprising the interacting, e.g., binding, domain may remain
associated with the solid material, which can be isolated and identified by amino acid
sequencing. Also, once the gene coding for the intracellular binding partner is
obtained, short gene segments can be engineered to express peptide fragments of the
protein, which can then be tested for binding activity and purified or synthesized.

30 The human HVR1d polypeptides and/or peptides of the present invention, or
immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic
drugs or compounds in a variety of drug screening techniques. The fragment employed
in such a screening assay may be free in solution, affixed to a solid support, borne on a
cell surface, or located intracellularly. The reduction or abolition of activity of the
35 formation of binding complexes between the ion channel protein and the agent being
tested can be measured. Thus, the present invention provides a method for screening or
assessing a plurality of compounds for their specific binding affinity with a HVR1d

polypeptide, or a bindable peptide fragment, of this invention, comprising providing a plurality of compounds, combining the HVR1d polypeptide, or a bindable peptide fragment, with each of a plurality of compounds for a time sufficient to allow binding under suitable conditions and detecting binding of the HVR1d polypeptide or peptide to each of the plurality of test compounds, thereby identifying the compounds that specifically bind to the HVR1d polypeptide or peptide.

Methods of identifying compounds that modulate the activity of the novel human HVR1d polypeptides and/or peptides are provided by the present invention and comprise combining a potential or candidate compound or drug modulator of calpain biological activity with an HVR1d polypeptide or peptide, for example, the HVR1d amino acid sequence as set forth in SEQ ID NOS:2, and measuring an effect of the candidate compound or drug modulator on the biological activity of the HVR1d polypeptide or peptide. Such measurable effects include, for example, physical binding interaction; the ability to cleave a suitable calpain substrate; effects on native and cloned HVR1d-expressing cell line; and effects of modulators or other calpain-mediated physiological measures.

Another method of identifying compounds that modulate the biological activity of the novel HVR1d polypeptides of the present invention comprises combining a potential or candidate compound or drug modulator of a calpain biological activity with a host cell that expresses the HVR1d polypeptide and measuring an effect of the candidate compound or drug modulator on the biological activity of the HVR1d polypeptide. The host cell can also be capable of being induced to express the HVR1d polypeptide, e.g., via inducible expression. Physiological effects of a given modulator candidate on the HVR1d polypeptide can also be measured. Thus, cellular assays for particular calpain modulators may be either direct measurement or quantification of the physical biological activity of the HVR1d polypeptide, or they may be measurement or quantification of a physiological effect. Such methods preferably employ a HVR1d polypeptide as described herein, or an overexpressed recombinant HVR1d polypeptide in suitable host cells containing an expression vector as described herein, wherein the HVR1d polypeptide is expressed, overexpressed, or undergoes upregulated expression.

Another aspect of the present invention embraces a method of screening for a compound that is capable of modulating the biological activity of a HVR1d polypeptide,

comprising providing a host cell containing an expression vector harboring a nucleic acid
5 sequence encoding a HVR1d polypeptide, or a functional peptide or portion thereof (e.g.,
SEQ ID NOS:2); determining the biological activity of the expressed HVR1d polypeptide
in the absence of a modulator compound; contacting the cell with the modulator
compound and determining the biological activity of the expressed HVR1d polypeptide
10 in the presence of the modulator compound. In such a method, a difference between the
activity of the HVR1d polypeptide in the presence of the modulator compound and in the
absence of the modulator compound indicates a modulating effect of the compound.

Essentially any chemical compound can be employed as a potential modulator or
ligand in the assays according to the present invention. Compounds tested as calpain
15 modulators can be any small chemical compound, or biological entity (e.g., protein,
sugar, nucleic acid, lipid). Test compounds will typically be small chemical molecules
and peptides. Generally, the compounds used as potential modulators can be dissolved
in aqueous or organic (e.g., DMSO-based) solutions. The assays are designed to screen
large chemical libraries by automating the assay steps and providing compounds from any
20 convenient source. Assays are typically run in parallel, for example, in microtiter formats
on microtiter plates in robotic assays. There are many suppliers of chemical compounds,
including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis,
MO), Fluka Chemika-Biochemika Analytika (Buchs, Switzerland), for example. Also,
25 compounds may be synthesized by methods known in the art.

High throughput screening methodologies are particularly envisioned for the
detection of modulators of the novel HVR1d polynucleotides and polypeptides described
herein. Such high throughput screening methods typically involve providing a
combinatorial chemical or peptide library containing a large number of potential
30 therapeutic compounds (e.g., ligand or modulator compounds). Such combinatorial
chemical libraries or ligand libraries are then screened in one or more assays to identify
those library members (e.g., particular chemical species or subclasses) that display a
desired characteristic activity. The compounds so identified can serve as conventional
lead compounds, or can themselves be used as potential or actual therapeutics.
35

A combinatorial chemical library is a collection of diverse chemical compounds
generated either by chemical synthesis or biological synthesis, by combining a number
of chemical building blocks (i.e., reagents such as amino acids). As an example, a linear

combinatorial library, e.g., a polypeptide or peptide library, is formed by combining a set
5 of chemical building blocks in every possible way for a given compound length (i.e., the
number of amino acids in a polypeptide or peptide compound). Millions of chemical
compounds can be synthesized through such combinatorial mixing of chemical building
blocks.

10 The preparation and screening of combinatorial chemical libraries is well known
to those having skill in the pertinent art. Combinatorial libraries include, without
limitation, peptide libraries (e.g. U.S. Patent No. 5,010,175; Furka, 1991, *Int. J. Pept.
Prot. Res.*, 37:487-493; and Houghton et al., 1991, *Nature*, 354:84-88). Other
chemistries for generating chemical diversity libraries can also be used. Nonlimiting
15 examples of chemical diversity library chemistries include, peptoids (PCT Publication
No. WO 91/019735), encoded peptides (PCT Publication No. WO 93/20242), random
bio-oligomers (PCT Publication No. WO 92/00091), benzodiazepines (U.S. Patent No.
5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et
al., 1993, *Proc. Natl. Acad. Sci. USA*, 90:6909-6913), vinylogous polypeptides (Hagihara
20 et al., 1992, *J. Amer. Chem. Soc.*, 114:6568), nonpeptidal peptidomimetics with glucose
scaffolding (Hirschmann et al., 1992, *J. Amer. Chem. Soc.*, 114:9217-9218), analogous
organic synthesis of small compound libraries (Chen et al., 1994, *J. Amer. Chem. Soc.*,
116:2661), oligocarbamates (Cho et al., 1993, *Science*, 261:1303), and/or peptidyl
25 phosphonates (Campbell et al., 1994, *J. Org. Chem.*, 59:658), nucleic acid libraries (see
Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (U.S. Patent No.
5,539,083), antibody libraries (e.g., Vaughn et al., 1996, *Nature Biotechnology*,
14(3):309-314) and PCT/US96/10287), carbohydrate libraries (e.g., Liang et al., 1996,
Science, 274-1520-1522) and U.S. Patent No. 5,593,853), small organic molecule
30 libraries (e.g., benzodiazepines, Baum C&EN, Jan. 18, 1993, page 33; and U.S. Patent
No. 5,288,514; isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and
metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735
and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; and the like).

35 Devices for the preparation of combinatorial libraries are commercially available
(e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY; Symphony, Rainin,
Woburn, MA; 433A Applied Biosystems, Foster City, CA; 9050 Plus, Millipore,
Bedford, MA). In addition, a large number of combinatorial libraries are commercially

available (e.g., ComGenex, Princeton, NJ; Asinex, Moscow, Russia; Tripos, Inc., St.
5 Louis, MO; ChemStar, Ltd., Moscow, Russia; 3D Pharmaceuticals, Exton, PA; Martek
Biosciences, Columbia, MD, and the like).

In one embodiment, the invention provides solid phase based *in vitro* assays in
a high throughput format, where the cell or tissue expressing an ion channel is attached
to a solid phase substrate. In such high throughput assays, it is possible to screen up to
10 several thousand different modulators or ligands in a single day. In particular, each well
of a microtiter plate can be used to perform a separate assay against a selected potential
modulator, or, if concentration or incubation time effects are to be observed, every 5-10
wells can test a single modulator. Thus, a single standard microtiter plate can assay about
15 96 modulators. If 1536 well plates are used, then a single plate can easily assay from
about 100 to about 1500 different compounds. It is possible to assay several different
plates per day; thus, for example, assay screens for up to about 6,000-20,000 different
compounds are possible using the described integrated systems.

In another of its aspects, the present invention encompasses screening and small
20 molecule (e.g., drug) detection assays which involve the detection or identification of
small molecules that can bind to a given protein, i.e., a HVR1d polypeptide or peptide.
Particularly preferred are assays suitable for high throughput screening methodologies.

In such binding-based detection, identification, or screening assays, a functional
25 assay is not typically required. All that is needed is a target protein, preferably
substantially purified, and a library or panel of compounds (e.g., ligands, drugs, small
molecules) or biological entities to be screened or assayed for binding to the protein
target. Preferably, most small molecules that bind to the target protein will modulate
activity in some manner, due to preferential, higher affinity binding to functional areas
30 or sites on the protein.

An example of such an assay is the fluorescence based thermal shift assay (3-
Dimensional Pharmaceuticals, Inc., 3DP, Exton, PA) as described in U.S. Patent Nos.
6,020,141 and 6,036,920 to Pantoliano et al.; see also, J. Zimmerman, 2000, *Gen. Eng.*
News, 20(8)). The assay allows the detection of small molecules (e.g., drugs, ligands)
35 that bind to expressed, and preferably purified, ion channel polypeptide based on affinity
of binding determinations by analyzing thermal unfolding curves of protein-drug or
ligand complexes. The drugs or binding molecules determined by this technique can be

further assayed, if desired, by methods, such as those described herein, to determine if the
5 molecules affect or modulate function or activity of the target protein.

To purify a HVR1d polypeptide or peptide to measure a biological binding or
ligand binding activity, the source may be a whole cell lysate that can be prepared by
successive freeze-thaw cycles (e.g., one to three) in the presence of standard protease
10 inhibitors. The HVR1d polypeptide may be partially or completely purified by standard
protein purification methods, e.g., affinity chromatography using specific antibody
described *infra*, or by ligands specific for an epitope tag engineered into the recombinant
HVR1d polypeptide molecule, also as described herein. Binding activity can then be
measured as described.

15 Compounds which are identified according to the methods provided herein, and
which modulate or regulate the biological activity or physiology of the HVR1d
polypeptides according to the present invention are a preferred embodiment of this
invention. It is contemplated that such modulatory compounds may be employed in
treatment and therapeutic methods for treating a condition that is mediated by the novel
20 HVR1d polypeptides by administering to an individual in need of such treatment a
therapeutically effective amount of the compound identified by the methods described
herein.

In addition, the present invention provides methods for treating an individual in
25 need of such treatment for a disease, disorder, or condition that is mediated by the
HVR1d polypeptides of the invention, comprising administering to the individual a
therapeutically effective amount of the HVR1d-modulating compound identified by a
method provided herein.

30

5.4.3. METHODS AND COMPOSITIONS FOR THE TREATMENT OF ION CHANNEL-RELATED DISORDERS

The present invention also relates to methods and compositions for the
treatment or modulation of any disorder or cellular process that is mediated or
35 regulated by hVR1d gene product expression or function, e.g., hVR1d-mediated cell
activation, signal transduction, cellular regulatory factor release, etc. Further, hVR1d
effector functions can be modulated via such methods and compositions.

The methods of the invention include methods that modulate hVR1d gene and
5 gene product activity. In certain instances, the treatment will require an increase,
upregulation or activation of hVR1d activity, while in other instances, the treatment
will require a decrease, downregulation or suppression of hVR1d activity. "Increase"
and "decrease" refer to the differential level of hVR1d activity relative to hVR1d
activity in the cell type of interest in the absence of modulatory treatment. Methods
10 for the decrease of hVR1d activity are discussed in Section 5.4.3.1, infra. Methods for
the increase of hVR1d activity are discussed in Section 5.4.3.2, infra. Methods which
can either increase or decrease hVR1d activity depending on the particular manner in
which the method is practiced are discussed in Section 5.4.3.3, infra.

15 5.4.3.1 METHODS FOR DECREASING hVR1d ACTIVITY

Successful treatment of ion channel/ionic homeostasis disorders, e.g., CNS
disorders, cardiac disorders or hypercalcemia, can be brought about by methods which
serve to decrease hVR1d activity. Activity can be decreased by, e.g., directly
decreasing hVR1d gene product, i.e., protein, activity and/or by decreasing the level of
20 hVR1d gene expression.

For example, compounds such as those identified through assays described in
Section 5.4.2., supra, that decrease hVR1d gene product activity can be used in
accordance with the invention to ameliorate symptoms associated with ion
channel/ionic homeostasis disorders. As discussed supra, such molecules can include,
25 but are not limited to peptides, including soluble peptides, and small organic or
inorganic molecules, and can be referred to as hVR1d antagonists. Techniques for the
determination of effective doses and administration of such compounds are described
in Section 5.5., infra.

In addition, antisense and ribozyme molecules that inhibit hVR1d gene
30 expression can also be used to reduce the level of hVR1d gene expression, thus
effectively reducing the level of hVR1d gene product present, thereby decreasing the
level of hVR1d protein activity. Still further, triple helix molecules can be utilized in
reducing the level of hVR1d gene expression. Such molecules can be designed to
reduce or inhibit either wild type, or if appropriate, mutant target gene activity.
35 Techniques for the production and use of such molecules are well known to those of
skill in the art.

Antisense approaches involve the design of oligonucleotides (either DNA or
5 RNA) that are complementary to hVR1d gene mRNA. The antisense oligonucleotides
will bind to the complementary hVR1d gene mRNA transcripts and prevent
translation. Absolute complementarity, although preferred, is not required. A
sequence "complementary" to a portion of an RNA, as referred to herein, means a
sequence having sufficient complementarity to be able to hybridize with the RNA,
10 forming a stable duplex; in the case of double-stranded antisense nucleic acids, a
single strand of the duplex DNA may thus be tested, or triplex formation may be
assayed. The ability to hybridize will depend on both the degree of complementarity
and the length of the antisense nucleic acid. Generally, the longer the hybridizing
nucleic acid, the more base mismatches with an RNA it may contain and still form a
15 stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a
tolerable degree of mismatch by use of standard procedures to determine the melting
point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the
5' untranslated sequence up to and including the AUG initiation codon, should work
20 most efficiently at inhibiting translation. However, sequences complementary to the
3' untranslated sequences of mRNAs have recently been shown to be effective at
inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, Nature
372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non-
translated, non-coding regions of, e.g., the hVR1d.1 or hVR1d.2 nucleic acids
25 depicted in FIG. 1 could be used in an antisense approach to inhibit translation of
endogenous hVR1d gene mRNA.

Oligonucleotides complementary to the 5' untranslated region of the mRNA
should include the complement of the AUG start codon. Antisense oligonucleotides
complementary to mRNA coding regions are less efficient inhibitors of translation but
30 could be used in accordance with the invention. Whether designed to hybridize to the
5', 3'- or coding region of target or pathway gene mRNA, antisense nucleic acids
should be at least six nucleotides in length, and are preferably oligonucleotides
ranging from 6 to about 50 nucleotides in length. In specific aspects, the
oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25
35 nucleotides or at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies
are first performed to quantitate the ability of the antisense oligonucleotide to inhibit

gene expression. It is preferred that these studies utilize controls that distinguish
5 between antisense gene inhibition and non-specific biological effects of
oligonucleotides. It is also preferred that these studies compare levels of the target
RNA or protein with that of an internal control RNA or protein. Additionally, results
obtained using the antisense oligonucleotide are preferably compared with those
obtained using a control oligonucleotide. It is preferred that the control
10 oligonucleotide is of approximately the same length as the antisense oligonucleotide
and that the nucleotide sequence of the control oligonucleotide differs from the
antisense sequence no more than is necessary to prevent specific hybridization to the
target sequence.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives
15 or modified versions thereof, single-stranded or double-stranded. The oligonucleotide
can be modified at the base moiety, sugar moiety, or phosphate backbone, for
example, to improve stability of the molecule, hybridization, etc.

The oligonucleotide may also include other appended groups such as peptides
(e.g., for targeting host cell receptors in vivo), or agents facilitating transport across
20 the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A.
86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT
Application No.

WO 88/09810) or the blood-brain barrier (see, e.g., PCT Application No. WO
89/10134), or hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988,
25 BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res.
5:539-549). For example, the oligonucleotide may be conjugated to another molecule,
e.g., a peptide, hybridization triggered cross-linking agent, transport agent,
hybridization-triggered cleavage agent, etc.

Oligonucleotides of the invention may be synthesized by standard methods
30 known in the art, e.g., by use of an automated DNA synthesizer (such as are
commercially available from Biosearch, Applied Biosystems, etc.). As examples,
phosphorothioate oligonucleotides may be synthesized by the method of Stein et al.
(1988, Nucl. Acids Res. 16:3209) and methylphosphonate oligonucleotides can be
prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc.
35 Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

The antisense molecules should be delivered to cells which express the hVR1d
gene in vivo. A number of methods have been developed for delivering antisense

DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue
5 site or modified antisense molecules designed to target the desired cells (e.g.,
antisense linked to peptides or antibodies that specifically bind receptors or antigens
expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of the
antisense sufficient to suppress translation of endogenous mRNAs. Thus, a preferred
10 approach utilizes a recombinant DNA construct in which the antisense
oligonucleotide is placed under the control of a strong pol III or pol II promoter. The
use of such a construct to transfect target cells in the patient will result in the
transcription of sufficient amounts of single stranded RNAs that will form
complementary base pairs with the endogenous hVR1d gene transcripts and thereby
15 prevent translation of the hVR1d gene mRNA. For example, a vector can be
introduced in vivo such that it is taken up by a cell and directs the transcription of an
antisense RNA.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific
cleavage of RNA (For a review, see, e.g., Rossi, J., 1994, Current Biology 4:469-471).
20 The mechanism of ribozyme action involves sequence-specific hybridization of the
ribozyme molecule to complementary target RNA, followed by an endonucleolytic
cleavage. The composition of ribozyme molecules must include one or more
sequences complementary to the target gene mRNA, and must include the well known
catalytic sequence responsible for mRNA cleavage. For this sequence, see United
25 States Patent No. 5,093,246, which is incorporated by reference herein in its entirety.
As such, within the scope of the invention are engineered hammerhead motif
ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage
of RNA sequences encoding target gene proteins. Ribozyme molecules designed to
catalytically cleave hVR1d gene mRNA transcripts can also be used to prevent
30 translation of hVR1d gene mRNA and expression of target or pathway genes. (See,
e.g., PCT Application No. WO 90/11364; Sarver et al., 1990, Science 247:1222-
1225).

The ribozymes of the present invention also include RNA endoribonucleases
(hereinafter referred to as "Cech-type ribozymes") such as the one which occurs
35 naturally in Tetrahymena Thermophila (known as the IVS, or L-19 IVS RNA) and
which has been extensively described by Thomas Cech and collaborators (Zaug, et al.,
1984, Science, 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et

al., 1986, Nature, 324:429-433; PCT Patent Application No. WO 88/04300; Been and
5 Cech, 1986, Cell, 47:207-216). The Cech-type ribozymes have an eight base pair
active site which hybridizes to a target RNA sequence, after which cleavage of the
target RNA takes place. The invention encompasses those Cech-type ribozymes
which target eight base-pair active site sequences that are present in an hVR1d gene.

As in the antisense approach, the ribozymes can be composed of modified
10 oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered
to cells which express the hVR1d gene in vivo. A preferred method of delivery
involves using a DNA construct "encoding" the ribozyme under the control of a strong
constitutive pol III or pol II promoter, so that transfected cells will produce sufficient
quantities of the ribozyme to destroy endogenous hVR1d gene messages and inhibit
15 translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower
intracellular concentration is required for efficiency.

Endogenous hVR1d gene expression can also be reduced by inactivating or
"knocking out" the target and/or pathway gene or its promoter using targeted
homologous recombination (see, e.g., Smithies et al., 1985, Nature 317:230-234;
20 Thomas & Capecchi, 1987, Cell 51:503-512; Thompson et al., 1989 Cell 5:313-321).
For example, a mutant, non-functional hVR1d gene (or a completely unrelated DNA
sequence) flanked by DNA homologous to the endogenous hVR1d gene (either the
coding regions or regulatory regions of the hVR1d gene) can be used, with or without
a selectable marker and/or a negative selectable marker, to transfect cells that express
25 the hVR1d gene in vivo. Insertion of the DNA construct, via targeted homologous
recombination, results in inactivation of the hVR1d gene. Such techniques can also
be utilized to generate ion/cation disorder animal models. It should be noted that this
approach can be adapted for use in humans provided the recombinant DNA constructs
are directly administered or targeted to the required site in vivo using appropriate viral
30 vectors, e.g., herpes virus vectors.

Alternatively, endogenous hVR1d gene expression can be reduced by targeting
deoxyribonucleotide sequences complementary to the regulatory region of the hVR1d
gene (i.e., the hVR1d gene promoter and/or enhancers) to form triple helical structures
that prevent transcription of the hVR1d gene in target cells in the body (see generally,
35 Helene, C., 1991, Anticancer Drug Des. 6(6):569-84; Helene, C., et al., 1992, Ann.
N.Y. Acad. Sci. 660:27-36; and Maher, L.J., 1992, Bioassays 14(12):807-15).

Nucleic acid molecules to be used in triple helix formation for the inhibition of transcription should be single stranded and composed of deoxynucleotides. The base composition of these oligonucleotides should be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of the duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC+ triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, containing a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands of the triplex.

Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of the duplex.

In instances wherein the antisense, ribozyme, and/or triple helix molecules described herein are utilized to inhibit mutant hVR1d gene expression, it is possible that the technique may so efficiently reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles that the concentration of normal target gene product present may be lower than is necessary for a normal phenotype. In such cases, to ensure that substantially normal levels of hVR1d gene activity are maintained, nucleic acid molecules that encode and express hVR1d polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy methods that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized. In instances where the target gene encodes an extracellular protein, it can be preferable to coadminister normal target gene protein in order to maintain the requisite level of target gene activity.

Antisense RNA and DNA, ribozyme, and triple helix molecules of the invention can be prepared by any method known in the art, e.g., methods for

chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well
5 known in the art such as solid phase phosphoramidite chemical synthesis.
Alternatively, RNA molecules can be generated by in vitro and in vivo transcription of
DNA sequences encoding the antisense RNA molecule. Such DNA sequences can be
incorporated into a wide variety of vectors which incorporate suitable RNA
polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively,
10 antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly,
depending on the promoter used, can be introduced stably into cell lines.

In addition, well-known modifications to DNA molecules can be introduced
into the hVR1d nucleic acid molecules of the invention as a means of increasing
intracellular stability and half-life. Possible modifications include, but are not limited
15 to, the addition of flanking sequences of ribo- or deoxy- nucleotides to the 5' and/or 3'
ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than
phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

5.4.3.2. METHODS FOR INCREASING hVR1d ACTIVITY

20 Successful treatment of ion/cation disorders can also be brought about by
techniques which serve to increase the level of hVR1d activity. Activity can be
increased by, for example, directly increasing hVR1d gene product activity and/or by
increasing the level of hVR1d gene expression.

For example, compounds such as those identified through the assays described
25 in Section 5.4.2., supra, that increase hVR1d activity can be used to treat ion/cation-
related disorders. Such molecules can include, but are not limited to peptides,
including soluble peptides, and small organic or inorganic molecules, and can be
referred to as hVR1d agonists.

For example, a compound can, at a level sufficient to treat ion/cation-related
30 disorders and symptoms, be administered to a patient exhibiting such symptoms. One
of skill in the art will readily know how to determine the concentration of effective,
non-toxic doses of the compound, utilizing techniques such as those described in
Section 5.5, infra.

Alternatively, in instances wherein the compound to be administered is a
35 peptide compound, DNA sequences encoding the peptide compound can be directly
administered to a patient exhibiting an ion/cation-related disorder or symptoms, at a
concentration sufficient to produce a level of peptide compound sufficient to

ameliorate the symptoms of the disorder. Any of the techniques discussed infra,
5 which achieve intracellular administration of compounds, such as, for example,
liposome administration, can be utilized for the administration of such DNA
molecules. In the case of peptide compounds which act extracellularly, the DNA
molecules encoding such peptides can be taken up and expressed by any cell type, so
long as a sufficient circulating concentration of peptide results for the elicitation of a
10 reduction in the ion/cation disorder symptoms.

In cases where the ion/cation disorder can be localized to a particular portion
or region of the body, the DNA molecules encoding such modulatory peptides may be
administered as part of a delivery complex. Such a delivery complex can comprise an
appropriate nucleic acid molecule and a targeting means. Such targeting means can
15 comprise, for example, sterols lipids, viruses or target cell specific binding agents.
Viral vectors can include, but are not limited to adenovirus, adeno-associated virus,
and retrovirus vectors, in addition to other particles that introduce DNA into cells,
such as liposomes.

Further, in instances wherein the ion/cation-related disorder involves an
20 aberrant hVR1d gene, patients can be treated by gene replacement therapy. One or
more copies of a normal hVR1d gene or a portion of the gene that directs the
production of a normal hVR1d protein with normal hVR1d protein function, can be
inserted into cells, via, for example a delivery complex as described supra.

Such gene replacement techniques can be accomplished either in vivo or in
25 vitro. Techniques which select for expression within the cell type of interest are
preferred. For in vivo applications, such techniques can, for example, include
appropriate local administration of hVR1d gene sequences.

Additional methods which may be utilized to increase the overall level of
hVR1d activity include the introduction of appropriate hVR1d gene-expressing cells,
30 preferably autologous cells, into a patient at positions and in numbers which are
sufficient to ameliorate the symptoms of the ion/cation-related disorder. Such cells
may be either recombinant or non-recombinant. Among the cells which can be
administered to increase the overall level of hVR1d gene expression in a patient are
normal cells, which express the hVR1d gene. The cells can be administered at the
35 anatomical site of expression, or as part of a tissue graft located at a different site in
the body. Such cell-based gene therapy techniques are well known to those skilled in

the art (see, e.g., Anderson, et al., United States Patent No. 5,399,349; Mulligan and
5 Wilson, United States Patent No. 5,460,959).

hVR1d gene sequences can also be introduced into autologous cells in vitro.
These cells expressing the hVR1d gene sequence can then be reintroduced, preferably
by intravenous administration, into the patient until the disorder is treated and
symptoms of the disorder are ameliorated.

10

5.4.3.3. ADDITIONAL MODULATORY TECHNIQUES

The present invention also includes modulatory techniques which, depending
on the specific application for which they are utilized, can yield either an increase or a
decrease in hVR1d activity levels leading to the amelioration of ion/cation-related
15 disorders such as those described above.

Antibodies exhibiting modulatory capability can be utilized according to the
methods of this invention to treat the ion/cation-related disorders. Depending on the
specific antibody, the modulatory effect can be an increase or decrease in hVR1d
activity. Such antibodies can be generated using standard techniques described in
20 Section 5.3, supra, against full length wild type or mutant hVR1d proteins, or against
peptides corresponding to portions of the proteins. The antibodies include but are not
limited to polyclonal, monoclonal, Fab fragments, single chain antibodies, chimeric
antibodies, etc.

Lipofectin or liposomes can be used to deliver the antibody or a fragment of
25 the Fab region which binds to the hVR1d gene product epitope to cells expressing the
gene product. Where fragments of the antibody are used, the smallest inhibitory
fragment which binds to the hVR1d protein's binding domain is preferred. For
example, peptides having an amino acid sequence corresponding to the domain of the
variable region of the antibody that binds to the hVR1d protein can be used. Such
30 peptides can be synthesized chemically or produced via recombinant DNA technology
using methods well known in the art (e.g., see Creighton, 1983, supra and Sambrook
et al., 1989, supra). Alternatively, single chain antibodies, such as neutralizing
antibodies, which bind to intracellular epitopes can also be administered. Such single
chain antibodies can be administered, for example, by expressing nucleotide
35 sequences encoding single-chain antibodies within the target cell population by
utilizing, for example, techniques such as those described in Marasco et al., 1993,
Proc. Natl. Acad. Sci. USA 90:7889-7893.

5 5.5. PHARMACEUTICAL PREPARATIONS
AND METHODS OF ADMINISTRATION

The compounds, e.g., nucleic acid sequences, proteins, polypeptides, peptides, and recombinant cells, described supra can be administered to a patient at therapeutically effective doses to treat or ameliorate ion/cation-related disorders. A therapeutically effective dose refers to that amount of a compound or cell population
10 sufficient to result in amelioration of the disorder symptoms, or alternatively, to that amount of a nucleic acid sequence sufficient to express a concentration of hVR1d gene product which results in the amelioration of the disorder symptoms.

Toxicity and therapeutic efficacy of compounds can be determined by standard
15 pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While
20 compounds that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds
25 lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to
30 achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

35 Pharmaceutical compositions for use in accordance with the present invention can be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

Thus, the compounds and their physiologically acceptable salts and solvents
5 can be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised
10 maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can
15 take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or
20 acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration can be suitably formulated to give
25 controlled release of the active compound.

For buccal administration the compositions can take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray
30 presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or
35 insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds can be formulated for parenteral administration (i.e.,
5 intravenous or intramuscular) by injection, via, for example, bolus injection or
continuous infusion. Formulations for injection can be presented in unit dosage form,
e.g., in ampoules or in multi-dose containers, with an added preservative. The
compositions can take such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing
10 and/or dispersing agents. Alternatively, the active ingredient can be in powder form
for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. It
is preferred that hVR1d-expressing cells be introduced into patients via intravenous
administration.

The compounds can also be formulated in rectal compositions such as
15 suppositories or retention enemas, e.g., containing conventional suppository bases
such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds can also
be formulated as a depot preparation. Such long acting formulations can be
administered by implantation (for example subcutaneously or intramuscularly) or by
20 intramuscular injection. Thus, for example, the compounds can be formulated with
suitable polymeric or hydrophobic materials (for example as an emulsion in an
acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for
example, as a sparingly soluble salt.

The compositions can, if desired, be presented in a pack or dispenser device
25 which can contain one or more unit dosage forms containing the active ingredient.
The pack can for example comprise metal or plastic foil, such as a blister pack. The
pack or dispenser device can be accompanied by instructions for administration.

30 6. EXAMPLE: IDENTIFICATION OF A NOVEL hVR1d GENE AND ITS ENCODED PROTEINS

The section below describes the identification of novel human gene sequences
encoding novel human ion channels.

35 6.1. CLONING OF NOVEL hVR1d DNA SEQUENCES

In general all routine molecular biology procedures followed standard
protocols or relied on widely available commercial kits and reagents. All sequencing

was done with an ABI 373 automated sequencer using commercial dye-terminator
5 chemistry.

Known sequence data for hVR1a, hVR1b, hVR1c, and hVR2 were used to screen the EST and genomic public databases. The sequence search program used was gapped BLAST (S.F. Altschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). The searches identified three Bacterial Artificial Chromosome (BAC) sequences in the
10 public domain high throughput genomic database which contained segments having a significant similarity to but not identical with the query sequences. The accession numbers for these BACs are; AC025125, AC027040, and AC027796. The segments having similarity to the vanilloid family of receptors were searched against the non-redundant protein and nucleic acid databases and these segments were found to
15 encode a potential novel vanilloid receptor. However, the sequence information obtained at this point was not sufficient to identify a complete coding sequence. Complete sequence data was then obtained using both 3' and 5' RACE procedures (M.A. Frohman et al., 1988, Proc. Natl. Acad. Sci. USA 85: 8998) and by sequencing cDNA clones isolated from a human brain library as follows:

20 A PCR primer pair designed from the genomic DNA sequences initially identified above as being homologous to vanilloid receptors, i.e., the BAC sequences, was used to screen a human brain cDNA library for potential cDNA clones. More specifically, a Frag3 primer pair, as follows, forward primer "Frag3-s" CGCAGTGCTGGA ACTCTTCA (SEQ ID NO:19) and reverse primer "Frag3-a"
25 CATCAGAGCAATGAGCATGTTGA (SEQ ID NO:20), in which the reverse primer contained biotin coupled to its 5' end, was used to amplify a biotinylated fragment of hVR1d sequences from the genomic DNA. This DNA fragment was gel purified, denatured and then hybridized to a circular, single-stranded human brain cDNA library constructed using f1 helper phage following standard protocols. Hybridization
30 was carried out at 42°C in 50% formamide, 1.5 M NaCl, 40 mM Na_xH_yPO₄ (pH 7.2), 5 mM EDTA, and 0.2% SDS.

Hybrids between the biotinylated DNA fragment and the circular DNA were captured on streptavidin magnetic beads. After thermal release from the beads, the single-stranded cDNA was converted to double-stranded form using a primer
35 complementary to a T7 promoter sequence in the cDNA cloning vector. The double-stranded cDNA was then introduced into E. coli host cells by electroporation and the resulting colonies were screened by PCR, using the original primer pair, to identify

the desired cDNA. Approximately 20 PCR positive clones were obtained. The insert
5 size was determined for all of the clones and two clones with the largest inserts were
selected for DNA sequencing.

Additional sequence information was obtained using the RACE method as
cited above. More specifically, a human fetal brain Marathon[®] cDNA library
prepared by CLONTECH Laboratories, Inc. was used as a template. A nested PCR
10 reaction was used to obtain 5' sequence data. The two gene-specific primers, derived
from the genomic sequence data, were "1D5R2"
(GCCCAGGATGTCGTTCTCTTCAGC (SEQ ID NO:21)) in the first round of
amplification and "1D5R3" (GATCCGCACTATCTCCTTGGTGTGTTGG (SEQ ID
NO:22)) in the subsequent round. A single round of amplification was used to obtain
15 3' sequence data using the gene-specific primer "1D3R2"
(ACTGAATGGAAGACGCACGTCTCCTTC (SEQ ID NO:23)). For both the 5' and
3' RACE amplifications, CLONTECH'S primer "AP1" was used as the second
primer. RACE products were cloned using Invitrogen Corporation's TOPO TA
Cloning[®] Kit following manufacturer's instructions. Insert size was assessed by
20 restriction digest and clones having the largest inserts were then sequenced.

The nucleic acid sequences derived by these procedures are depicted in FIGS.
1A and 1B which identify, respectively, two splice variants of the coding sequence for
novel cDNA clone hVR1d, i.e., hVR1d.1 and hVR1d.2. The derived protein, i.e.,
amino acid, sequences encoded by the hVR1d.1 and hVR1d.2 splice variants are
25 depicted in FIGS. 2A and 2B, respectively.

Example 2 - Expression Profiling Of The Novel Human hVR1d.1 and hVR1d.2 Polypeptides.

Expression profiling studies utilizing the hVR1d nucleic acid sequences
30 described above were carried out as follows: PCR primers were designed from the
BAC sequences identified supra was used to measure tissue levels of hVR1d mRNA
by quantitative PCR using Applied Biosystems' GeneAmp 5700. The forward primer
was TGACCTGAACATCCAGCAGA (SEQ ID NO:24) and the reverse primer was
AGCATGTTGAGGAGGAGAACA (SEQ ID NO:25). The primers did not
35 distinguish between hVR1d.1 and hVR1d.2. In the PCR procedure, first strand cDNA
was made from commercially available mRNA isolated from various tissue sources
(CLONTECH). In addition, the relative amount of cDNA used in each assay was

determined by performing a parallel experiment using a primer pair for cyclophilin, a gene expressed in equal amounts in all tissues. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample and these data were used for normalization of the data obtained with the hVR1d primer pair. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data is presented in FIG. 4.

As depicted in FIG. 4, hVR1d is highly expressed in various brain tissues as well as spinal cord tissue. With regard to the brain tissues, hVR1d is most highly expressed in the corpus callosum (CC), caudate nucleus (CN), and amygdala (A) of the brain.

Moreover, additional expression profiling experiments were performed to identify the relative expression of the hVR1d splice variant, hVR1d.2, nucleic acid in various tissues, including brain subregions. The experiments were performed as described above using the primer pair that follows. The forward primer was CGGAAACCTCGGTGTAGAAG (SEQ ID NO:26) and the reverse primer was TCATCCCTCAAAGCCTCTCT (SEQ ID NO:27).

As shown in Figure 5, the hVR1d.2 polypeptide had a very similar expression profile as the hVR1d.1 polypeptide. However, the hVR1d.2 polypeptide did show some differential expression in the brain subregions, as shown in Figure 6. Specifically, the hVR1d.2 polypeptide was significantly more expressed in thalamus and substantia nigra, with a lower level of expression in amygdala, as compared to the hVR1d.1 polypeptide. The observed differential expression emphasizes the potentially related, yet diverse, roles of the hVR1d.1 and hVR1d.2 polypeptides, and may suggest that either one of the polypeptides may have utility as a druggable target for the treatment of different neural diseases and/or disorders.

Example 3 – Method of Creating N- and C-terminal Deletion Mutants Corresponding to the HVR1d.1 and hVR1d.2 polypeptides of the Present Invention.

As described elsewhere herein, the present invention encompasses the creation of N- and C-terminal deletion mutants, in addition to any combination of N- and C-terminal deletions thereof, corresponding to the HVR1d.1 and hVR1d.2 polypeptides of the present invention. A number of methods are available to one skilled in the art for creating such mutants. Such methods may include a combination of PCR amplification and gene cloning methodology. Although one of skill in the art of molecular biology,

through the use of the teachings provided or referenced herein, and/or otherwise known
5 in the art as standard methods, could readily create each deletion mutant of the present
invention, exemplary methods are described below.

Briefly, using the isolated cDNA clone encoding the full-length HVR1d.1 or
hVR1d.2 polypeptide sequence, appropriate primers of about 15-25 nucleotides derived
10 from the desired 5' and 3' positions of SEQ ID NO:1 or SEQ ID NO:3 may be designed
to PCR amplify, and subsequently clone, the intended N- and/or C-terminal deletion
mutant. Such primers could comprise, for example, an initiation and stop codon for the
5' and 3' primer, respectively. Such primers may also comprise restriction sites to
facilitate cloning of the deletion mutant post amplification. Moreover, the primers may
15 comprise additional sequences, such as, for example, flag-tag sequences, kozac
sequences, or other sequences discussed and/or referenced herein.

For example, in the case of the H394 to R720 N-terminal deletion mutant, the
following primers could be used to amplify a cDNA fragment corresponding to this
deletion mutant:

20

| | |
|--------------------|---|
| 5' Primer | 5'-GCAGCA <u>GCGGCCGC</u> CACATGTTCTTTCTGTCCTTCTGC -3' (SEQ ID NO:28) <i>NotI</i> |
| 25 3' Primer | 5'- GCAGCA <u>GTCGAC</u> CCTCACAGCGACAGTACCTGTTCG -3' (SEQ ID NO:29) <i>Sall</i> |

30 For example, in the case of the M1 to N626 C-terminal deletion mutant, the
following primers could be used to amplify a cDNA fragment corresponding to this
deletion mutant:

35

| | |
|--------------|---|
| 5' Primer | 5'- GCAGCA <u>GCGGCCGC</u> ATGAGCTTTATTGTCAGGCCACGAG -3' (SEQ ID NO:30) <i>NotI</i> |
|--------------|---|

| | |
|-------------------|---|
| 5 3' Primer | 5'- GCAGCA <u>GTCGAC</u> GTTGAGGAGGAGAACAAAGGTGAGG -3' (SEQ ID NO:31) <i>Sall</i> |
|-------------------|---|

Representative PCR amplification conditions are provided below, although the skilled artisan would appreciate that other conditions may be required for efficient amplification. A 100 ul PCR reaction mixture may be prepared using 10ng of the template DNA (cDNA clone of HVR1d.1 and hVR1d.2), 200 uM 4dNTPs, 1uM primers, 0.25U Taq DNA polymerase (PE), and standard Taq DNA polymerase buffer. Typical PCR cycling condition are as follows:

20-25 cycles: 45 sec, 93 degrees
2 min, 50 degrees
2 min, 72 degrees
1 cycle: 10 min, 72 degrees

After the final extension step of PCR, 5U Klenow Fragment may be added and incubated for 15 min at 30 degrees.

Upon digestion of the fragment with the NotI and Sall restriction enzymes, the fragment could be cloned into an appropriate expression and/or cloning vector which has been similarly digested (e.g., pSport1, among others). The skilled artisan would appreciate that other plasmids could be equally substituted, and may be desirable in certain circumstances. The digested fragment and vector are then ligated using a DNA ligase, and then used to transform competent E.coli cells using methods provided herein and/or otherwise known in the art.

The 5' primer sequence for amplifying any additional N-terminal deletion mutants may be determined by reference to the following formula:

$(S+(X * 3))$ to $((S+(X * 3))+25)$, wherein 'S' is equal to the nucleotide position of the initiating start codon of the HVR1d.1 or hVR1d.2 gene (SEQ ID NO:1 or SEQ ID NO:3), and 'X' is equal to the most N-terminal amino acid of the intended N-terminal deletion mutant. The first term will provide the start 5' nucleotide position of the 5' primer, while the second term will provide the end 3' nucleotide position of the 5' primer

corresponding to sense strand of SEQ ID NO:1 or SEQ ID NO:3. Once the
5 corresponding nucleotide positions of the primer are determined, the final nucleotide
sequence may be created by the addition of applicable restriction site sequences to the 5'
end of the sequence, for example. As referenced herein, the addition of other sequences
to the 5' primer may be desired in certain circumstances (e.g., kozac sequences, etc.).

10 The 3' primer sequence for amplifying any additional N-terminal deletion
mutants may be determined by reference to the following formula:

(S+(X * 3)) to ((S+(X * 3))-25), wherein 'S' is equal to the nucleotide position
of the initiating start codon of the HVR1d.1 or hVR1d.2 gene (SEQ ID NO:1 or SEQ ID
NO:3), and 'X' is equal to the most C-terminal amino acid of the intended N-terminal
15 deletion mutant. The first term will provide the start 5' nucleotide position of the 3'
primer, while the second term will provide the end 3' nucleotide position of the 3' primer
corresponding to the anti-sense strand of SEQ ID NO:1 or SEQ ID NO:3. Once the
corresponding nucleotide positions of the primer are determined, the final nucleotide
sequence may be created by the addition of applicable restriction site sequences to the 5'
20 end of the sequence, for example. As referenced herein, the addition of other sequences
to the 3' primer may be desired in certain circumstances (e.g., stop codon sequences,
etc.). The skilled artisan would appreciate that modifications of the above nucleotide
positions may be necessary for optimizing PCR amplification.

25 The same general formulas provided above may be used in identifying the 5' and
3' primer sequences for amplifying any C-terminal deletion mutant of the present
invention. Moreover, the same general formulas provided above may be used in
identifying the 5' and 3' primer sequences for amplifying any combination of N-terminal
and C-terminal deletion mutant of the present invention. The skilled artisan would
30 appreciate that modifications of the above nucleotide positions may be necessary for
optimizing PCR amplification.

35 **Example 4 - Method Of Enhancing The Biological Activity/Functional Characteristics Of Invention Through Molecular Evolution.**

Although many of the most biologically active proteins known are highly
effective for their specified function in an organism, they often possess characteristics
that make them undesirable for transgenic, therapeutic, pharmaceutical, and/or industrial

applications. Among these traits, a short physiological half-life is the most prominent
5 problem, and is present either at the level of the protein, or the level of the proteins
mRNA. The ability to extend the half-life, for example, would be particularly important
for a proteins use in gene therapy, transgenic animal production, the bioprocess
production and purification of the protein, and use of the protein as a chemical modulator
among others. Therefore, there is a need to identify novel variants of isolated proteins
10 possessing characteristics which enhance their application as a therapeutic for treating
diseases of animal origin, in addition to the proteins applicability to common industrial
and pharmaceutical applications.

Thus, one aspect of the present invention relates to the ability to enhance specific
15 characteristics of invention through directed molecular evolution. Such an enhancement
may, in a non-limiting example, benefit the inventions utility as an essential component
in a kit, the inventions physical attributes such as its solubility, structure, or codon
optimization, the inventions specific biological activity, including any associated
enzymatic activity, the proteins enzyme kinetics, the proteins K_i , K_{cat} , K_m , V_{max} , K_d ,
20 protein-protein activity, protein-DNA binding activity, antagonist/inhibitory activity
(including direct or indirect interaction), agonist activity (including direct or indirect
interaction), the proteins antigenicity (e.g., where it would be desirable to either increase
or decrease the antigenic potential of the protein), the immunogenicity of the protein, the
25 ability of the protein to form dimers, trimers, or multimers with either itself or other
proteins, the antigenic efficacy of the invention, including its subsequent use a
preventative treatment for disease or disease states, or as an effector for targeting diseased
genes. Moreover, the ability to enhance specific characteristics of a protein may also be
applicable to changing the characterized activity of an enzyme to an activity completely
30 unrelated to its initially characterized activity. Other desirable enhancements of the
invention would be specific to each individual protein, and would thus be well known in
the art and contemplated by the present invention.

For example, an engineered ion channel may be constitutively active upon
binding of its cognate ligand. Alternatively, an engineered ion channel may be
35 constitutively active in the absence of ligand binding. In yet another example, an
engineered ion channel may be capable of being activated with less than all of the
regulatory factors and/or conditions typically required for ion channel activation (e.g.,

ligand binding, phosphorylation, conformational changes, calcium flux, etc.). Such ion
5 channel would be useful in screens to identify ion channel modulators, among other uses
described herein.

Directed evolution is comprised of several steps. The first step is to establish a
library of variants for the gene or protein of interest. The most important step is to then
select for those variants that entail the activity you wish to identify. The design of the
10 screen is essential since your screen should be selective enough to eliminate non-useful
variants, but not so stringent as to eliminate all variants. The last step is then to repeat
the above steps using the best variant from the previous screen. Each successive cycle,
can then be tailored as necessary, such as increasing the stringency of the screen, for
15 example.

Over the years, there have been a number of methods developed to introduce
mutations into macromolecules. Some of these methods include, random mutagenesis,
“error-prone” PCR, chemical mutagenesis, site-directed mutagenesis, and other methods
well known in the art (for a comprehensive listing of current mutagenesis methods, see
20 Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold
Spring, NY (1982)). Typically, such methods have been used, for example, as tools for
identifying the core functional region(s) of a protein or the function of specific domains
of a protein (if a multi-domain protein). However, such methods have more recently been
25 applied to the identification of macromolecule variants with specific or enhanced
characteristics.

Random mutagenesis has been the most widely recognized method to date.
Typically, this has been carried out either through the use of “error-prone” PCR (as
described in Moore, J., et al, *Nature Biotechnology* 14:458, (1996), or through the
30 application of randomized synthetic oligonucleotides corresponding to specific regions
of interest (as described by Derbyshire, K.M. et al, *Gene*, 46:145-152, (1986), and Hill,
DE, et al, *Methods Enzymol.*, 55:559-568, (1987). Both approaches have limits to the
level of mutagenesis that can be obtained. However, either approach enables the
investigator to effectively control the rate of mutagenesis. This is particularly important
35 considering the fact that mutations beneficial to the activity of the enzyme are fairly rare.
In fact, using too high a level of mutagenesis may counter or inhibit the desired benefit
of a useful mutation.

While both of the aforementioned methods are effective for creating randomized
5 pools of macromolecule variants, a third method, termed "DNA Shuffling", or "sexual
PCR" (WPC, Stemmer, PNAS, 91:10747, (1994)) has recently been elucidated. DNA
shuffling has also been referred to as "directed molecular evolution", "exon-shuffling",
"directed enzyme evolution", "in vitro evolution", and "artificial evolution". Such
10 reference terms are known in the art and are encompassed by the invention. This new,
preferred, method apparently overcomes the limitations of the previous methods in that
it not only propagates positive traits, but simultaneously eliminates negative traits in the
resulting progeny.

DNA shuffling accomplishes this task by combining the principal of in vitro
15 recombination, along with the method of "error-prone" PCR. In effect, you begin with
a randomly digested pool of small fragments of your gene, created by Dnase I digestion,
and then introduce said random fragments into an "error-prone" PCR assembly reaction.
During the PCR reaction, the randomly sized DNA fragments not only hybridize to their
cognate strand, but also may hybridize to other DNA fragments corresponding to
20 different regions of the polynucleotide of interest – regions not typically accessible via
hybridization of the entire polynucleotide. Moreover, since the PCR assembly reaction
utilizes "error-prone" PCR reaction conditions, random mutations are introduced during
the DNA synthesis step of the PCR reaction for all of the fragments -further diversifying
25 the potential hybridization sites during the annealing step of the reaction.

A variety of reaction conditions could be utilized to carry-out the DNA shuffling
reaction. However, specific reaction conditions for DNA shuffling are provided, for
example, in PNAS, 91:10747, (1994). Briefly:

Prepare the DNA substrate to be subjected to the DNA shuffling reaction.
30 Preparation may be in the form of simply purifying the DNA from contaminating cellular
material, chemicals, buffers, oligonucleotide primers, deoxynucleotides, RNAs, etc., and
may entail the use of DNA purification kits as those provided by Qiagen, Inc., or by the
Promega, Corp., for example.

Once the DNA substrate has been purified, it would be subjected to Dnase I
35 digestion. About 2-4ug of the DNA substrate(s) would be digested with .0015 units of
Dnase I (Sigma) per ul in 100ul of 50mM Tris-HCL, pH 7.4/1mM MgCl₂ for 10-20 min.
at room temperature. The resulting fragments of 10-50bp could then be purified by

running them through a 2% low-melting point agarose gel by electrophoresis onto DE81
5 ion-exchange paper (Whatman) or could be purified using Microcon concentrators
(Amicon) of the appropriate molecular weight cutoff, or could use oligonucleotide
purification columns (Qiagen), in addition to other methods known in the art. If using
DE81 ion-exchange paper, the 10-50bp fragments could be eluted from said paper using
10 1M NaCl, followed by ethanol precipitation.

The resulting purified fragments would then be subjected to a PCR assembly
reaction by re-suspension in a PCR mixture containing: 2mM of each dNTP, 2.2mM
MgCl₂, 50 mM KCl, 10mM Tris•HCl, pH 9.0, and 0.1% Triton X-100, at a final
fragment concentration of 10-30ng/ul. No primers are added at this point. *Taq* DNA
15 polymerase (Promega) would be used at 2.5 units per 100ul of reaction mixture. A PCR
program of 94 C for 60s; 94 C for 30s, 50-55 C for 30s, and 72 C for 30s using 30-45
cycles, followed by 72 C for 5min using an MJ Research (Cambridge, MA) PTC-150
thermocycler. After the assembly reaction is completed, a 1:40 dilution of the resulting
primerless product would then be introduced into a PCR mixture (using the same buffer
20 mixture used for the assembly reaction) containing 0.8um of each primer and subjecting
this mixture to 15 cycles of PCR (using 94 C for 30s, 50 C for 30s, and 72 C for 30s).
The referred primers would be primers corresponding to the nucleic acid sequences of
the polynucleotide(s) utilized in the shuffling reaction. Said primers could consist of
25 modified nucleic acid base pairs using methods known in the art and referred to else
where herein, or could contain additional sequences (i.e., for adding restriction sites,
mutating specific base-pairs, etc.).

The resulting shuffled, assembled, and amplified product can be purified using
methods well known in the art (e.g., Qiagen PCR purification kits) and then subsequently
30 cloned using appropriate restriction enzymes.

Although a number of variations of DNA shuffling have been published to date,
such variations would be obvious to the skilled artisan and are encompassed by the
invention. The DNA shuffling method can also be tailored to the desired level of
mutagenesis using the methods described by Zhao, et al. (Nucl Acid Res., 25(6):1307-
35 1308, (1997).

As described above, once the randomized pool has been created, it can then be
subjected to a specific screen to identify the variant possessing the desired

characteristic(s). Once the variant has been identified, DNA corresponding to the variant
5 could then be used as the DNA substrate for initiating another round of DNA shuffling.
This cycle of shuffling, selecting the optimized variant of interest, and then re-shuffling,
can be repeated until the ultimate variant is obtained. Examples of model screens applied
to identify variants created using DNA shuffling technology may be found in the
following publications: J. C., Moore, et al., J. Mol. Biol., 272:336-347, (1997), F.R.,
10 Cross, et al., Mol. Cell. Biol., 18:2923-2931, (1998), and A. Cramer, et al., Nat.
Biotech., 15:436-438, (1997).

DNA shuffling has several advantages. First, it makes use of beneficial
mutations. When combined with screening, DNA shuffling allows the discovery of the
15 best mutational combinations and does not assume that the best combination contains all
the mutations in a population. Secondly, recombination occurs simultaneously with point
mutagenesis. An effect of forcing DNA polymerase to synthesize full-length genes from
the small fragment DNA pool is a background mutagenesis rate. In combination with a
stringent selection method, enzymatic activity has been evolved up to 16000 fold increase
20 over the wild-type form of the enzyme. In essence, the background mutagenesis yielded
the genetic variability on which recombination acted to enhance the activity.

A third feature of recombination is that it can be used to remove deleterious
mutations. As discussed above, during the process of the randomization, for every one
25 beneficial mutation, there may be at least one or more neutral or inhibitory mutations.
Such mutations can be removed by including in the assembly reaction an excess of the
wild-type random-size fragments, in addition to the random-size fragments of the
selected mutant from the previous selection. During the next selection, some of the most
active variants of the polynucleotide/polypeptide/enzyme, should have lost the inhibitory
30 mutations.

Finally, recombination enables parallel processing. This represents a significant
advantage since there are likely multiple characteristics that would make a protein more
desirable (e.g. solubility, activity, etc.). Since it is increasingly difficult to screen for
more than one desirable trait at a time, other methods of molecular evolution tend to be
35 inhibitory. However, using recombination, it would be possible to combine the
randomized fragments of the best representative variants for the various traits, and then
select for multiple properties at once.

DNA shuffling can also be applied to the polynucleotides and polypeptides of the present invention to decrease their immunogenicity in a specified host, particularly if the polynucleotides and polypeptides provide a therapeutic use. For example, a particular variant of the present invention may be created and isolated using DNA shuffling technology. Such a variant may have all of the desired characteristics, though may be highly immunogenic in a host due to its novel intrinsic structure. Specifically, the desired characteristic may cause the polypeptide to have a non-native structure which could no longer be recognized as a "self" molecule, but rather as a "foreign", and thus activate a host immune response directed against the novel variant. Such a limitation can be overcome, for example, by including a copy of the gene sequence for a xenobiotic ortholog of the native protein in with the gene sequence of the novel variant gene in one or more cycles of DNA shuffling. The molar ratio of the ortholog and novel variant DNAs could be varied accordingly. Ideally, the resulting hybrid variant identified would contain at least some of the coding sequence which enabled the xenobiotic protein to evade the host immune system, and additionally, the coding sequence of the original novel variant that provided the desired characteristics.

Likewise, the invention encompasses the application of DNA shuffling technology to the evolution of polynucleotides and polypeptides of the invention, wherein one or more cycles of DNA shuffling include, in addition to the gene template DNA, oligonucleotides coding for known allelic sequences, optimized codon sequences, known variant sequences, known polynucleotide polymorphism sequences, known ortholog sequences, known homolog sequences, additional homologous sequences, additional non-homologous sequences, sequences from another species, and any number and combination of the above.

In addition to the described methods above, there are a number of related methods that may also be applicable, or desirable in certain cases. Representative among these are the methods discussed in PCT applications WO 98/31700, and WO 98/32845, which are hereby incorporated by reference. Furthermore, related methods can also be applied to the polynucleotide sequences of the present invention in order to evolve invention for creating ideal variants for use in gene therapy, protein engineering, evolution of whole cells containing the variant, or in the evolution of entire enzyme pathways containing polynucleotides of the invention as described in PCT applications WO 98/13485, WO

98/13487, WO 98/27230, WO 98/31837, and Cramer, A., et al., Nat. Biotech., 15:436-
5 438, (1997), respectively.

Additional methods of applying "DNA Shuffling" technology to the polynucleotides and polypeptides of the present invention, including their proposed applications, may be found in US Patent No. 5,605,793; PCT Application No. WO 95/22625; PCT Application No. WO 97/20078; PCT Application No. WO 97/35966; and
10 PCT Application No. WO 98/42832; PCT Application No. The forgoing are hereby incorporated in their entirety herein for all purposes.

Example 5 - Method of Assessing the Putative Ion Channel Activity of the hVR1d 15 Polypeptides.

A number of methods may be employed to assess the potential ion channel activity of the hVR1d polypeptides. One preferred method is described below

CHO-K1 cells transfected with a suitable mammalian expression vector comprising the hVR1d encoding polynucleotide sequence is prepared using methods
20 known in the art. The transfected cells are transferred to cover slips 12 hours after transfection, and electrophysiological measurements are made 24 hours after transfection ($22 \pm 2^\circ\text{C}$). The hVR1d -expressing CHO-K1 cells are detected by GFP fluorescence. Membrane currents are digitized at 10 or 20 kHz and digitally filtered off line at 1 kHz. Voltage stimuli lasting 500 ms are delivered at 5-s intervals, with either voltage ramps
25 or voltage steps from 100 to +100 mV. The internal pipette solution for macroscopic and single-channel currents may contain 145 mM Cs-methanesulfonate, 8 mM NaCl, 5 mM ATP, 1 mM MgCl_2 , 10 mM EGTA, 4.1 mM CaCl_2 , and 10 mM Hepes, with pH adjusted to 7.2 with CsOH after addition of ATP. The standard extracellular solution may contain
30 140 mM NaCl, 5 mM CsCl, 2.8 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 10 mM Hepes, and 10 mM glucose, with pH adjusted to 7.4 with NaOH. Relative ion permeabilities may be measured with the pipette solution containing 145 mM Cs-methanesulfonate, 10 mM CsCl, 5 mM ATP, 10 mM EGTA, and 10 mM Hepes (pH 7.2) and the external solution containing 110 mM NMDG+, 30 mM X^+ (Na^+ , Ca^{2+} , K^+ , or Cs^+), 10 mM Hepes, and
35 10 mM glucose (pH 7.4). The relative permeability for monovalent ions may be calculated according to the equation $P_{\text{X}}/P_{\text{Cs}} = ([\text{Cs}^+]_o/[\text{X}^+]_o)\exp[F(E_{\text{X}} - E_{\text{Cs}})/RT]$. The $P_{\text{Ca}}/P_{\text{Cs}}$ permeability ratio is calculated according to the equation $P_{\text{Ca}}/P_{\text{Cs}} =$

{[Cs+]oexp(FECs/RT)exp(FECa/RT)[exp(FECa/RT)+1]}/(4[Ca2+]o), where R, T, and
5 F are the gas constant, absolute temperature, and Faraday's constant, respectively.
Statistical comparisons are made with the two-way analysis of variance (ANOVA) and
two-tailed t test with Bonferroni correction; $P < 0.05$ indicated statistical significance.

10 **Example 6 - Bacterial Expression Of A Polypeptide.**

A polynucleotide encoding a polypeptide of the present invention is amplified
using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA
sequence, to synthesize insertion fragments. The primers used to amplify the cDNA
insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end
15 of the primers in order to clone the amplified product into the expression vector. For
example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial
expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes
antibiotic resistance (Ampr), a bacterial origin of replication (ori), an IPTG-regulatable
promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and
20 restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment
is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial
RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen,
25 Inc.) which contains multiple copies of the plasmid pREP4, that expresses the lacI
repressor and also confers kanamycin resistance (Kanr). Transformants are identified by
their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are
selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid
30 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The
O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are
grown to an optical density 600 (O.D.600) of between 0.4 and 0.6. IPTG (Isopropyl-B-
D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces
35 by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by
centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent
6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is

removed by centrifugation, and the supernatant containing the polypeptide is loaded onto
5 a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
QIAGEN, Inc., supra). Proteins with a 6 x His tag bind to the Ni-NTA resin with high
affinity and can be purified in a simple one-step procedure (for details see: The
QIAexpressionist (1995) QIAGEN, Inc., supra).

10 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8,
the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed
with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with
6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered
15 saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the
protein can be successfully refolded while immobilized on the Ni-NTA column. The
recommended conditions are as follows: renature using a linear 6M-1M urea gradient in
500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors.
The renaturation should be performed over a period of 1.5 hours or more. After
20 renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole
is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer
plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree
C.

25 **Example 7 - Purification Of A Polypeptide From An Inclusion Body.**

The following alternative method can be used to purify a polypeptide expressed
in E coli when it is present in the form of inclusion bodies. Unless otherwise specified,
all of the following steps are conducted at 4-10 degree C.

30 Upon completion of the production phase of the E. coli fermentation, the cell
culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation
at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit
weight of cell paste and the amount of purified protein required, an appropriate amount
of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50
35 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high
shear mixer.

The cells are then lysed by passing the solution through a microfluidizer
5 (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles,
15 the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential
20 filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with
25 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem
30 columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50
35 mM sodium acetate, pH 6.5. Fractions are collected under constant A280 monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above
5 refolding and purification steps. No major contaminant bands should be observed from
Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded.
The purified protein can also be tested for endotoxin/LPS contamination, and typically
the LPS content is less than 0.1 ng/ml according to LAL assays.

10 **Example 8 - Cloning And Expression Of A Polypeptide In A Baculovirus
Expression System.**

In this example, the plasmid shuttle vector pAc373 is used to insert a
polynucleotide into a baculovirus to express a polypeptide. A typical baculovirus
15 expression vector contains the strong polyhedrin promoter of the Autographa californica
nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites, which
may include, for example BamHI, Xba I and Asp718. The polyadenylation site of the
simian virus 40 ("SV40") is often used for efficient polyadenylation. For easy selection
of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under
20 control of a weak Drosophila promoter in the same orientation, followed by the
polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both
sides by viral sequences for cell-mediated homologous recombination with wild-type
viral DNA to generate a viable virus that express the cloned polynucleotide.

25 Many other baculovirus vectors can be used in place of the vector above, such as
pVL941 and pAcIM1, as one skilled in the art would readily appreciate, as long as the
construct provides appropriately located signals for transcription, translation, secretion
and the like, including a signal peptide and an in-frame AUG as required. Such vectors
are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

30 A polynucleotide encoding a polypeptide of the present invention is amplified
using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA
sequence, to synthesize insertion fragments. The primers used to amplify the cDNA
insert should preferably contain restriction sites at the 5' end of the primers in order to
clone the amplified product into the expression vector. Specifically, the cDNA sequence
35 contained in the deposited clone, including the AUG initiation codon and the naturally
associated leader sequence identified elsewhere herein (if applicable), is amplified using
PCR protocol. If the naturally occurring signal sequence is used to produce the protein,

the vector used does not need a second signal peptide. Alternatively, the vector can be
5 modified to include a baculovirus leader sequence, using the standard methods described
in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell
Culture Procedures" Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

10 The amplified fragment is isolated from a 1% agarose gel using a commercially
available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.). The fragment then is digested
with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and
optionally, can be dephosphorylated using calf intestinal phosphatase, using routine
15 procedures known in the art. The DNA is then isolated from a 1% agarose gel using a
commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4
DNA ligase. E. coli HB101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene
Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and
20 spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA
from individual colonies and analyzing the digestion product by gel electrophoresis. The
sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transformed with 1.0 ug
25 of a commercially available linearized baculovirus DNA ("BaculoGoldtm baculovirus
DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner
et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGoldtm virus
DNA and 5ug of the plasmid are mixed in a sterile well of a microtiter plate containing
50ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD).
30 Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated
for 15 minutes at room temperature. Then the transfection mixture is added drop-wise
to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml
Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C.
The transfection solution is then removed from the plate and 1 ml of Grace's insect
35 medium supplemented with 10% fetal calf serum is added. Cultivation is then continued
at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as
5 described by Summers and Smith, supra. An agarose gel with "Blue Gal" (Life
Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-
expressing clones, which produce blue-stained plaques. (A detailed description of a
"plaque assay" of this type can also be found in the user's guide for insect cell culture and
10 baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After
appropriate incubation, blue stained plaques are picked with the tip of a micropipettor
(e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in
a microcentrifuge tube containing 200 ul of Grace's medium and the suspension
containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm
15 dishes. Four days later the supernatants of these culture dishes are harvested and then
they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's
medium supplemented with 10% heat-inactivated FBS. The cells are infected with the
recombinant baculovirus containing the polynucleotide at a multiplicity of infection
20 ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is
removed and is replaced with SF900 II medium minus methionine and cysteine (available
from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of 35S-methionine
and 5 uCi 35S-cysteine (available from Amersham) are added. The cells are further
25 incubated for 16 hours and then are harvested by centrifugation. The proteins in the
supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by
autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified
protein may be used to determine the amino terminal sequence of the produced protein.
30

Example 9 - Expression Of A Polypeptide In Mammalian Cells.

The polypeptide of the present invention can be expressed in a mammalian cell.
A typical mammalian expression vector contains a promoter element, which mediates the
initiation of transcription of mRNA, a protein coding sequence, and signals required for
35 the termination of transcription and polyadenylation of the transcript. Additional
elements include enhancers, Kozak sequences and intervening sequences flanked by
donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with

the early and late promoters from SV40, the long terminal repeats (LTRs) from
5 Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus
(CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for
example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat
(ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0,
10 and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela,
293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail
QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the
15 polynucleotide integrated into a chromosome. The co-transformation with a selectable
marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation
of the transformed cells.

The transformed gene can also be amplified to express large amounts of the
encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing
20 cell lines that carry several hundred or even several thousand copies of the gene of
interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L.
and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and
Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is
25 the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991);
Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the
mammalian cells are grown in selective medium and the cells with the highest resistance
are selected. These cell lines contain the amplified gene(s) integrated into a chromosome.

Chinese hamster ovary (CHO) and NSO cells are often used for the production of
30 proteins.

A polynucleotide of the present invention is amplified according to the protocol
outlined in herein. If the naturally occurring signal sequence is used to produce the
protein, the vector does not need a second signal peptide. Alternatively, if the naturally
35 occurring signal sequence is not used, the vector can be modified to include a
heterologous signal sequence. (See, e.g., WO 96/34891.) The amplified fragment is
isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101

Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes
5 and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for
10 instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transformation. Five µg of an expression plasmid is cotransformed with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2-neo contains
15 a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about
20 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate
25 (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

30 **Example 10 - Protein Fusions.**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example described herein; see also EP A 394,827;
35 Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular

localization, while covalent heterodimer or homodimers can increase or decrease the
5 activity of a fusion protein. Fusion proteins can also create chimeric molecules having
more than one function. Finally, fusion proteins can increase solubility and/or stability
of the fused protein compared to the non-fused protein. All of the types of fusion
proteins described above can be made by modifying the following protocol, which
10 outlines the fusion of a polypeptide to an IgG molecule.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using
primers that span the 5' and 3' ends of the sequence described below. These primers also
should have convenient restriction enzyme sites that will facilitate cloning into an
expression vector, preferably a mammalian expression vector. Note that the
15 polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be
produced.

The naturally occurring signal sequence may be used to produce the protein (if
applicable). Alternatively, if the naturally occurring signal sequence is not used, the
vector can be modified to include a heterologous signal sequence. (See, e.g., WO
20 96/34891 and/or US Patent No. 6,066,781, *supra*.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACACACATGCCACACCGT
25 GCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGG
TGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGG
CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAG
CACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAT
30 GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCG
AGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACA
CCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTG
CCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
35 GCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC

ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCGACGGCCGCGAC
5 TCTAGAGGAT (SEQ ID NO:32)

Example 11 - Production Of An Antibody From A Polypeptide.

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing
10 a polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce
15 polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol.
20 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium;
25 however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma
30 cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained
35 through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be
5 produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes
use of the fact that antibodies are themselves antigens, and therefore, it is possible to
obtain an antibody that binds to a second antibody. In accordance with this method,
protein specific antibodies are used to immunize an animal, preferably a mouse. The
10 splenocytes of such an animal are then used to produce hybridoma cells, and the
hybridoma cells are screened to identify clones that produce an antibody whose ability
to bind to the protein-specific antibody can be blocked by the polypeptide. Such
antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be
used to immunize an animal to induce formation of further protein-specific antibodies.

15 It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies
of the present invention may be used according to the methods disclosed herein. Such
fragments are typically produced by proteolytic cleavage, using enzymes such as papain
(to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively,
protein-binding fragments can be produced through the application of recombinant DNA
20 technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized"
chimeric monoclonal antibodies. Such antibodies can be produced using genetic
constructs derived from hybridoma cells producing the monoclonal antibodies described
25 above. Methods for producing chimeric antibodies are known in the art. (See, for
review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986);
Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al.,
EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne
et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

30 Moreover, in another preferred method, the antibodies directed against the
polypeptides of the present invention may be produced in plants. Specific methods are
disclosed in US Patent Nos. 5,959,177, and 6,080,560, which are hereby incorporated in
their entirety herein. The methods not only describe methods of expressing antibodies,
but also the means of assembling foreign multimeric proteins in plants (i.e., antibodies,
35 etc.), and the subsequent secretion of such antibodies from the plant.

The present invention is not to be limited in scope by the specific
embodiments described herein, which are intended as single illustrations of individual

aspects of the invention, and functionally equivalent methods and components are
5 within the scope of the invention. Indeed, various modifications of the invention, in
addition to those shown and described herein will become apparent to those skilled in
the art from the foregoing description and accompanying drawings. Such
modifications are intended to fall within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent
10 applications, journal articles, abstracts, laboratory manuals, books, or other
disclosures) in the Background of the Invention, Detailed Description, and Examples
is hereby incorporated herein by reference. Further, the hard copy of the sequence
listing submitted herewith and the corresponding computer readable form are both
incorporated herein by reference in their entireties.

15

20

25

30

35

We claim:

5

1. An isolated nucleic acid comprising a member of the group consisting of:

10

(a) a nucleic acid sequence that encodes a polypeptide having the amino acid sequence of FIG. 2A or FIG. 2B (SEQ ID NO. 2 or 4);

15

(b) An isolated nucleic acid comprising a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid molecule of claim 1 and encoding a hVR1d polypeptide having an activity of a naturally-occurring hVR1d protein;

20

(c) An isolated nucleic acid comprising the nucleic acid sequence of FIG. 1A;

(d) An isolated nucleic acid comprising the nucleic acid sequence of FIG. 1B;

25

(e) An isolated polynucleotide having the nucleic acid sequence of ATCC Accession No. _____;

(f) An isolated polynucleotide having the nucleic acid sequence according to nucleotides 4 to 2160 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;

30

(g) An isolated polynucleotide having the nucleic acid sequence according to nucleotides 1 to 2160 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;

35

(h) An isolated polynucleotide having the nucleic acid sequence according to nucleotides 4 to 2235 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide of SEQ ID NO:4 minus the start codon;

(i) An isolated polynucleotide having the nucleic acid sequence according to nucleotides 1 to 2235 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide of SEQ ID NO:4 including the start codon;

- 5 (j) the complement of the nucleic acid sequence of any one of (a) thru (i);
- (k) An isolated nucleic acid wherein a nucleic acid of any one of (a) thru (j) that encodes an hVR1d protein or polypeptide is linked in frame to a nucleic acid sequence that encodes a heterologous protein or peptide;
- 10 (l) A nucleic acid comprising a nucleic acid sequence encoding (a) a deletion mutant of hVR1d.1; (b) a deletion mutant of hVR1d.2; or (c) the complement of the nucleic acid sequences of (a) or (b);
- (m) A nucleic acid comprising a nucleic acid sequence encoding (a) a substitution mutant of hVR1d.1; (b) a substitution mutant of hVR1d.2; or (c) the complement of the nucleic acid sequences of (a) or (b);
- 15
- 2 A recombinant vector comprising a nucleic acid of claim 1.
- 20
3. An expression vector comprising a nucleic acid of claim 1 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the nucleic acid in a host cell.
- 25 4. A genetically engineered host cell containing a nucleic acid of claim 1.
5. A genetically engineered host cell containing a nucleic acid of claim 1 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the
- 30 nucleic acid sequence in a host cell.
6. A method of making an hVR1d polypeptide comprising the steps of:
- (a) culturing the host cell of claim 4 in an appropriate culture medium to produce an hVR1d polypeptide; and
- 35 (b) isolating the hVR1d polypeptide.
7. A method of making an hVR1d polypeptide comprising the steps of:

- 5 (a) culturing the host cell of claim 5 in an appropriate culture medium to produce an hVR1d polypeptide; and
(b) isolating the hVR1d polypeptide.

8. The method of claim 6 or 7, wherein the hVR1d polypeptide is hVR1d1.1 or hVR1d.2 or a functionally equivalent derivative thereof.

10

9. An antibody preparation which is specifically reactive with an epitope of an hVR1d polypeptide.

10. A transgenic animal comprising a nucleic acid of claim 1.

15

11. A substantially pure polypeptide encoded by a nucleic acid of claim 1.

12. A substantially pure human hVR1d polypeptide as depicted in FIGS. 2A or 2B (SEQ ID NO: 2 or 4).

20

13. A substantially pure polypeptide which is at least 90% identical to the polypeptide as set forth in FIGS. 2A or 2B (SEQ ID NO: 2 or 4).

14. A fusion protein comprising a polypeptide of claim 13 and a second
25 heterologous polypeptide.

15. A pharmaceutical preparation comprising a therapeutically effective amount of the polypeptide of claim 11 and a pharmaceutically acceptable carrier.

30 16. A test kit for detecting and/or quantitating a wild type or mutant hVR1d nucleic acid molecule in a sample, comprising the steps of contacting the sample with a nucleic acid of claim 1; and detecting and/or quantitating the label as an indication of the presence or absence and/or amount of a wild type or mutant hVR1d nucleic acid.

35

17. A method for identifying compounds that modulate hVR1d activity comprising:

5. (a) contacting a test compound to a cell that expresses a hVR1d gene;
- (b) measuring the level of hVR1d gene expression in the cell; and
- (c) comparing the level obtained in (b) with the hVR1d gene expression obtained in the absence of the compound;
- such that if the level obtained in (b) differs from that obtained in the absence of the
- 10 compound, a compound that modulates hVR1d activity is identified.

18. A method for identifying compounds that regulate ion channel-related disorders, comprising:

- 15 (a) contacting a test compound with a cell which expresses a nucleic acid of claim 1 and
- (b) determining whether the test compound modulates hVR1d activity.

19. A method for identifying compounds that regulate ion channel-related disorders, comprising:

- 20 (a) contacting a test compound with a cell or cell lysate containing a reporter gene operatively associated with a hVR1d regulatory element; and
- (b) detecting expression of the reporter gene product.

25 20. A method for identifying compounds that regulate ion channel-related disorders comprising:

- (a) contacting a test compound with a cell or cell lysate containing hVR1d transcripts; and
- 30 (b) detecting the translation of the hVR1d transcript.

21. A method for modulating ion channel-related disorders in a subject, comprising administering to the subject a therapeutically effective amount of a hVR1d polypeptide.

35 22. A method for the treatment of ion channel-related disorders, comprising modulating the activity of a hVR1d polypeptide.

5 23. The method of claim 22, wherein the method comprises administering
an effective amount of a compound that agonizes or antagonizes the activity of the
hVR1d polypeptide.

 24. A method for the treatment of ion channel-related disorders,
10 comprising administering an effective amount of a compound that decreases
expression of a hVR1d gene.

 25) A method of identifying a compound that modulates the biological
activity of hVR1d, comprising:
15 (a) combining a candidate modulator compound with hVR1d
 having the sequence set forth in SEQ ID NO:2; and
 (b) measuring an effect of the candidate modulator compound on
 the activity of hVR1d.

20 26) A compound that modulates the biological activity of human hVR1d as
identified by the method according to claim 25.

25

30

35

FIG. 1A

| | | |
|-----|---|-----|
| 1 | ATGAGCTTTATTTGCAGGCCACGAGGAGGGGGCAGGCTGGAGACAGATTCCAGGGTGGCA | 60 |
| 1 | M S F I C R P R G G G R L E T D S R V A | 20 |
| 61 | GCAGGGGGGTGGACAGCGGGAAGCCATACAGTGGGCAAAGAGCAAAAGGCCTCAGATACG | 120 |
| 21 | A G G W T A G S H T V G K E Q K A S D T | 40 |
| 121 | TCACCCATGGGCCACAGAGAGCAAGGAGCCAGCATAGGAGACGGAGGAGAAACAGCTGGA | 180 |
| 41 | S P M G H R E Q G A S I G D G G E T A G | 60 |
| 181 | GAGGGAGGAGAGCGGCCAAGTGTAAGGTCTGGGAGTGGAGATGTGGAGCAGGGGCTTGGG | 240 |
| 61 | E G G E R P S V R S G S G D V E Q G L G | 80 |
| 241 | GTCTGCGGCTGCAGCAACCACACCCTCTGGGCTGGGAGGGCCAAGGGCAGCCGGGGCCCT | 300 |
| 81 | V C G C S N H T L W A G R A K G S R G P | 100 |
| 301 | CCTGTAACCTCCACCCATGGCCCTGCCTGCAGACTTCCTCATGCACAAGCTGACGGCCTCC | 360 |
| 101 | P V T P P M A L P A D F L M H K L T A S | 120 |
| 361 | GACACGGGGAAGACCTGCCTGATGAAGGCCTTGTTAAACATCAACCCCAACACCAAGGAG | 420 |
| 121 | D T G K T C L M K A L L N I N P N T K E | 140 |
| 421 | ATAGTGGGATCCTGCTTGCTTTGCTGAAGAGAACGACATCCTGGGCAGGTTTCATCAAC | 480 |
| 141 | I V R I L L A F A E E N D I L G R F I N | 160 |
| 481 | GCCGAGTACACAGAGGAGGCCTATGAAGGGCAGACGGCGCTGAACATCGCCATCGAGCGG | 540 |
| 161 | A E Y T E E A Y E G Q T A L N I A I E R | 180 |
| 541 | CGGCAGGGGGACATCGCAGCCCTGCTCATCGCCGCCGGCGCCGACGTCAACGCGCACGCC | 600 |
| 181 | R Q G D I A A L L I A A G A D V N A H A | 200 |
| 601 | AAGGGGGCCTTCTTCAACCCCAAGTACCAACACGAAGGCTTCTACTTCGGTGAGAGGCCC | 660 |
| 201 | K G A F F N P K Y Q H E G F Y F G E T P | 220 |
| 661 | CTGGCCCTGGCAGCATGCACCAACCAGCCGAGATTGTGCAGCTGCTGATGGAGCACGAG | 720 |
| 221 | L A L A A C T N Q P E I V Q L L M E H E | 240 |
| 721 | CAGACGGACATCACCTCGCGGGACTCACGAGGCAACAACATCCTTCACGCCCTGGTGACC | 780 |
| 241 | Q T D I T S R D S R G N N I L H A L V T | 260 |
| 781 | GTGGCCGAGGACTTCAAGACGCAGAATGACTTTGTGAAGCGCATGTACGACATGATCCTA | 840 |
| 261 | V A E D F K T Q N D F V K R M Y D M I L | 280 |
| 841 | CTGCGGAGTGGCAACTGGGAGCTGGAGACCACTCGCAACAACGATGGCCTCACGCCGCTG | 900 |
| 281 | L R S G N W E L E T T R N N D G L T P L | 300 |

FIG. 1A (cont'd)

901 CAGCTGGCCGCCAAGATGGGCAAGGCGGAGATCCTGAAGTACATCCTCAGTCGTGAGATC 960
301 Q L A A K M G K A E I L K Y I L S R E I 320

961 AAGGAGAAGCGGCTCCGGAGCCTGTCCAGGAAGTTCACCGACTGGGCGTACGGACCCGTG 1020
321 K E K R L R S L S R K F T D W A Y G P V 340

1021 TCATCCTCCCTCTACGACCTCACCAACGTGGACACCACCACGGACAACCTCAGTGCTGGAA 1080
341 S S S L Y D L T N V D T T T D N S V L E 360

1081 ATCACTGTCTACAACACCAACATCGACAACCGGCATGAGATGCTGACCCTGGAGCCGCTG 1140
361 I T V Y N T N I D N R H E M L T L E P L 380

1141 CACACGCTGCTGCATATGAAGTGGAAGAAGTTTGCCAAGCACATGTTCTTTCTGTCCTTC 1200
381 H T L L H M K W K K F A K H M F F L S F 400

1201 TGCTTTTATTTCTTCTACAACATCACCCCTGACCCTCGTCTCGTACTACCGCCCCGGGAG 1260
401 C F Y F F Y N I T L T L V S Y Y R P R E 420

1261 GAGGAGGCCATCCCGCACCCCTTGGCCCTGACGCACAAGATGGGGTGGCTGCAGCTCCTA 1320
421 E E A I P H P L A L T H K M G W L Q L L 440

1321 GGGAGGATGTTTGTGCTCATCTGGGCCATGTGCATCTCTGTGAAAGAGGGCATTGCCATC 1380
441 G R M F V L I W A M C I S V K E G I A I 460

1381 TTCCTGCTGAGACCCTCGGATCTGCAGTCCATCCTCTCGGATGCCTGGTTCCACTTTGTC 1440
461 F L L R P S D L Q S I L S D A W F H F V 480

1441 TTTTTTATCCAAGCTGTGCTTGTGATACTGTCTGTCTTCTTGTACTTGTTTGCCTACAAA 1500
481 F F I Q A V L V I L S V F L Y L F A Y K 500

1501 GAGTACCTCGCCTGCCTCGTGTGGCCATGGCCCTGGGCTGGGCGAACATGCTCTACTAT 1560
501 E Y L A C L V L A M A L G W A N M L Y Y 520

1561 ACGCGGGGTTTCCAGTCCATGGGCATGTACAGCGTCATGATCCAGAAGGTCATTTTGCAT 1620
521 T R G F Q S M G M Y S V M I Q K V I L H 540

1621 GATGTTCTGAAGTTCTTGTGTTGTATATATCGCGTTTTTGCTTGGATTTGGAGTAGCCTTG 1680
541 D V L K F L F V Y I A F L L G F G V A L 560

1681 GCCTCGCTGATCGAGAAGTGTCCCAAAGACAACAAGGACTGCAGCTCCTACGGCAGCTTC 1740
561 A S L I E K C P K D N K D C S S Y G S F 580

1741 AGCGACGCACTGCTGGAACCTCTTCAAGCTCACCATAGGCCTGGGTGAYCTGAACATCCAG 1800
581 S D A V L E L F K L T I G L G D L N I Q 600

FIG. 1A (cont'd)

| | | |
|------|--|------|
| 1801 | CAGAACTCCAAGTATCCCATTTCTCTTTCTGTTTCCTGCTCATCACCTATGTCATCCTCACC | 1860 |
| 601 | Q N S K Y P I L F L F L L I T Y V I L T | 620 |
| 1861 | TTTGTTCTCCTCCTCAACATGCTCATTGCTCTGATGGGCGAGACTGTGGAGAACGTCTCC | 1920 |
| 621 | F V L L L N M L I A L M G E T V E N V S | 640 |
| 1921 | AAGGAGAGCGAACGCATCTGGCGCCTGCAGAGAGCCAGGACCATCTTGGAGTTTGAGAAA | 1980 |
| 641 | K E S E R I W R L Q R A R T I L E F E K | 660 |
| 1981 | ATGTTACCAGAATGGCTGAGGAGCAGATTCCGGATGGGAGAGCTGTGCAAAGTGGCCGAG | 2040 |
| 661 | M L P E W L R S R F R M G E L C K V A E | 680 |
| 2041 | GATGATTTCCGACTGTGTTTGCGGATCAATGAGGTGAAGTGGACTGAATGGAAGACGCAC | 2100 |
| 681 | D D F R L C L R I N E V K W T E W K T H | 700 |
| 2101 | GTCTCCTTCCTTAACGAAGACCCGGGGCCTGTAAGACGAACAGGTACTGTCGCTGTGAGG | 2160 |
| 701 | V S F L N E D P G P V R R T G T V A V R | 720 |
| 2161 | TGA | 2163 |

FIG. 1B

1 ATGAGCTTTATTTGCAGGCCACGAGGAGGGGGCAGGCTGGAGACAGATTCCAGGGTGGCA 60
1 M S F I C R P R G G G R L E T D S R V A 20

61 GCAGGGGGGTGGACAGCGGGAAGCCATACAGTGGGCAAAGAGCAAAGGCCTCAGATACG 120
21 A G G W T A G S H T V G K E Q K A S D T 40

121 TCACCCATGGGCCACAGAGAGCAAGGAGCCAGCATAGGAGACGGAGGAGAAACAGCTGGA 180
41 S P M G H R E Q G A S I G D G G E T A G 60

181 GAGGGAGGAGAGCGGCCAAGTGTAAGGTCTGGGAGTGGAGATGTGGAGCAGGGGCTTGGG 240
61 E G G E R P S V R S G S G D V E Q G L G 80

241 GTCTGCGGCTGCAGCAACCACACCTCTGGGCTGGGAGGGCCAAGGGCAGCCGGGGCCCT 300
81 V C G C S N H T L W A G R A K G S R G P 100

301 CCTGTAACCTCCACCCATGGCCCTGCCTGCAGACTTCCTCATGCACAAGCTGACGGCCTCC 360
101 P V T P P M A L P A D F L M H K L T A S 120

361 GACACGGGGAAGACCTGCCTGATGAAGGCCTTGTTAAACATCAACCCCAACACCAAGGAG 420
121 D T G K T C L M K A L L N I N P N T K E 140

421 ATAGTGCGGATCCTGCTTGCCTTTGCTGAAGAGAACGACATCCTGGGCAGGTTTCATCAAC 480
141 I V R I L L A F A E E N D I L G R F I N 160

481 GCCGAGTACACAGAGGAGGCCTATGAAGGGCAGACGGCGCTGAACATCGCCATCGAGCGG 540
161 A E Y T E E A Y E G Q T A L N I A I E R 180

541 CGGCAGGGGGACATCGCAGCCCTGCTCATCGCCGCGCGCGCGACGTCAACGCGCACGCC 600
181 R Q G D I A A L L I A A G A D V N A H A 200

601 AAGGGGGCCTTCTTCAACCCCAAGTACCAACACGAAGGCTTCTACTTCGGTGAGACGCCC 660
201 K G A F F N P K Y Q H E G F Y F G E T P 220

661 CTGGCCCTGGCAGCATGCACCAACCAGCCCGAGATTGTGCAGCTGCTGATGGAGCACGAG 720
221 L A L A A C T N Q P E I V Q L L M E H E 240

721 CAGACGGACATCACCTCGCGGACTCACGAGGCAACAACATCCTTCACGCCCTGGTGACC 780
241 Q T D I T S R D S R G N N I L H A L V T 260

781 GTGGCCGAGGACTTCAAGACGCAGAATGACTTTGTGAAGCGCATGTACGACATGATCCTA 840
261 V A E D F K T Q N D F V K R M Y D M I L 280

841 CTGCGGAGTGGCAACTGGGAGCTGGAGACCACTCGCAACAACGATGGCCTCACGCCGCTG 900
281 L R S G N W E L E T T R N N D G L T P L 300

FIG. 1B (cont'd)

| | | |
|------|--|------|
| 901 | CAGCTGGCCGCCAAGATGGGCAAGGCGGAGATCCTGAAGTACATCCTCAGTCGTGAGATC | 960 |
| 301 | Q L A A K M G K A E I L K Y I L S R E I | 320 |
| 961 | AAGGAGAAGCGGCTCCGGAGCCTGTCCAGGAAGTTCACCGACTGGGCGTACGGACCCGTG | 1020 |
| 321 | K E K R L R S L S R K F T D W A Y G P V | 340 |
| 1021 | TCATCCTCCCTCTACGACCTCACCAACGTGGACACCACCACGGACAACCTCAGTGCTGGAA | 1080 |
| 341 | S S S L Y D L T N V D T T T D N S V L E | 360 |
| 1081 | ATCACTGTCTACAACACCAACATCGACAACCGGCATGAGATGCTGACCCTGGAGCCGCTG | 1140 |
| 361 | I T V Y N T N I D N R H E M L T L E P L | 380 |
| 1141 | CACACGCTGCTGCATATGAAGTGGAAGAAGTTTGCCAAGCACATGTTCTTTCTGTCTTC | 1200 |
| 381 | H T L L H M K W K K F A K H M F F L S F | 400 |
| 1201 | TGCTTTTATTTCTTCTTACAACATCACCCCTGACCCTCGTCTCGTACTACCGACCCCGGGAG | 1260 |
| 401 | C F Y F F Y N I T L T L V S Y Y R P R E | 420 |
| 1261 | GAGGAGGCCATCCCGCACCCCTTGCCCTGACGCACAAGATGGGGTGGCTGCAGCTCCTA | 1320 |
| 421 | E E A I P H P L A L T H K M G W L Q L L | 440 |
| 1321 | GGGAGGATGTTTGTGCTCATCTGGGCCATGTGCATCTCTGTGAAAGAGGGCATTGCCATC | 1380 |
| 441 | G R M F V L I W A M C I S V K E G I A I | 460 |
| 1381 | TTCCTGCTGAGACCCCTCGGATCTGCAGTCCATCCTCTCGGATGCCTGGTTCCACTTTGTCT | 1440 |
| 461 | F L L R P S D L Q S I L S D A W F H F V | 480 |
| 1441 | TTTTTTATCCAAGCTGTGCTTGTGATACTGTCTGTCTTCTTGTACTTGTTTGCCTACAAA | 1500 |
| 481 | F F I Q A V L V I L S V F L Y L F A Y K | 500 |
| 1501 | GAGTACCTCGCCTGCCTCGTGCTGGCCATGGCCCTGGGCTGGGCGAACATGCTCTACTAT | 1560 |
| 501 | E Y L A C L V L A M A L G W A N M L Y Y | 520 |
| 1561 | ACGCGGGGTTTCCAGTCCATGGGCATGTACAGCGTCATGATCCAGAAGGTCATTTTGCAT | 1620 |
| 521 | T R G F Q S M G M Y S V M I Q K V I L H | 540 |
| 1621 | GATGTTCTGAAGTTCTTGTGTTGTATATATCGCGTTTTTGCTTGGATTTGGAGTAGCCTTG | 1680 |
| 541 | D V L K F L F V Y I A F L L G F G V A L | 560 |
| 1681 | GCCTCGCTGATCGAGAAGTGTCCCAAAGACAACAAGGACTGCAGCTCCTACGGCAGCTTC | 1740 |
| 561 | A S L I E K C P K D N K D C S S Y G S F | 580 |
| 1741 | AGCGACGCAGTGCTGGAACCTCTTCAAGCTCACCATAGGCCTGGGTGAYCTGAACATCCAG | 1800 |
| 581 | S D A V L E L F K L T I G L G D L N I Q | 600 |

FIG. 1B (cont'd)

| | | |
|------|---|------|
| 1801 | CAGAACTCCAAGTATCCCATTCTCTTTCTGTTCTGCTCATCACCTATGTCATCCTCACC | 1860 |
| 601 | Q N S K Y P I L F L F L L I T Y V I L T | 620 |
| 1861 | TTTGTTCTCCTCCTCAACATGCTCATTGCTCTGATGGGCGAGACTGTGGAGAACGTCTCC | 1920 |
| 621 | F V L L L N M L I A L M G E T V E N V S | 640 |
| 1921 | AAGGAGAGCGAACGCATCTGGCGCCTGCAGAGAGCCAGGACCATCTTGAGAGTTTGAGAAA | 1980 |
| 641 | K E S E R I W R L Q R A R T I L E F E K | 660 |
| 1981 | ATGTTACCAGAATGGCTGAGGAGCAGATTCCGGATGGGAGAGCTGTGCAAAGTGGCCGAG | 2040 |
| 661 | M L P E W L R S R F R M G E L C K V A E | 680 |
| 2041 | GATGATTTCGACTGTGTTTGCGGATCAATGAGGTGAAGTGGACTGAATGGAAGACGCAC | 2100 |
| 681 | D D F R L C L R I N E V K W T E W K T H | 700 |
| 2101 | GTCTCCTTCCTTAACGAAGACCCGGGGCCTGTAAGACGAACAGATTTCAACAAAATCCAA | 2160 |
| 701 | V S F L N E D P G P V R R T D F N K I Q | 720 |
| 2161 | GATTCTTCCAGGAACAACAGCAAAACCACTCTCAATGCATTTGAAGAAGTCGAGGAATTC | 2220 |
| 721 | D S S R N N S K T T L N A F E E V E E F | 740 |
| 2221 | CCGGAACCTCGGTGTAG | 2238 |
| 741 | P E T S V | 745 |

1 MSFICRPRGG GRLETDSRVA AGGWTAGSHT VGKEQKASDT SPMGHREQGA
51 SIGDGGETAG EGGERPSVRS GSGDVEQGLG VCGCSNHTLW AGRAKGSRGP
101 PVTTPMALPA DFLMHKLTAS DTGKTCLMKA LLNINPNTKE IVRILLAFAE
151 ENDILGRFIN AEYTEEAYEG QTALNIAIER ROGDIAALLI AAGADVNAHA
201 KGAFFNPKYQ HEGFYFGETP LALAACTNOP EIVOLLMEHE QTDITSRDSR
251 GNNILHALVT VAEDFKTQND FVKRMYDMIL LRSGNWELET TRNNDGLTPL
301 QLAAKMGAKE ILKYILSREI KEKRLRSLSR KFTDWAYGPV SSSLYDLTNV
351 DTTTDSNVLE ITVYNTNIDN RHEMLTLEPL HTLLHMKWKK FAKHMFFLSF
401 CFYFFYNITL TLVSYYRPRE EEAIPHPLAL THKMGLQLL GRMFVLIWAM
451 CISVKEGIAI FLLRPSDLQS ILSDAWFHFV FFIQAVLVIL SVFLYLFAVK
501 EYLACLVLAM ALGWANMLYY TRGFQSMGMY SVMIQKVILH DVLKFLFVYI
551 AFLLGFGVAL ASLIEKCPKD NKD CSSYGSF SDAVLELFKL TIGLGDLNIQ
601 QNSKYPILFL FLLITYVILT FVLLLNMLIA LMGETVENVS KESERIWRLO
651 RARTILEFEK MLPEWLRSRF RMGELCKVAE DDFRLCLRIN EVKWTEWKTH
701 VSFLNEDPGP VRRTGTVAVR

FIG. 2A

1 MSFICRPRGG GRLETDSRVA AGGWTAGSHT VGKEQKASDT SPMGHREQGA
51 SIGDGGETAG EGGERPSVRS GSGDVEQGLG VCGCSNHTLW AGRAKGSRGP
101 PVTTPMALPA DFLMHKLTAS DTGKTCLMKA LLNINPNTKE IVRILLAFAE
151 ENDILGRFIN AEYTEEAYEG QTALNIAIER ROGDIAALLI AAGADVNAHA
201 KGAFFNPKYQ HEGFYFGETP LALAACTNOP EIVQLLMEHE QTDITSRDSR
251 GNNILHALVT VAEDFKTQND FVKRMYDMIL LRSGNWELET TRNNDGLTPL
301 QLAAKMGAKE ILKYILSREI KEKRLRSLSR KFTDWAYGPV SSSLYDLTNV
351 DTTTDSNVLE ITVYNTNIDN RHEMLTLEPL HTLLHMKWKK FAKHMFFLSF
401 CFYFFYNITL TLVSYYRPRE EEAIPHPLAL THKMGWLQLL GRMFVLIWAM
451 CISVKEGIAI FLLRPSDLQS ILSDAWFHFV FFIQAVLVIL SVFLYLFAYK
501 EYLACLVLAM ALGWANMLYY TRGFQSMGMY SVMIOKVILH DVLKFLFVYI
551 AFLLGFGVAL ASLIEKCPKD NKD CSSYGSF SDAVLELFKL TIGLGDDLNIQ
601 QNSKYPILFL FLLITYVILT FVLLLNMLIA LMGETVENVS KESERIWRLO
651 RARTILEFEK MLPEWLRSRF RMGELCKVAE DDFRLCLRIN EVKWTEWKTH
701 VSFLNEDPGP VVRTDENKIQ DSSRNNSKTT LNAFEEVEEF PETS

FIG. 2B

Fig. 3

| | | | | |
|---------|-------|--|------------------------------------|-----|
| | | 1 | | 50 |
| hVR1d | (1) | ----- | | |
| hVR1d.2 | (1) | ----- | | |
| hVR1 | (1) | ----- | MKKWSSTD LGAAADPLQKDTCPD | |
| hVR2 | (1) | ----- | | |
| ORTPC4 | (1) | MADSSEGPRAGPGEVAELPGDESGTPGGEAFPLSSLANLFEGEDGSLSPS | | |
| hECaC | (1) | ----- | | |
| | | 51 | | 100 |
| hVR1d | (1) | ---MSFIERP----- | RGGRLETDSEAAAGCTGSHG | |
| hVR1d.2 | (1) | ---MSFIERP----- | RGGRLETDSEAAAGCTGSHG | |
| hVR1 | (24) | PLDGPNSRPPPAKP----- | QLSTSSITRLFGKDEEAFPCP | |
| hVR2 | (1) | --MTSPSSP----- | VFRLETLDGGOIDGSEADRGDF | |
| ORTPC4 | (51) | PADASRPFGPDGRPNLRMKFQGAFRKEVP | IDL E TL AE SV GPI | |
| hECaC | (1) | ----- | MGPI | |
| | | 101 | | 150 |
| hVR1d | (34) | EQKASDISPMCHREQASIGDGGETAGEG | ERPSVRSRGDVEQGLGCG | |
| hVR1d.2 | (34) | EQKASDISPMCHREQASIGDGGETAGEG | ERPSVRSRGDVEQGLGCG | |
| hVR1 | (66) | EEGELDCETITVPVITIQP-GD-PTGRLLSQSVASSEKTLR | D | |
| hVR2 | (33) | GSC-----PPMESQFGEDR-KFAPQIRVNL | YRKGGA PDPNR D | |
| ORTPC4 | (101) | LAPMDLFDYCTYHHESDNKEWRKKIIEKQPQSP | P PQ PPIIKV N | |
| hECaC | (8) | EKC-----LI CLW KF RWF | R W Q DEQN Q | |
| | | 151 | | 200 |
| hVR1d | (84) | CSNHTLWAGRAK GPPAPP LPALM | ATAS TGKTCLMKALI | |
| hVR1d.2 | (84) | CSNHTLWAGRAK GPPAPP LPALM | ATAS TGKTCLMKALI | |
| hVR1 | (115) | RRSFEAVAGINODLSLILLOKS KLTNE | PETGKTCLMKALI | |
| hVR2 | (76) | RDRFNAVSRVPEDLAGLPEILSKTSKLTDSB | TGTGKTCLMKALI | |
| ORTPC4 | (151) | RPIFEIVSR SADLGLLPALL HKRLTDEH | RPTGKTCLPKALI | |
| hECaC | (41) | KRW PLLLAEDN | QALNKLK EDCKV Q GAMGETALHIA | |
| | | 201 | | 250 |
| hVR1d | (133) | NINPT I RLLAFAENDILG | NABYTEAYEGOTALHIAIERF | |
| hVR1d.2 | (133) | NINPT I RLLAFAENDILG | NABYTEAYEGOTALHIAIERF | |
| hVR1 | (165) | NLDGONTTIP LLEIAFQDSLKESNASYTD | SYYGOTALHIAIERF | |
| hVR2 | (126) | NLDGCVNACILP LLOIDSNPOPNNAQCTD | SYYGEGALHIAIEF | |
| ORTPC4 | (201) | NLDNGRNTIP LLDIAERENNREBN | PERDIYEGOTALHIAIERFC | |
| hECaC | (89) | YDN----- | LEAAMVLM AAEI FEPMT ELYEGOTALHIA V | |
| | | 251 | | 300 |
| hVR1d | (183) | GDIALAAGADVNAHAKCAFFNPYQHE | GFYFGETPLA LAACTNQE | |
| hVR1d.2 | (183) | GDIALAAGADVNAHAKCAFFNPYQHE | GFYFGETPLA LAACTNQE | |
| hVR1 | (215) | CAVTLLEN GADVNAHAKCDFFK | KGRFGFYFGELPLSLA ACTNCLG | |
| hVR2 | (176) | QCVKLLVEN GAVNAHARACCRFF | KGQG-TCFYFGELPLSLA ACTHON | |
| ORTPC4 | (251) | KHYVELLVAAGADVNAHAKCRFF | PKDEGGYFYFGELPLSLA ACTNQE | |
| hECaC | (130) | INVRALAAARASVSARACTAFR | PCNL FYFGELPLSLA ACTNQE | |
| | | 301 | | 350 |
| hVR1d | (233) | VLLME--EQDI SRDSRGNSLHALVTVA | F T NDFV MYD | |
| hVR1d.2 | (233) | VLLME--EQDI SRDSRGNSLHALVTVA | F T NDFV MYD | |
| hVR1 | (265) | VKELLSA SWQTADISARDSVGN TVLHALVEADN | A ENTKEVT MYE | |
| hVR2 | (225) | VSYLLEI PHQPASTGATDS | GNTVLHALVM SDN AENIA VTM YD | |
| ORTPC4 | (301) | VNYLTEI PHKKADRR | DSRGNTVLHALVA ADN ENTKEVT MYD | |
| hECaC | (179) | VRLLEI G--ADIRAGDSLGN TVLHIL LQP | -----KTF C MYD | |

Fig. 3 (cont'd)

| | | | | |
|---------|-------|-------|------------------|------------------------------------|
| | | 351 | | 400 |
| hVR1d | (281) | L | -----SGNWELET | ERNNDGLTPLQLAAKMGKAEILILREIKEKRLF |
| hVR1d.2 | (281) | L | -----SGNWELET | ERNNDGLTPLQLAAKMGKAEILILREIKEKRLF |
| hVR1 | (315) | L | LGAKLHPTLKLEE | TNCGMTPLALAACTGKIGAAILOREIQEPECF |
| hVR2 | (275) | Q | AGARLCPTVQLED | ERNLDELTPKLAAKEGKIEIPILORESG--LS |
| ORTPC4 | (351) | L | CARLFPDSNLEA | LNNDSLPLMMAAKTGKIGIPILIRET |
| hECaC | (221) | S | YDRGDHLQPL | LIPNFGGLTPKLA |
| | | 401 | | 450 |
| hVR1d | (327) | S | LSRKFTDWAYGPV | SSSLYDLTNVDTT |
| hVR1d.2 | (327) | S | LSRKFTDWAYGPV | SSSLYDLTNVDTT |
| hVR1 | (365) | H | LSRKFTDWAYGPV | SSSLYDLTNVDTT |
| hVR2 | (323) | H | LSRKFTDWAYGPV | SSSLYDLTNVDTT |
| ORTPC4 | (401) | H | LSRKFTDWAYGPV | SSSLYDLTNVDTT |
| hECaC | (262) | -K | RKFTDWAYGPV | SSSLYDLTNVDTT |
| | | 451 | | 500 |
| hVR1d | (375) | L | LEPLTLLH | KWKKEFAKHFFLFCFYFYNITTLVSYRPREE--- |
| hVR1d.2 | (375) | L | LEPLTLLH | KWKKEFAKHFFLFCFYFYNITTLVSYRPREE--- |
| hVR1 | (414) | L | LEPLTLLH | KWKKEFAKHFFLFCFYFYNITTLVSYRPREE--- |
| hVR2 | (371) | L | LEPLTLLH | KWKKEFAKHFFLFCFYFYNITTLVSYRPREE--- |
| ORTPC4 | (450) | L | LEPLTLLH | KWKKEFAKHFFLFCFYFYNITTLVSYRPREE--- |
| hECaC | (308) | L | LEPLTLLH | KWKKEFAKHFFLFCFYFYNITTLVSYRPREE--- |
| | | 501 | | 550 |
| hVR1d | (422) | ----- | EAIPHPLAL | THKMGWLQLLRMVL |
| hVR1d.2 | (422) | ----- | EAIPHPLAL | THKMGWLQLLRMVL |
| hVR1 | (458) | ----- | VDGLP | PFKMEKGDY |
| hVR2 | (416) | ----- | KKQAAPH | KA |
| ORTPC4 | (494) | ----- | LEGT | PPYPYR |
| hECaC | (358) | N | RTSPRDNTLLQOKLLQ | EAYM |
| | | 551 | | 600 |
| hVR1d | (462) | L | FPDSD | ----- |
| hVR1d.2 | (462) | L | FPDSD | ----- |
| hVR1 | (497) | L | QERPS | ----- |
| hVR2 | (455) | W | RPHVF | ----- |
| ORTPC4 | (533) | L | KCPG | ----- |
| hECaC | (408) | R | MGVTRF | ----- |
| | | 601 | | 650 |
| hVR1d | (510) | L | LGWANMLYYTRGFQ | SMGMYSVMIQKVIL |
| hVR1d.2 | (510) | L | LGWANMLYYTRGFQ | SMGMYSVMIQKVIL |
| hVR1 | (545) | L | LGWANMLYYTRGFQ | SMGMYSVMIQKVIL |
| hVR2 | (503) | L | LGWANMLYYTRGFQ | SMGMYSVMIQKVIL |
| ORTPC4 | (582) | L | LGWANMLYYTRGFQ | SMGMYSVMIQKVIL |
| hECaC | (458) | L | LGWANMLYYTRGFQ | SMGMYSVMIQKVIL |
| | | 651 | | 700 |
| hVR1d | (560) | L | SLIEKCP | DNKDC |
| hVR1d.2 | (560) | L | SLIEKCP | DNKDC |
| hVR1 | (595) | L | SLIEKCP | DNKDC |
| hVR2 | (553) | L | SLIEKCP | DNKDC |
| ORTPC4 | (632) | L | SLIEKCP | DNKDC |
| hECaC | (508) | L | SLIEKCP | DNKDC |

Fig. 3 (cont'd)

| | | | | |
|---------|-------|-----------|-----------|-----------------------------------|
| | | 701 | | 750 |
| hVR1d | (590) | LTIGGDLN | QQNSKYP | FLLLVILTFVLLLNMLIALMGETVE |
| hVR1d.2 | (590) | LTIGGDLN | QQNSKYP | FLLLVILTFVLLLNMLIALMGETVE |
| hVR1 | (641) | FTIGMGDL | ETENYDAK | YFLLVILTFVLLLNMLIALMGETVN |
| hVR2 | (603) | FTIGMGDL | LAQEL | LSRGMVLLVILTFVLLLNMLIALMGETVN |
| ORTPC4 | (676) | LTIGMGDL | ELSSKYP | VFLLLVILTFVLLLNMLIALMGETVG |
| hECaC | (536) | LFITIDGPA | LYNMLP | YVSTITYKAFATLMLLNMLIALMGETHW |
| | | 751 | | 800 |
| hVR1d | (640) | SKESER | IWKLORAT | ILTEKMLPEWLRSRF--RMGELCKV-----EDD |
| hVR1d.2 | (640) | SKESER | IWKLORAT | ILTEKMLPEWLRSRF--RMGELCKV-----EDD |
| hVR1 | (691) | ACESN | IWKLORAT | ILTEKMLPEWLRSRF--RMGELCKV-----EDD |
| hVR2 | (653) | SPSWS | IWKLORAT | ILTEKMLPEWLRSRF--RMGELCKV-----EDD |
| ORTPC4 | (726) | SKES | HIWKLORAT | ILTEKMLPEWLRSRF--RMGELCKV-----EDD |
| hECaC | (586) | SKES | HIWKLORAT | ILTEKMLPEWLRSRF--RMGELCKV-----EDD |
| | | 801 | | 850 |
| hVR1d | (683) | ERLCER | INEVNT | EWKTHVSLNEDP--GP-VRTGVR----- |
| hVR1d.2 | (683) | ERLCER | INEVNT | EWKTHVSLNEDP--GP-VRTGVR----- |
| hVR1 | (739) | ERLCER | INEVNT | EWKTHVSLNEDP--GP-VRTGVR----- |
| hVR2 | (700) | ERLCER | INEVNT | EWKTHVSLNEDP--GP-VRTGVR----- |
| ORTPC4 | (774) | RRWCER | INEVNT | EWKTHVSLNEDP--GP-VRTGVR----- |
| hECaC | (627) | DRWCER | INEVNT | EWKTHVSLNEDP--GP-VRTGVR----- |
| | | 851 | | 900 |
| hVR1d | (721) | ----- | ----- | ----- |
| hVR1d.2 | (723) | ----- | ----- | ----- |
| hVR1 | (789) | KNFALVP | ELREASAR | ERSAQPEVYLRFSGSLKPEDAEVFKPAASGE |
| hVR2 | (742) | PPKDE | GAEENYVP | LLQSN----- |
| ORTPC4 | (823) | SSVVP | RVNELNK | SNEDVVVPLSMGNPRCDGHQGYPRKWR |
| hECaC | (677) | LSPMP | SSRSR | SAWERLRGTLRRDLRGIINRGLEDGEWEYQI |
| | | 901 | | |
| hVR1d | (721) | - | | |
| hVR1d.2 | (746) | - | | |
| hVR1 | (839) | K | | |
| hVR2 | (765) | - | | |
| ORTPC4 | (872) | - | | |
| hECaC | (726) | - | | |




FIG. 4

FIG 5.





FIG 6.



SEQUENCE LISTING

<110> Bristol-Myers Squibb Company

<120> NOVEL HUMAN NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING A NOVE
HUMAN ION CHANNEL EXPRESSED IN SPINAL CORD AND BRAIN

<130> D0109PCT

<150> 60/250,587

<151> 2000-12-01

<160> 31

<170> PatentIn version 3.0

<210> 1

<211> 2163

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(2160)

<400> 1

| | |
|---|-----|
| atg agc ttt att tgc agg cca cga gga ggg ggc agg ctg gag aca gat | 48 |
| Met Ser Phe Ile Cys Arg Pro Arg Gly Gly Gly Arg Leu Glu Thr Asp | |
| 1 5 10 15 | |
| tcc agg gtg gca gca ggg ggg tgg aca gcg gga agc cat aca gtg ggc | 96 |
| Ser Arg Val Ala Ala Gly Gly Trp Thr Ala Gly Ser His Thr Val Gly | |
| 20 25 30 | |
| aaa gag caa aag gcc tca gat acg tca ccc atg ggc cac aga gag caa | 144 |
| Lys Glu Gln Lys Ala Ser Asp Thr Ser Pro Met Gly His Arg Glu Gln | |
| 35 40 45 | |
| gga gcc agc ata gga gac gga gga gaa aca gct gga gag gga gga gag | 192 |
| Gly Ala Ser Ile Gly Asp Gly Gly Glu Thr Ala Gly Glu Gly Gly Glu | |
| 50 55 60 | |
| cgg cca agt gta agg tct ggg agt gga gat gtg gag cag ggg ctt ggg | 240 |
| Arg Pro Ser Val Arg Ser Gly Ser Gly Asp Val Glu Gln Gly Leu Gly | |
| 65 70 75 80 | |
| gtc tgc ggc tgc agc aac cac acc ctc tgg gct ggg agg gcc aag ggc | 288 |
| Val Cys Gly Cys Ser Asn His Thr Leu Trp Ala Gly Arg Ala Lys Gly | |
| 85 90 95 | |
| agc cgg ggc cct cct gta act cca ccc atg gcc ctg cct gca gac ttc | 336 |
| Ser Arg Gly Pro Pro Val Thr Pro Pro Met Ala Leu Pro Ala Asp Phe | |
| 100 105 110 | |
| ctc atg cac aag ctg acg gcc tcc gac acg ggg aag acc tgc ctg atg | 384 |
| Leu Met His Lys Leu Thr Ala Ser Asp Thr Gly Lys Thr Cys Leu Met | |
| 115 120 125 | |

| | |
|---|------|
| aag gcc ttg tta aac atc aac ccc aac acc aag gag ata gtg cgg atc Lys Ala Leu Leu Asn Ile Asn Pro Asn Thr Lys Glu Ile Val Arg Ile 130 135 140 | 432 |
| ctg ctt gcc ttt gct gaa gag aac gac atc ctg ggc agg ttc atc aac Leu Leu Ala Phe Ala Glu Glu Asn Asp Ile Leu Gly Arg Phe Ile Asn 145 150 155 160 | 480 |
| gcc gag tac aca gag gag gcc tat gaa ggg cag acg gcg ctg aac atc Ala Glu Tyr Thr Glu Glu Ala Tyr Glu Gly Gln Thr Ala Leu Asn Ile 165 170 175 | 528 |
| gcc atc gag cgg cgg cag ggg gac atc gca gcc ctg ctc atc gcc gcc Ala Ile Glu Arg Arg Gln Gly Asp Ile Ala Ala Leu Leu Ile Ala Ala 180 185 190 | 576 |
| ggc gcc gac gtc aac gcg cac gcc aag ggg gcc ttc ttc aac ccc aag Gly Ala Asp Val Asn Ala His Ala Lys Gly Ala Phe Phe Asn Pro Lys 195 200 205 | 624 |
| tac caa cac gaa ggc ttc tac ttc ggt gag acg ccc ctg gcc ctg gca Tyr Gln His Glu Gly Phe Tyr Phe Gly Glu Thr Pro Leu Ala Leu Ala 210 215 220 | 672 |
| gca tgc acc aac cag ccc gag att gtg cag ctg ctg atg gag cac gag Ala Cys Thr Asn Gln Pro Glu Ile Val Gln Leu Leu Met Glu His Glu 225 230 235 240 | 720 |
| cag acg gac atc acc tcg cgg gac tca cga ggc aac aac atc ctt cac Gln Thr Asp Ile Thr Ser Arg Asp Ser Arg Gly Asn Asn Ile Leu His 245 250 255 | 768 |
| gcc ctg gtg acc gtg gcc gag gac ttc aag acg cag aat gac ttt gtg Ala Leu Val Thr Val Ala Glu Asp Phe Lys Thr Gln Asn Asp Phe Val 260 265 270 | 816 |
| aag cgc atg tac gac atg atc cta ctg cgg agt ggc aac tgg gag ctg Lys Arg Met Tyr Asp Met Ile Leu Leu Arg Ser Gly Asn Trp Glu Leu 275 280 285 | 864 |
| gag acc act cgc aac aac gat ggc ctc acg ccg ctg cag ctg gcc gcc Glu Thr Thr Arg Asn Asn Asp Gly Leu Thr Pro Leu Gln Leu Ala Ala 290 295 300 | 912 |
| aag atg ggc aag gcg gag atc ctg aag tac atc ctc agt cgt gag atc Lys Met Gly Lys Ala Glu Ile Leu Lys Tyr Ile Leu Ser Arg Glu Ile 305 310 315 320 | 960 |
| aag gag aag cgg ctc cgg agc ctg tcc agg aag ttc acc gac tgg gcg Lys Glu Lys Arg Leu Arg Ser Leu Ser Arg Lys Phe Thr Asp Trp Ala 325 330 335 | 1008 |
| tac gga ccc gtg tca tcc tcc ctc tac gac ctc acc aac gtg gac acc Tyr Gly Pro Val Ser Ser Ser Leu Tyr Asp Leu Thr Asn Val Asp Thr 340 345 350 | 1056 |

| | |
|---|------|
| acc acg gac aac tca gtg ctg gaa atc act gtc tac aac acc aac atc Thr Thr Asp Asn Ser Val Leu Glu Ile Thr Val Tyr Asn Thr Asn Ile 355 360 365 | 1104 |
| gac aac cgg cat gag atg ctg acc ctg gag ccg ctg cac acg ctg ctg Asp Asn Arg His Glu Met Leu Thr Leu Glu Pro Leu His Thr Leu Leu 370 375 380 | 1152 |
| cat atg aag tgg aag aag ttt gcc aag cac atg ttc ttt ctg tcc ttc His Met Lys Trp Lys Lys Phe Ala Lys His Met Phe Phe Leu Ser Phe 385 390 395 400 | 1200 |
| tgc ttt tat ttc ttc tac aac atc acc ctg acc ctc gtc tcg tac tac Cys Phe Tyr Phe Phe Tyr Asn Ile Thr Leu Thr Leu Val Ser Tyr Tyr 405 410 415 | 1248 |
| cgc ccc cgg gag gag gag gcc atc ccg cac ccc ttg gcc ctg acg cac Arg Pro Arg Glu Glu Glu Ala Ile Pro His Pro Leu Ala Leu Thr His 420 425 430 | 1296 |
| aag atg ggg tgg ctg cag ctc cta ggg agg atg ttt gtg ctc atc tgg Lys Met Gly Trp Leu Gln Leu Leu Gly Arg Met Phe Val Leu Ile Trp 435 440 445 | 1344 |
| gcc atg tgc atc tct gtg aaa gag ggc att gcc atc ttc ctg ctg aga Ala Met Cys Ile Ser Val Lys Glu Gly Ile Ala Ile Phe Leu Leu Arg 450 455 460 | 1392 |
| ccc tcg gat ctg cag tcc atc ctc tcg gat gcc tgg ttc cac ttt gtc Pro Ser Asp Leu Gln Ser Ile Leu Ser Asp Ala Trp Phe His Phe Val 465 470 475 480 | 1440 |
| ttt ttt atc caa gct gtg ctt gtg ata ctg tct gtc ttc ttg tac ttg Phe Phe Ile Gln Ala Val Leu Val Ile Leu Ser Val Phe Leu Tyr Leu 485 490 495 | 1488 |
| ttt gcc tac aaa gag tac ctc gcc tgc ctc gtg ctg gcc atg gcc ctg Phe Ala Tyr Lys Glu Tyr Leu Ala Cys Leu Val Leu Ala Met Ala Leu 500 505 510 | 1536 |
| ggc tgg gcg aac atg ctc tac tat acg cgg ggt ttc cag tcc atg ggc Gly Trp Ala Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln Ser Met Gly 515 520 525 | 1584 |
| atg tac agc gtc atg atc cag aag gtc att ttg cat gat gtt ctg aag Met Tyr Ser Val Met Ile Gln Lys Val Ile Leu His Asp Val Leu Lys 530 535 540 | 1632 |
| ttc ttg ttt gta tat atc gcg ttt ttg ctt gga ttt gga gta gcc ttg Phe Leu Phe Val Tyr Ile Ala Phe Leu Leu Gly Phe Gly Val Ala Leu 545 550 555 560 | 1680 |
| gcc tcg ctg atc gag aag tgt ccc aaa gac aac aag gac tgc agc tcc Ala Ser Leu Ile Glu Lys Cys Pro Lys Asp Asn Lys Asp Cys Ser Ser 565 570 575 | 1728 |
| tac ggc agc ttc agc gac gca gtg ctg gaa ctc ttc aag ctc acc ata | 1776 |

Tyr Gly Ser Phe Ser Asp Ala Val Leu Glu Leu Phe Lys Leu Thr Ile
 580 585 590

ggc ctg ggt gay ctg aac atc cag cag aac tcc aag tat ccc att ctc 1824
 Gly Leu Gly Asp Leu Asn Ile Gln Gln Asn Ser Lys Tyr Pro Ile Leu
 595 600 605

ttt ctg ttc ctg ctc atc acc tat gtc atc ctc acc ttt gtt ctc ctc 1872
 Phe Leu Phe Leu Leu Ile Thr Tyr Val Ile Leu Thr Phe Val Leu Leu
 610 615 620

ctc aac atg ctc att gct ctg atg ggc gag act gtg gag aac gtc tcc 1920
 Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Glu Asn Val Ser
 625 630 635 640

aag gag agc gaa cgc atc tgg cgc ctg cag aga gcc agg acc atc ttg 1968
 Lys Glu Ser Glu Arg Ile Trp Arg Leu Gln Arg Ala Arg Thr Ile Leu
 645 650 655

gag ttt gag aaa atg tta cca gaa tgg ctg agg agc aga ttc cgg atg 2016
 Glu Phe Glu Lys Met Leu Pro Glu Trp Leu Arg Ser Arg Phe Arg Met
 660 665 670

gga gag ctg tgc aaa gtg gcc gag gat gat ttc cga ctg tgt ttg cgg 2064
 Gly Glu Leu Cys Lys Val Ala Glu Asp Asp Phe Arg Leu Cys Leu Arg
 675 680 685

atc aat gag gtg aag tgg act gaa tgg aag acg cac gtc tcc ttc ctt 2112
 Ile Asn Glu Val Lys Trp Thr Glu Trp Lys Thr His Val Ser Phe Leu
 690 695 700

aac gaa gac ccg ggg cct gta aga cga aca ggt act gtc gct gtg agg 2160
 Asn Glu Asp Pro Gly Pro Val Arg Arg Thr Gly Thr Val Ala Val Arg
 705 710 715 720

tga 2163

<210> 2
 <211> 720
 <212> PRT
 <213> Homo sapiens
 <400> 2

Met Ser Phe Ile Cys Arg Pro Arg Gly Gly Gly Arg Leu Glu Thr Asp
 1 5 10 15

Ser Arg Val Ala Ala Gly Gly Trp Thr Ala Gly Ser His Thr Val Gly
 20 25 30

Lys Glu Gln Lys Ala Ser Asp Thr Ser Pro Met Gly His Arg Glu Gln
 35 40 45

Gly Ala Ser Ile Gly Asp Gly Gly Glu Thr Ala Gly Glu Gly Gly Glu
50 55 60

Arg Pro Ser Val Arg Ser Gly Ser Gly Asp Val Glu Gln Gly Leu Gly
65 70 75 80

Val Cys Gly Cys Ser Asn His Thr Leu Trp Ala Gly Arg Ala Lys Gly
85 90 95

Ser Arg Gly Pro Pro Val Thr Pro Pro Met Ala Leu Pro Ala Asp Phe
100 105 110

Leu Met His Lys Leu Thr Ala Ser Asp Thr Gly Lys Thr Cys Leu Met
115 120 125

Lys Ala Leu Leu Asn Ile Asn Pro Asn Thr Lys Glu Ile Val Arg Ile
130 135 140

Leu Leu Ala Phe Ala Glu Glu Asn Asp Ile Leu Gly Arg Phe Ile Asn
145 150 155 160

Ala Glu Tyr Thr Glu Glu Ala Tyr Glu Gly Gln Thr Ala Leu Asn Ile
165 170 175

Ala Ile Glu Arg Arg Gln Gly Asp Ile Ala Ala Leu Leu Ile Ala Ala
180 185 190

Gly Ala Asp Val Asn Ala His Ala Lys Gly Ala Phe Phe Asn Pro Lys
195 200 205

Tyr Gln His Glu Gly Phe Tyr Phe Gly Glu Thr Pro Leu Ala Leu Ala
210 215 220

Ala Cys Thr Asn Gln Pro Glu Ile Val Gln Leu Leu Met Glu His Glu
225 230 235 240

Gln Thr Asp Ile Thr Ser Arg Asp Ser Arg Gly Asn Asn Ile Leu His
245 250 255

Ala Leu Val Thr Val Ala Glu Asp Phe Lys Thr Gln Asn Asp Phe Val
260 265 270

Lys Arg Met Tyr Asp Met Ile Leu Leu Arg Ser Gly Asn Trp Glu Leu

275

280

285

Glu Thr Thr Arg Asn Asn Asp Gly Leu Thr Pro Leu Gln Leu Ala Ala
 290 295 300

Lys Met Gly Lys Ala Glu Ile Leu Lys Tyr Ile Leu Ser Arg Glu Ile
 305 310 315 320

Lys Glu Lys Arg Leu Arg Ser Leu Ser Arg Lys Phe Thr Asp Trp Ala
 325 330 335

Tyr Gly Pro Val Ser Ser Ser Leu Tyr Asp Leu Thr Asn Val Asp Thr
 340 345 350

Thr Thr Asp Asn Ser Val Leu Glu Ile Thr Val Tyr Asn Thr Asn Ile
 355 360 365

Asp Asn Arg His Glu Met Leu Thr Leu Glu Pro Leu His Thr Leu Leu
 370 375 380

His Met Lys Trp Lys Lys Phe Ala Lys His Met Phe Phe Leu Ser Phe
 385 390 395 400

Cys Phe Tyr Phe Phe Tyr Asn Ile Thr Leu Thr Leu Val Ser Tyr Tyr
 405 410 415

Arg Pro Arg Glu Glu Glu Ala Ile Pro His Pro Leu Ala Leu Thr His
 420 425 430

Lys Met Gly Trp Leu Gln Leu Leu Gly Arg Met Phe Val Leu Ile Trp
 435 440 445

Ala Met Cys Ile Ser Val Lys Glu Gly Ile Ala Ile Phe Leu Leu Arg
 450 455 460

Pro Ser Asp Leu Gln Ser Ile Leu Ser Asp Ala Trp Phe His Phe Val
 465 470 475 480

Phe Phe Ile Gln Ala Val Leu Val Ile Leu Ser Val Phe Leu Tyr Leu
 485 490 495

Phe Ala Tyr Lys Glu Tyr Leu Ala Cys Leu Val Leu Ala Met Ala Leu
 500 505 510

Gly Trp Ala Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln Ser Met Gly
 515 520 525

Met Tyr Ser Val Met Ile Gln Lys Val Ile Leu His Asp Val Leu Lys
 530 535 540

Phe Leu Phe Val Tyr Ile Ala Phe Leu Leu Gly Phe Gly Val Ala Leu
 545 550 555 560

Ala Ser Leu Ile Glu Lys Cys Pro Lys Asp Asn Lys Asp Cys Ser Ser
 565 570 575

Tyr Gly Ser Phe Ser Asp Ala Val Leu Glu Leu Phe Lys Leu Thr Ile
 580 585 590

Gly Leu Gly Asp Leu Asn Ile Gln Gln Asn Ser Lys Tyr Pro Ile Leu
 595 600 605

Phe Leu Phe Leu Leu Ile Thr Tyr Val Ile Leu Thr Phe Val Leu Leu
 610 615 620

Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Glu Asn Val Ser
 625 630 635 640

Lys Glu Ser Glu Arg Ile Trp Arg Leu Gln Arg Ala Arg Thr Ile Leu
 645 650 655

Glu Phe Glu Lys Met Leu Pro Glu Trp Leu Arg Ser Arg Phe Arg Met
 660 665 670

Gly Glu Leu Cys Lys Val Ala Glu Asp Asp Phe Arg Leu Cys Leu Arg
 675 680 685

Ile Asn Glu Val Lys Trp Thr Glu Trp Lys Thr His Val Ser Phe Leu
 690 695 700

Asn Glu Asp Pro Gly Pro Val Arg Arg Thr Gly Thr Val Ala Val Arg
 705 710 715 720

<210> 3
 <211> 2238
 <212> DNA

```

<213> Homo sapiens

<220>
<221> CDS
<222> (1) .. (2235)

<400> 3
atg agc ttt att tgc agg cca cga gga ggg ggc agg ctg gag aca gat      48
Met Ser Phe Ile Cys Arg Pro Arg Gly Gly Gly Arg Leu Glu Thr Asp
1          5          10          15

tcc agg gtg gca gca ggg ggg tgg aca gcg gga agc cat aca gtg ggc      96
Ser Arg Val Ala Ala Gly Gly Trp Thr Ala Gly Ser His Thr Val Gly
          20          25          30

aaa gag caa aag gcc tca gat acg tca ccc atg ggc cac aga gag caa      144
Lys Glu Gln Lys Ala Ser Asp Thr Ser Pro Met Gly His Arg Glu Gln
          35          40          45

gga gcc agc ata gga gac gga gga gaa aca gct gga gag gga gga gag      192
Gly Ala Ser Ile Gly Asp Gly Gly Glu Thr Ala Gly Glu Gly Gly Glu
          50          55          60

cgg cca agt gta agg tct ggg agt gga gat gtg gag cag ggg ctt ggg      240
Arg Pro Ser Val Arg Ser Gly Ser Gly Asp Val Glu Gln Gly Leu Gly
65          70          75          80

gtc tgc ggc tgc agc aac cac acc ctc tgg gct ggg agg gcc aag ggc      288
Val Cys Gly Cys Ser Asn His Thr Leu Trp Ala Gly Arg Ala Lys Gly
          85          90          95

agc cgg ggc cct cct gta act cca ccc atg gcc ctg cct gca gac ttc      336
Ser Arg Gly Pro Pro Val Thr Pro Pro Met Ala Leu Pro Ala Asp Phe
          100          105          110

ctc atg cac aag ctg acg gcc tcc gac acg ggg aag acc tgc ctg atg      384
Leu Met His Lys Leu Thr Ala Ser Asp Thr Gly Lys Thr Cys Leu Met
          115          120          125

aag gcc ttg tta aac atc aac ccc aac acc aag gag ata gtg cgg atc      432
Lys Ala Leu Leu Asn Ile Asn Pro Asn Thr Lys Glu Ile Val Arg Ile
          130          135          140

ctg ctt gcc ttt gct gaa gag aac gac atc ctg ggc agg ttc atc aac      480
Leu Leu Ala Phe Ala Glu Glu Asn Asp Ile Leu Gly Arg Phe Ile Asn
145          150          155          160

gcc gag tac aca gag gag gcc tat gaa ggg cag acg gcg ctg aac atc      528
Ala Glu Tyr Thr Glu Glu Ala Tyr Glu Gly Gln Thr Ala Leu Asn Ile
          165          170          175

gcc atc gag cgg cgg cag ggg gac atc gca gcc ctg ctc atc gcc gcc      576
Ala Ile Glu Arg Arg Gln Gly Asp Ile Ala Ala Leu Leu Ile Ala Ala
          180          185          190

ggc gcc gac gtc aac gcg cac gcc aag ggg gcc ttc ttc aac ccc aag      624
Gly Ala Asp Val Asn Ala His Ala Lys Gly Ala Phe Phe Asn Pro Lys

```

| 195 | 200 | 205 | |
|---|-----|-----|------|
| tac caa cac gaa ggc ttc tac ttc ggt gag acg ccc ctg gcc ctg gca | | | 672 |
| Tyr Gln His Glu Gly Phe Tyr Phe Gly Glu Thr Pro Leu Ala Leu Ala | | | |
| 210 | 215 | 220 | |
| gca tgc acc aac cag ccc gag att gtg cag ctg ctg atg gag cac gag | | | 720 |
| Ala Cys Thr Asn Gln Pro Glu Ile Val Gln Leu Leu Met Glu His Glu | | | |
| 225 | 230 | 235 | 240 |
| cag acg gac atc acc tcg cgg gac tca cga ggc aac aac atc ctt cac | | | 768 |
| Gln Thr Asp Ile Thr Ser Arg Asp Ser Arg Gly Asn Asn Ile Leu His | | | |
| 245 | 250 | 255 | |
| gcc ctg gtg acc gtg gcc gag gac ttc aag acg cag aat gac ttt gtg | | | 816 |
| Ala Leu Val Thr Val Ala Glu Asp Phe Lys Thr Gln Asn Asp Phe Val | | | |
| 260 | 265 | 270 | |
| aag cgc atg tac gac atg atc cta ctg cgg agt ggc aac tgg gag ctg | | | 864 |
| Lys Arg Met Tyr Asp Met Ile Leu Leu Arg Ser Gly Asn Trp Glu Leu | | | |
| 275 | 280 | 285 | |
| gag acc act cgc aac aac gat ggc ctc acg ccg ctg cag ctg gcc gcc | | | 912 |
| Glu Thr Thr Arg Asn Asn Asp Gly Leu Thr Pro Leu Gln Leu Ala Ala | | | |
| 290 | 295 | 300 | |
| aag atg ggc aag gcg gag atc ctg aag tac atc ctc agt cgt gag atc | | | 960 |
| Lys Met Gly Lys Ala Glu Ile Leu Lys Tyr Ile Leu Ser Arg Glu Ile | | | |
| 305 | 310 | 315 | 320 |
| aag gag aag cgg ctc cgg agc ctg tcc agg aag ttc acc gac tgg gcg | | | 1008 |
| Lys Glu Lys Arg Leu Arg Ser Leu Ser Arg Lys Phe Thr Asp Trp Ala | | | |
| 325 | 330 | 335 | |
| tac gga ccc gtg tca tcc tcc ctc tac gac ctc acc aac gtg gac acc | | | 1056 |
| Tyr Gly Pro Val Ser Ser Ser Leu Tyr Asp Leu Thr Asn Val Asp Thr | | | |
| 340 | 345 | 350 | |
| acc acg gac aac tca gtg ctg gaa atc act gtc tac aac acc aac atc | | | 1104 |
| Thr Thr Asp Asn Ser Val Leu Glu Ile Thr Val Tyr Asn Thr Asn Ile | | | |
| 355 | 360 | 365 | |
| gac aac cgg cat gag atg ctg acc ctg gag ccg ctg cac acg ctg ctg | | | 1152 |
| Asp Asn Arg His Glu Met Leu Thr Leu Glu Pro Leu His Thr Leu Leu | | | |
| 370 | 375 | 380 | |
| cat atg aag tgg aag aag ttt gcc aag cac atg ttc ttt ctg tcc ttc | | | 1200 |
| His Met Lys Trp Lys Lys Phe Ala Lys His Met Phe Phe Leu Ser Phe | | | |
| 385 | 390 | 395 | 400 |
| tgc ttt tat ttc ttc tac aac atc acc ctg acc ctc gtc tcg tac tac | | | 1248 |
| Cys Phe Tyr Phe Phe Tyr Asn Ile Thr Leu Thr Leu Val Ser Tyr Tyr | | | |
| 405 | 410 | 415 | |
| cga ccc cgg gag gag gag gcc atc ccg cac ccc ttg gcc ctg acg cac | | | 1296 |
| Arg Pro Arg Glu Glu Glu Ala Ile Pro His Pro Leu Ala Leu Thr His | | | |
| 420 | 425 | 430 | |

| | |
|---|------|
| aag atg ggg tgg ctg cag ctc cta ggg agg atg ttt gtg ctc atc tgg Lys Met Gly Trp Leu Gln Leu Leu Gly Arg Met Phe Val Leu Ile Trp 435 440 445 | 1344 |
| gcc atg tgc atc tct gtg aaa gag ggc att gcc atc ttc ctg ctg aga Ala Met Cys Ile Ser Val Lys Glu Gly Ile Ala Ile Phe Leu Leu Arg 450 455 460 | 1392 |
| ccc tcg gat ctg cag tcc atc ctc tcg gat gcc tgg ttc cac ttt gtc Pro Ser Asp Leu Gln Ser Ile Leu Ser Asp Ala Trp Phe His Phe Val 465 470 475 480 | 1440 |
| ttt ttt atc caa gct gtg ctt gtg ata ctg tct gtc ttc ttg tac ttg Phe Phe Ile Gln Ala Val Leu Val Ile Leu Ser Val Phe Leu Tyr Leu 485 490 495 | 1488 |
| ttt gcc tac aaa gag tac ctc gcc tgc ctc gtg ctg gcc atg gcc ctg Phe Ala Tyr Lys Glu Tyr Leu Ala Cys Leu Val Leu Ala Met Ala Leu 500 505 510 | 1536 |
| ggc tgg gcg aac atg ctc tac tat acg cgg ggt ttc cag tcc atg ggc Gly Trp Ala Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln Ser Met Gly 515 520 525 | 1584 |
| atg tac agc gtc atg atc cag aag gtc att ttg cat gat gtt ctg aag Met Tyr Ser Val Met Ile Gln Lys Val Ile Leu His Asp Val Leu Lys 530 535 540 | 1632 |
| ttc ttg ttt gta tat atc gcg ttt ttg ctt gga ttt gga gta gcc ttg Phe Leu Phe Val Tyr Ile Ala Phe Leu Leu Gly Phe Gly Val Ala Leu 545 550 555 560 | 1680 |
| gcc tcg ctg atc gag aag tgt ccc aaa gac aac aag gac tgc agc tcc Ala Ser Leu Ile Glu Lys Cys Pro Lys Asp Asn Lys Asp Cys Ser Ser 565 570 575 | 1728 |
| tac ggc agc ttc agc gac gca gtg ctg gaa ctc ttc aag ctc acc ata Tyr Gly Ser Phe Ser Asp Ala Val Leu Glu Leu Phe Lys Leu Thr Ile 580 585 590 | 1776 |
| ggc ctg ggt gay ctg aac atc cag cag aac tcc aag tat ccc att ctc Gly Leu Gly Asp Leu Asn Ile Gln Gln Asn Ser Lys Tyr Pro Ile Leu 595 600 605 | 1824 |
| ttt ctg ttc ctg ctc atc acc tat gtc atc ctc acc ttt gtt ctc ctc Phe Leu Phe Leu Leu Ile Thr Tyr Val Ile Leu Thr Phe Val Leu Leu 610 615 620 | 1872 |
| ctc aac atg ctc att gct ctg atg ggc gag act gtg gag aac gtc tcc Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Glu Asn Val Ser 625 630 635 640 | 1920 |
| aag gag agc gaa cgc atc tgg cgc ctg cag aga gcc agg acc atc ttg Lys Glu Ser Glu Arg Ile Trp Arg Leu Gln Arg Ala Arg Thr Ile Leu 645 650 655 | 1968 |

gag ttt gag aaa atg tta cca gaa tgg ctg agg agc aga ttc cgg atg 2016
 Glu Phe Glu Lys Met Leu Pro Glu Trp Leu Arg Ser Arg Phe Arg Met
 660 665 670

 gga gag ctg tgc aaa gtg gcc gag gat gat ttc cga ctg tgt ttg cgg 2064
 Gly Glu Leu Cys Lys Val Ala Glu Asp Asp Phe Arg Leu Cys Leu Arg
 675 680 685

 atc aat gag gtg aag tgg act gaa tgg aag acg cac gtc tcc ttc ctt 2112
 Ile Asn Glu Val Lys Trp Thr Glu Trp Lys Thr His Val Ser Phe Leu
 690 695 700

 aac gaa gac ccg ggg cct gta aga cga aca gat ttc aac aaa atc caa 2160
 Asn Glu Asp Pro Gly Pro Val Arg Arg Thr Asp Phe Asn Lys Ile Gln
 705 710 715 720

 gat tct tcc agg aac aac agc aaa acc act ctc aat gca ttt gaa gaa 2208
 Asp Ser Ser Arg Asn Asn Ser Lys Thr Thr Leu Asn Ala Phe Glu Glu
 725 730 735

 gtc gag gaa ttc ccg gaa acc tcg gtg tag 2238
 Val Glu Glu Phe Pro Glu Thr Ser Val
 740 745

<210> 4
 <211> 745
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Ser Phe Ile Cys Arg Pro Arg Gly Gly Gly Arg Leu Glu Thr Asp
1 5 10 15

Ser Arg Val Ala Ala Gly Gly Trp Thr Ala Gly Ser His Thr Val Gly
20 25 30

Lys Glu Gln Lys Ala Ser Asp Thr Ser Pro Met Gly His Arg Glu Gln
35 40 45

Gly Ala Ser Ile Gly Asp Gly Gly Glu Thr Ala Gly Glu Gly Gly Glu
50 55 60

Arg Pro Ser Val Arg Ser Gly Ser Gly Asp Val Glu Gln Gly Leu Gly
65 70 75 80

Val Cys Gly Cys Ser Asn His Thr Leu Trp Ala Gly Arg Ala Lys Gly
85 90 95

Ser Arg Gly Pro Pro Val Thr Pro Pro Met Ala Leu Pro Ala Asp Phe

100

105

110

Leu Met His Lys Leu Thr Ala Ser Asp Thr Gly Lys Thr Cys Leu Met
115 120 125

Lys Ala Leu Leu Asn Ile Asn Pro Asn Thr Lys Glu Ile Val Arg Ile
130 135 140

Leu Leu Ala Phe Ala Glu Glu Asn Asp Ile Leu Gly Arg Phe Ile Asn
145 150 155 160

Ala Glu Tyr Thr Glu Glu Ala Tyr Glu Gly Gln Thr Ala Leu Asn Ile
165 170 175

Ala Ile Glu Arg Arg Gln Gly Asp Ile Ala Ala Leu Leu Ile Ala Ala
180 185 190

Gly Ala Asp Val Asn Ala His Ala Lys Gly Ala Phe Phe Asn Pro Lys
195 200 205

Tyr Gln His Glu Gly Phe Tyr Phe Gly Glu Thr Pro Leu Ala Leu Ala
210 215 220

Ala Cys Thr Asn Gln Pro Glu Ile Val Gln Leu Leu Met Glu His Glu
225 230 235 240

Gln Thr Asp Ile Thr Ser Arg Asp Ser Arg Gly Asn Asn Ile Leu His
245 250 255

Ala Leu Val Thr Val Ala Glu Asp Phe Lys Thr Gln Asn Asp Phe Val
260 265 270

Lys Arg Met Tyr Asp Met Ile Leu Leu Arg Ser Gly Asn Trp Glu Leu
275 280 285

Glu Thr Thr Arg Asn Asn Asp Gly Leu Thr Pro Leu Gln Leu Ala Ala
290 295 300

Lys Met Gly Lys Ala Glu Ile Leu Lys Tyr Ile Leu Ser Arg Glu Ile
305 310 315 320

Lys Glu Lys Arg Leu Arg Ser Leu Ser Arg Lys Phe Thr Asp Trp Ala
325 330 335

Tyr Gly Pro Val Ser Ser Ser Leu Tyr Asp Leu Thr Asn Val Asp Thr
 340 345 350

Thr Thr Asp Asn Ser Val Leu Glu Ile Thr Val Tyr Asn Thr Asn Ile
 355 360 365

Asp Asn Arg His Glu Met Leu Thr Leu Glu Pro Leu His Thr Leu Leu
 370 375 380

His Met Lys Trp Lys Lys Phe Ala Lys His Met Phe Phe Leu Ser Phe
 385 390 395 400

Cys Phe Tyr Phe Phe Tyr Asn Ile Thr Leu Thr Leu Val Ser Tyr Tyr
 405 410 415

Arg Pro Arg Glu Glu Glu Ala Ile Pro His Pro Leu Ala Leu Thr His
 420 425 430

Lys Met Gly Trp Leu Gln Leu Leu Gly Arg Met Phe Val Leu Ile Trp
 435 440 445

Ala Met Cys Ile Ser Val Lys Glu Gly Ile Ala Ile Phe Leu Leu Arg
 450 455 460

Pro Ser Asp Leu Gln Ser Ile Leu Ser Asp Ala Trp Phe His Phe Val
 465 470 475 480

Phe Phe Ile Gln Ala Val Leu Val Ile Leu Ser Val Phe Leu Tyr Leu
 485 490 495

Phe Ala Tyr Lys Glu Tyr Leu Ala Cys Leu Val Leu Ala Met Ala Leu
 500 505 510

Gly Trp Ala Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln Ser Met Gly
 515 520 525

Met Tyr Ser Val Met Ile Gln Lys Val Ile Leu His Asp Val Leu Lys
 530 535 540

Phe Leu Phe Val Tyr Ile Ala Phe Leu Leu Gly Phe Gly Val Ala Leu
 545 550 555 560

Ala Ser Leu Ile Glu Lys Cys Pro Lys Asp Asn Lys Asp Cys Ser Ser
 565 570 575

Tyr Gly Ser Phe Ser Asp Ala Val Leu Glu Leu Phe Lys Leu Thr Ile
 580 585 590

Gly Leu Gly Asp Leu Asn Ile Gln Gln Asn Ser Lys Tyr Pro Ile Leu
 595 600 605

Phe Leu Phe Leu Leu Ile Thr Tyr Val Ile Leu Thr Phe Val Leu Leu
 610 615 620

Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Glu Asn Val Ser
 625 630 635 640

Lys Glu Ser Glu Arg Ile Trp Arg Leu Gln Arg Ala Arg Thr Ile Leu
 645 650 655

Glu Phe Glu Lys Met Leu Pro Glu Trp Leu Arg Ser Arg Phe Arg Met
 660 665 670

Gly Glu Leu Cys Lys Val Ala Glu Asp Asp Phe Arg Leu Cys Leu Arg
 675 680 685

Ile Asn Glu Val Lys Trp Thr Glu Trp Lys Thr His Val Ser Phe Leu
 690 695 700

Asn Glu Asp Pro Gly Pro Val Arg Arg Thr Asp Phe Asn Lys Ile Gln
 705 710 715 720

Asp Ser Ser Arg Asn Asn Ser Lys Thr Thr Leu Asn Ala Phe Glu Glu
 725 730 735

Val Glu Glu Phe Pro Glu Thr Ser Val
 740 745

<210> 5
 <211> 839
 <212> PRT
 <213> Homo sapiens

<400> 5

Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu

| | | | |
|---|-----|-----|-----|
| 1 | 5 | 10 | 15 |
| Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg | 20 | 25 | 30 |
| Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg | 35 | 40 | 45 |
| Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro | 50 | 55 | 60 |
| His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro | 65 | 70 | 75 |
| Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu | 85 | 90 | 95 |
| Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu | 100 | 105 | 110 |
| Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln | 115 | 120 | 125 |
| Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu | 130 | 135 | 140 |
| Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu | 145 | 150 | 155 |
| Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu | 165 | 170 | 175 |
| Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn | 180 | 185 | 190 |
| Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile | 195 | 200 | 205 |
| Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn | 210 | 215 | 220 |
| Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr | 225 | 230 | 235 |
| Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala | 245 | 250 | 255 |
| Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser | 260 | 265 | 270 |
| Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val | 275 | 280 | 285 |
| Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys | 290 | 295 | 300 |
| Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu | | | |

16

| 610 | 615 | 620 |
|--|-----|-----|
| Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys 625 630 635 640 | | |
| Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe 645 650 655 | | |
| Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr 660 665 670 | | |
| Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn 675 680 685 | | |
| Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile 690 695 700 | | |
| Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala 705 710 715 720 | | |
| Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys 725 730 735 | | |
| Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr 740 745 750 | | |
| Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu 755 760 765 | | |
| Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser 770 775 780 | | |
| Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala 785 790 795 800 | | |
| Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg 805 810 815 | | |
| Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser 820 825 830 | | |
| Pro Ala Ala Ser Gly Glu Lys 835 | | |

<210> 6
 <211> 764
 <212> PRT
 <213> Homo sapiens

<400> 6

| |
|--|
| Met Thr Ser Pro Ser Ser Ser Pro Val Phe Arg Leu Glu Thr Leu Asp 1 5 10 15 |
| Gly Gly Gln Glu Asp Gly Ser Glu Ala Asp Arg Gly Lys Leu Asp Phe 20 25 30 |

Gly Ser Gly Leu Pro Pro Met Glu Ser Gln Phe Gln Gly Glu Asp Arg
 35 40 45
 Lys Phe Ala Pro Gln Ile Arg Val Asn Leu Asn Tyr Arg Lys Gly Thr
 50 55 60
 Gly Ala Ser Gln Pro Asp Pro Asn Arg Phe Asp Arg Asp Arg Leu Phe
 65 70 75 80
 Asn Ala Val Ser Arg Gly Val Pro Glu Asp Leu Ala Gly Leu Pro Glu
 85 90 95
 Tyr Leu Ser Lys Thr Ser Lys Tyr Leu Thr Asp Ser Glu Tyr Thr Glu
 100 105 110
 Gly Ser Thr Gly Lys Thr Cys Leu Met Lys Ala Val Leu Asn Leu Lys
 115 120 125
 Asp Gly Val Asn Ala Cys Ile Leu Pro Leu Leu Gln Ile Asp Arg Asp
 130 135 140
 Ser Gly Asn Pro Gln Pro Leu Val Asn Ala Gln Cys Thr Asp Asp Tyr
 145 150 155 160
 Tyr Arg Gly His Ser Ala Leu His Ile Ala Ile Glu Lys Arg Ser Leu
 165 170 175
 Gln Cys Val Lys Leu Leu Val Glu Asn Gly Ala Asn Val His Ala Arg
 180 185 190
 Ala Cys Gly Arg Phe Phe Gln Lys Gly Gln Gly Thr Cys Phe Tyr Phe
 195 200 205
 Gly Glu Leu Pro Leu Ser Leu Ala Ala Cys Thr Lys Gln Trp Asp Val
 210 215 220
 Val Ser Tyr Leu Leu Glu Asn Pro His Gln Pro Ala Ser Leu Gln Ala
 225 230 235 240
 Thr Asp Ser Gln Gly Asn Thr Val Leu His Ala Leu Val Met Ile Ser
 245 250 255
 Asp Asn Ser Ala Glu Asn Ile Ala Leu Val Thr Ser Met Tyr Asp Gly
 260 265 270
 Leu Leu Gln Ala Gly Ala Arg Leu Cys Pro Thr Val Gln Leu Glu Asp
 275 280 285
 Ile Arg Asn Leu Gln Asp Leu Thr Pro Leu Lys Leu Ala Ala Lys Glu
 290 295 300
 Gly Lys Ile Glu Ile Phe Arg His Ile Leu Gln Arg Glu Phe Ser Gly
 305 310 315 320
 Leu Ser His Leu Ser Arg Lys Phe Thr Glu Trp Cys Tyr Gly Pro Val
 325 330 335

Arg Val Ser Leu Tyr Asp Leu Ala Ser Val Asp Ser Cys Glu Glu Asn
 340 345 350
 Ser Val Leu Glu Ile Ile Ala Phe His Cys Lys Ser Pro His Arg His
 355 360 365
 Arg Met Val Val Leu Glu Pro Leu Asn Lys Leu Leu Gln Ala Lys Trp
 370 375 380
 Asp Leu Leu Ile Pro Lys Phe Phe Leu Asn Phe Leu Cys Asn Leu Ile
 385 390 395 400
 Tyr Met Phe Ile Phe Thr Ala Val Ala Tyr His Gln Pro Thr Leu Lys
 405 410 415
 Lys Gln Ala Ala Pro His Leu Lys Ala Glu Val Gly Asn Ser Met Leu
 420 425 430
 Leu Thr Gly His Ile Leu Ile Leu Leu Gly Gly Ile Tyr Leu Leu Val
 435 440 445
 Gly Gln Leu Trp Tyr Phe Trp Arg Arg His Val Phe Ile Trp Ile Ser
 450 455 460
 Phe Ile Asp Ser Tyr Phe Glu Ile Leu Phe Leu Phe Gln Ala Leu Leu
 465 470 475 480
 Thr Val Val Ser Gln Val Leu Cys Phe Leu Ala Ile Glu Trp Tyr Leu
 485 490 495
 Pro Leu Leu Val Ser Ala Leu Val Leu Gly Trp Leu Asn Leu Leu Tyr
 500 505 510
 Tyr Thr Arg Gly Phe Gln His Thr Gly Ile Tyr Ser Val Met Ile Gln
 515 520 525
 Lys Val Ile Leu Arg Asp Leu Leu Arg Phe Leu Leu Ile Tyr Leu Val
 530 535 540
 Phe Leu Phe Gly Phe Ala Val Ala Leu Val Ser Leu Ser Gln Glu Ala
 545 550 555 560
 Trp Arg Pro Glu Ala Pro Thr Gly Pro Asn Ala Thr Glu Ser Val Gln
 565 570 575
 Pro Met Glu Gly Gln Glu Asp Glu Gly Asn Gly Ala Gln Tyr Arg Gly
 580 585 590
 Ile Leu Glu Ala Ser Leu Glu Leu Phe Lys Phe Thr Ile Gly Met Gly
 595 600 605
 Glu Leu Ala Phe Gln Glu Gln Leu His Phe Arg Gly Met Val Leu Leu
 610 615 620
 Leu Leu Leu Ala Tyr Val Leu Leu Thr Tyr Ile Leu Leu Leu Asn Met
 625 630 635 640

Leu Ile Ala Leu Met Ser Glu Thr Val Asn Ser Val Ala Thr Asp Ser
 645 650 655
 Trp Ser Ile Trp Lys Leu Gln Lys Ala Ile Ser Val Leu Glu Met Glu
 660 665 670
 Asn Gly Tyr Trp Trp Cys Arg Lys Lys Gln Arg Ala Gly Val Met Leu
 675 680 685
 Thr Val Gly Thr Lys Pro Asp Gly Ser Pro Asp Glu Arg Trp Cys Phe
 690 695 700
 Arg Val Glu Glu Val Asn Trp Ala Ser Trp Glu Gln Thr Leu Pro Thr
 705 710 715 720
 Leu Cys Glu Asp Pro Ser Gly Ala Gly Val Pro Arg Thr Leu Glu Asn
 725 730 735
 Pro Val Leu Ala Ser Pro Pro Lys Glu Asp Glu Asp Gly Ala Ser Glu
 740 745 750
 Glu Asn Tyr Val Pro Val Gln Leu Leu Gln Ser Asn
 755 760
 <210> 7
 <211> 871
 <212> PRT
 <213> Homo sapiens
 <400> 7
 Met Ala Asp Ser Ser Glu Gly Pro Arg Ala Gly Pro Gly Glu Val Ala
 1 5 10 15
 Glu Leu Pro Gly Asp Glu Ser Gly Thr Pro Gly Gly Glu Ala Phe Pro
 20 25 30
 Leu Ser Ser Leu Ala Asn Leu Phe Glu Gly Glu Asp Gly Ser Leu Ser
 35 40 45
 Pro Ser Pro Ala Asp Ala Ser Arg Pro Ala Gly Pro Gly Asp Gly Arg
 50 55 60
 Pro Asn Leu Arg Met Lys Phe Gln Gly Ala Phe Arg Lys Gly Val Pro
 65 70 75 80
 Asn Pro Ile Asp Leu Leu Glu Ser Thr Leu Tyr Glu Ser Ser Val Val
 85 90 95
 Pro Gly Pro Lys Lys Ala Pro Met Asp Ser Leu Phe Asp Tyr Gly Thr
 100 105 110
 Tyr Arg His His Ser Ser Asp Asn Lys Arg Trp Arg Lys Lys Ile Ile
 115 120 125
 Glu Lys Gln Pro Gln Ser Pro Lys Ala Pro Ala Pro Gln Pro Pro Pro
 130 135 140

Ile Leu Lys Val Phe Asn Arg Pro Ile Leu Phe Asp Ile Val Ser Arg
 145 150 155 160
 Gly Ser Thr Ala Asp Leu Asp Gly Leu Leu Pro Phe Leu Leu Thr His
 165 170 175
 Lys Lys Arg Leu Thr Asp Glu Glu Phe Arg Glu Pro Ser Thr Gly Lys
 180 185 190
 Thr Cys Leu Pro Lys Ala Leu Leu Asn Leu Ser Asn Gly Arg Asn Asp
 195 200 205
 Thr Ile Pro Val Leu Leu Asp Ile Ala Glu Arg Thr Gly Asn Met Arg
 210 215 220
 Glu Phe Ile Asn Ser Pro Phe Arg Asp Ile Tyr Tyr Arg Gly Gln Thr
 225 230 235 240
 Ala Leu His Ile Ala Ile Glu Arg Arg Cys Lys His Tyr Val Glu Leu
 245 250 255
 Leu Val Ala Gln Gly Ala Asp Val His Ala Gln Ala Arg Gly Arg Phe
 260 265 270
 Phe Gln Pro Lys Asp Glu Gly Gly Tyr Phe Tyr Phe Gly Glu Leu Pro
 275 280 285
 Leu Ser Leu Ala Ala Cys Thr Asn Gln Pro His Ile Val Asn Tyr Leu
 290 295 300
 Thr Glu Asn Pro His Lys Lys Ala Asp Met Arg Arg Gln Asp Ser Arg
 305 310 315 320
 Gly Asn Thr Val Leu His Ala Leu Val Ala Ile Ala Asp Asn Thr Arg
 325 330 335
 Glu Asn Thr Lys Phe Val Thr Lys Met Tyr Asp Leu Leu Leu Leu Lys
 340 345 350
 Cys Ala Arg Leu Phe Pro Asp Ser Asn Leu Glu Ala Val Leu Asn Asn
 355 360 365
 Asp Gly Leu Ser Pro Leu Met Met Ala Ala Lys Thr Gly Lys Ile Gly
 370 375 380
 Ile Phe Gln His Ile Ile Arg Arg Glu Val Thr Asp Glu Asp Thr Arg
 385 390 395 400
 His Leu Ser Arg Lys Phe Lys Asp Trp Ala Tyr Gly Pro Val Tyr Ser
 405 410 415
 Ser Leu Tyr Asp Leu Ser Ser Leu Asp Thr Cys Gly Glu Glu Ala Ser
 420 425 430
 Val Leu Glu Ile Leu Val Tyr Asn Ser Lys Ile Glu Asn Arg His Glu
 435 440 445

Met Leu Ala Val Glu Pro Ile Asn Glu Leu Leu Arg Asp Lys Trp Arg
 450 455 460
 Lys Phe Gly Ala Val Ser Phe Tyr Ile Asn Val Val Ser Tyr Leu Cys
 465 470 475 480
 Ala Met Val Ile Phe Thr Leu Thr Ala Tyr Tyr Gln Pro Leu Glu Gly
 485 490 495
 Thr Pro Pro Tyr Pro Tyr Arg Thr Thr Val Asp Tyr Leu Arg Leu Ala
 500 505 510
 Gly Glu Val Ile Thr Leu Phe Thr Gly Val Leu Phe Phe Phe Thr Asn
 515 520 525
 Ile Lys Asp Leu Phe Met Lys Lys Cys Pro Gly Val Asn Ser Leu Phe
 530 535 540
 Ile Asp Gly Ser Phe Gln Leu Leu Tyr Phe Ile Tyr Ser Val Leu Val
 545 550 555 560
 Ile Val Ser Ala Ala Leu Tyr Leu Ala Gly Ile Glu Ala Tyr Leu Ala
 565 570 575
 Val Met Val Phe Ala Leu Val Leu Gly Trp Met Asn Ala Leu Tyr Phe
 580 585 590
 Thr Arg Gly Leu Lys Leu Thr Gly Thr Tyr Ser Ile Met Ile Gln Lys
 595 600 605
 Ile Leu Phe Lys Asp Leu Phe Arg Phe Leu Leu Val Tyr Leu Leu Phe
 610 615 620
 Met Ile Gly Tyr Ala Ser Ala Leu Val Ser Leu Leu Asn Pro Cys Ala
 625 630 635 640
 Asn Met Lys Val Cys Asn Glu Asp Gln Thr Asn Cys Thr Val Pro Thr
 645 650 655
 Tyr Pro Ser Cys Arg Asp Ser Glu Thr Phe Ser Thr Phe Leu Leu Asp
 660 665 670
 Leu Phe Lys Leu Thr Ile Gly Met Gly Asp Leu Glu Met Leu Ser Ser
 675 680 685
 Thr Lys Tyr Pro Val Val Phe Ile Ile Leu Leu Val Thr Tyr Ile Ile
 690 695 700
 Leu Thr Phe Val Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu
 705 710 715 720
 Thr Val Gly Gln Val Ser Lys Glu Ser Lys His Ile Trp Lys Leu Gln
 725 730 735
 Trp Ala Thr Thr Ile Leu Asp Ile Glu Arg Ser Phe Pro Val Phe Leu
 740 745 750

Arg Lys Ala Phe Arg Ser Gly Glu Met Val Thr Val Gly Lys Ser Ser
 755 760 765
 Asp Gly Thr Pro Asp Arg Arg Trp Cys Phe Arg Val Asp Glu Val Asn
 770 775 780
 Trp Ser His Trp Asn Gln Asn Leu Gly Ile Ile Asn Glu Asp Pro Gly
 785 790 795 800
 Lys Asn Glu Thr Tyr Gln Tyr Tyr Gly Phe Ser His Thr Val Gly Arg
 805 810 815
 Leu Arg Arg Asp Arg Trp Ser Ser Val Val Pro Arg Val Val Glu Leu
 820 825 830
 Asn Lys Asn Ser Asn Pro Asp Glu Val Val Val Pro Leu Asp Ser Met
 835 840 845
 Gly Asn Pro Arg Cys Asp Gly His Gln Gln Gly Tyr Pro Arg Lys Trp
 850 855 860
 Arg Thr Glu Asp Ala Pro Leu
 865 870

<210> 8
 <211> 725
 <212> PRT
 <213> Homo sapiens

<400> 8

Met Gly Leu Ser Leu Pro Lys Glu Lys Gly Leu Ile Leu Cys Leu Trp
 1 5 10 15
 Ser Lys Phe Cys Arg Trp Phe Gln Arg Arg Glu Ser Trp Ala Gln Ser
 20 25 30
 Arg Asp Glu Gln Asn Leu Leu Gln Gln Lys Arg Ile Trp Glu Ser Pro
 35 40 45
 Leu Leu Leu Ala Ala Lys Asp Asn Asp Val Gln Ala Leu Asn Lys Leu
 50 55 60
 Leu Lys Tyr Glu Asp Cys Lys Val His Gln Arg Gly Ala Met Gly Glu
 65 70 75 80
 Thr Ala Leu His Ile Ala Ala Leu Tyr Asp Asn Leu Glu Ala Ala Met
 85 90 95
 Val Leu Met Glu Ala Ala Pro Glu Leu Val Phe Glu Pro Met Thr Ser
 100 105 110
 Glu Leu Tyr Glu Gly Gln Thr Ala Leu His Ile Ala Val Val Asn Gln
 115 120 125
 Asn Met Asn Leu Val Arg Ala Leu Leu Ala Arg Arg Ala Ser Val Ser

| 130 | 135 | 140 |
|--|-----|---------|
| Ala Arg Ala Thr Gly Thr Ala Phe Arg Arg Ser Pro Cys Asn Leu Ile 145 | 150 | 155 160 |
| Tyr Phe Gly Glu His Pro Leu Ser Phe Ala Ala Cys Val Asn Ser Glu 165 | 170 | 175 |
| Glu Ile Val Arg Leu Leu Ile Glu His Gly Ala Asp Ile Arg Ala Gln 180 | 185 | 190 |
| Asp Ser Leu Gly Asn Thr Val Leu His Ile Leu Ile Leu Gln Pro Asn 195 | 200 | 205 |
| Lys Thr Phe Ala Cys Gln Met Tyr Asn Leu Leu Leu Ser Tyr Asp Arg 210 | 215 | 220 |
| His Gly Asp His Leu Gln Pro Leu Asp Leu Val Pro Asn His Gln Gly 225 | 230 | 235 240 |
| Leu Thr Pro Phe Lys Leu Ala Gly Val Glu Gly Asn Thr Val Met Phe 245 | 250 | 255 |
| Gln His Leu Met Gln Lys Arg Lys His Thr Gln Trp Thr Tyr Gly Pro 260 | 265 | 270 |
| Leu Thr Ser Thr Leu Tyr Asp Leu Thr Glu Ile Asp Ser Ser Gly Asp 275 | 280 | 285 |
| Glu Gln Ser Leu Leu Glu Leu Ile Ile Thr Thr Lys Lys Arg Glu Ala 290 | 295 | 300 |
| Arg Gln Ile Leu Asp Gln Thr Pro Val Lys Glu Leu Val Ser Leu Lys 305 | 310 | 315 320 |
| Trp Lys Arg Tyr Gly Arg Pro Tyr Phe Cys Met Leu Gly Ala Ile Tyr 325 | 330 | 335 |
| Leu Leu Tyr Ile Ile Cys Phe Thr Met Cys Cys Ile Tyr Arg Pro Leu 340 | 345 | 350 |
| Lys Pro Arg Thr Asn Asn Arg Thr Ser Pro Arg Asp Asn Thr Leu Leu 355 | 360 | 365 |
| Gln Gln Lys Leu Leu Gln Glu Ala Tyr Met Thr Pro Lys Asp Asp Ile 370 | 375 | 380 |
| Arg Leu Val Gly Glu Leu Val Thr Val Ile Gly Ala Ile Ile Ile Leu 385 | 390 | 395 400 |
| Leu Val Glu Val Pro Asp Ile Phe Arg Met Gly Val Thr Arg Phe Phe 405 | 410 | 415 |
| Gly Gln Thr Ile Leu Gly Gly Pro Phe His Val Leu Ile Ile Thr Tyr 420 | 425 | 430 |
| Ala Phe Met Val Leu Val Thr Met Val Met Arg Leu Ile Ser Ala Ser | | |

| 435 | | | | | 440 | | | | | 445 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Glu | Val | Val | Pro | Met | Ser | Phe | Ala | Leu | Val | Leu | Gly | Trp | Cys | Asn |
| 450 | | | | | | 455 | | | | | 460 | | | | |
| Val | Met | Tyr | Phe | Ala | Arg | Gly | Phe | Gln | Met | Leu | Gly | Pro | Phe | Thr | Ile |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 |
| Met | Ile | Gln | Lys | Met | Ile | Phe | Gly | Asp | Leu | Met | Arg | Phe | Cys | Trp | Leu |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Met | Ala | Val | Val | Ile | Leu | Gly | Phe | Ala | Ser | Ala | Phe | Tyr | Ile | Ile | Phe |
| | | | 500 | | | | | 505 | | | | | 510 | | |
| Gln | Thr | Glu | Asp | Pro | Glu | Glu | Leu | Gly | His | Phe | Tyr | Asp | Tyr | Pro | Met |
| | | 515 | | | | | 520 | | | | | 525 | | | |
| Ala | Leu | Phe | Ser | Thr | Phe | Glu | Leu | Phe | Leu | Thr | Ile | Ile | Asp | Gly | Pro |
| | 530 | | | | | 535 | | | | | 540 | | | | |
| Ala | Asn | Tyr | Asn | Val | Asp | Leu | Pro | Phe | Met | Tyr | Ser | Ile | Thr | Tyr | Ala |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 |
| Ala | Phe | Ala | Ile | Ile | Ala | Thr | Leu | Leu | Met | Leu | Asn | Leu | Leu | Ile | Ala |
| | | | | 565 | | | | | 570 | | | | | 575 | |
| Met | Met | Gly | Asp | Thr | His | Trp | Arg | Val | Ala | His | Glu | Arg | Asp | Glu | Leu |
| | | | 580 | | | | | 585 | | | | | 590 | | |
| Trp | Arg | Ala | Gln | Ile | Val | Ala | Thr | Thr | Val | Met | Leu | Glu | Arg | Lys | Leu |
| | | 595 | | | | | 600 | | | | | 605 | | | |
| Pro | Arg | Cys | Leu | Trp | Pro | Arg | Ser | Gly | Ile | Cys | Gly | Arg | Glu | Tyr | Gly |
| | 610 | | | | | 615 | | | | | 620 | | | | |
| Leu | Gly | Asp | Arg | Trp | Phe | Leu | Arg | Val | Glu | Asp | Arg | Gln | Asp | Leu | Asn |
| 625 | | | | | 630 | | | | | 635 | | | | | 640 |
| Arg | Gln | Arg | Ile | Gln | Arg | Tyr | Ala | Gln | Ala | Phe | His | Thr | Arg | Gly | Ser |
| | | | | 645 | | | | | 650 | | | | | 655 | |
| Glu | Asp | Leu | Asp | Lys | Asp | Ser | Val | Glu | Lys | Leu | Glu | Leu | Gly | Cys | Pro |
| | | | 660 | | | | | 665 | | | | | 670 | | |
| Phe | Ser | Pro | His | Leu | Ser | Leu | Pro | Met | Pro | Ser | Val | Ser | Arg | Ser | Thr |
| | | 675 | | | | | 680 | | | | | 685 | | | |
| Ser | Arg | Ser | Ser | Ala | Asn | Trp | Glu | Arg | Leu | Arg | Gln | Gly | Thr | Leu | Arg |
| | 690 | | | | | 695 | | | | | 700 | | | | |
| Arg | Asp | Leu | Arg | Gly | Ile | Ile | Asn | Arg | Gly | Leu | Glu | Asp | Gly | Glu | Ser |
| 705 | | | | | 710 | | | | | 715 | | | | | 720 |
| Trp | Glu | Tyr | Gln | Ile | | | | | | | | | | | |
| | | | | 725 | | | | | | | | | | | |

<210> 9

<211> 21
<212> PRT
<213> Homo sapiens

<400> 9

Met Phe Phe Leu Ser Phe Cys Phe Tyr Phe Phe Tyr Asn Ile Thr Leu
1 5 10 15

Thr Leu Val Ser Tyr
20

<210> 10
<211> 25
<212> PRT
<213> Homo sapiens

<400> 10

Leu Leu Gly Arg Met Phe Val Leu Ile Trp Ala Met Cys Ile Ser Val
1 5 10 15

Lys Glu Gly Ile Ala Ile Phe Leu Leu
20 25

<210> 11
<211> 21
<212> PRT
<213> Homo sapiens

<400> 11

Phe Val Phe Phe Ile Gln Ala Val Leu Val Ile Leu Ser Val Phe Leu
1 5 10 15

Tyr Leu Phe Ala Tyr
20

<210> 12
<211> 19
<212> PRT
<213> Homo sapiens

<400> 12

Tyr Leu Ala Cys Leu Val Leu Ala Met Ala Leu Gly Trp Ala Asn Met
1 5 10 15

Leu Tyr Tyr

<210> 13
<211> 20
<212> PRT
<213> Homo sapiens

<400> 13

Phe Leu Phe Val Tyr Ile Ala Phe Leu Leu Gly Phe Gly Val Ala Leu
 1 5 10 15

Ala Ser Leu Ile
 20

<210> 14
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 14

Ile Leu Phe Leu Phe Leu Leu Ile Thr Tyr Val Ile Leu Thr Phe Val
 1 5 10 15

Leu Leu Leu

<210> 15.
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 15

Tyr Arg Pro Arg Glu Glu Glu Ala Ile Pro His Pro Leu Ala Leu Thr
 1 5 10 15

His Lys Met Gly Trp Leu Gln
 20

<210> 16
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 16

Arg Pro Ser Asp Leu Gln Ser Ile Leu Ser Asp Ala Trp Phe His
 1 5 10 15

<210> 17
 <211> 40
 <212> PRT
 <213> Homo sapiens

<400> 17

Thr Arg Gly Phe Gln Ser Met Gly Met Tyr Ser Val Met Ile Gln Lys
 1 5 10 15

Val Ile Leu His Asp Val Leu Lys Phe Leu Phe Val Tyr Ile Ala Phe
 20 25 30

Leu Leu Gly Phe Gly Val Ala Leu

35

40

<210> 18
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 18

Glu Lys Cys Pro Lys Asp Asn Lys Asp Cys Ser Ser Tyr Gly Ser Phe
 1 5 10 15

Ser Asp Ala Val Leu Glu Leu Phe Lys Leu Thr Ile Gly Leu Gly Asp
 20 25 30

Leu Asn Ile Gln Gln Asn Ser Lys Tyr Pro
 35 40

<210> 19
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 19
 cgcagtgcctg gaactcttca

20

<210> 20
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 20
 catcagagca atgagcatgt tga

23

<210> 21
 <211> 24
 <212> DNA
 <213> Homo sapiens

<400> 21
 gcccaggatg tcgttctctt cagc

24

<210> 22
 <211> 26
 <212> DNA
 <213> Homo sapiens

<400> 22
 gatccgcact atctccttgg tggttg

26

<210> 23
 <211> 27
 <212> DNA

<213> Homo sapiens

<400> 23

actgaatgga agacgcacgt ctccttc

27

<210> 24

<211> 20

<212> DNA

<213> Homo sapiens

<400> 24

tgacctgaac atccagcaga

20

<210> 25

<211> 21

<212> DNA

<213> Homo sapiens

<400> 25

agcatgttga ggaggagaac a

21

<210> 26

<211> 20

<212> DNA

<213> Homo sapiens

<400> 26

cggaaacctc ggtgtagaag

20

<210> 27

<211> 20

<212> DNA

<213> Homo sapiens

<400> 27

tcatccctca aagcctctct

20

<210> 28

<211> 38

<212> DNA

<213> Homo sapiens

<400> 28

gcagcagcgg ccgccacatg ttctttctgt ccttctgc

38

<210> 29

<211> 36

<212> DNA

<213> Homo sapiens

<400> 29

gcagcagtcg accctcacag cgacagtacc tgttcg

36

<210> 30

<211> 39

<212> DNA

<213> Homo sapiens

<400> 30

gcagcagcgg ccgcatgagc tttatttgca ggccacgag

39

<210> 31

<211> 37

<212> DNA

<213> Homo sapiens

<400> 31

gcagcagtcg acgttgagga ggagaacaaa ggtgagg

37

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/044210 A3

(51) International Patent Classification⁷: **C12N 15/12**,
15/62, 15/63, 1/21, 5/10, C07K 14/705, 16/28, A01K
67/027, A61K 38/17, C12Q 1/68, G01N 33/68

(21) International Application Number: PCT/US01/45336

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/250,587 1 December 2000 (01.12.2000) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; P.O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).

(72) Inventors: **GAUGHAN, Glen**; 30 Mansfield Drive #1503,
Northford, CT 06472 (US). **FEDER, John**; 277 Dutch-
town Zion Road, Belle Mead, NJ 08502 (US). **NELSON,**
Thomas; 12 Azalea Court, Lawrenceville, NJ 08648 (US).
MINTIER, Gabe; 318 Morrison Ave., Hightstown, NJ
08520 (US). **RAMANATHAN, Chandra**; 41 Alison AV-
enue, Wallingford, CT 06492 (US).

(74) Agents: **D'AMICO, Stephen** et al.; Bristol-Myers Squibb
Company, P.O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
6 November 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL HUMAN NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING A NOVEL HUMAN ION CHANNEL EXPRESSED IN SPINAL CORD AND BRAIN

(57) Abstract: The present invention relates to novel human nucleic acid molecules encoding novel human cation channels, and proteins and polypeptides encoded by such nucleic acid molecules. More specifically, the nucleic acid molecules of the invention include novel human genes, e.g., hVR1d.1 and hVR1d.2, that encode proteins or polypeptides that are expressed in spinal cord and brain tissues and display sequence homology and structural homology to the vanilloid and TRP (transient receptor potential) families of cation channel proteins. The proteins and polypeptides of the invention directed to this novel human cation channel may be therapeutically valuable targets for drug delivery in the treatment of human diseases that involve calcium, sodium, potassium or other ionic homeostatic dysfunction, such as central nervous system (CNS) disorders, e.g., degenerative neurological disorders such as Alzheimer's disease or Parkinson's disease, or other disorders such as chronic pain, anxiety and depression, stroke, cardiac disorders, e.g., arrhythmia, diabetes, hypercalcemia, hypocalcemia, hypercalciuria, hypocalciuria, or ion disorders associated with immunological disorders, gastro-intestinal (GI) tract disorders or renal or liver disease.

WO 02/044210 A3

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 01/45336

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/62 C12N15/63 C12N1/21 C12N5/10
 C07K14/705 C07K16/28 A01K67/027 A61K38/17 C12Q1/68
 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, CHEM ABS Data, EMBASE, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | WO 99 09140 A (BRAKE ANTHONY ; JULIUS DAVID J (US); UNIV CALIFORNIA (US); CATERINA) 25 February 1999 (1999-02-25) Chicken VR1 capsaicin receptor shows 48% identity with SEQ ID N°4 in 615 aa overlap; see also pages 11-15 --- | 1-25 |
| Y | WO 99 00115 A (DAVIS JOHN ; PARSONS ANDREW (GB); BENHAM CHRISTOPHER DAVID (GB); SM) 7 January 1999 (1999-01-07) claims 1-10 and pages 1-6 --- | 17-25 |
| Y | WO 99 37765 A (SMITHKLINE BEECHAM PLC) 29 July 1999 (1999-07-29) see pages 6-12 --- -/-- | 1-25 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 May 2003

Date of mailing of the international search report

02/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Vix, O

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 01/45336

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | LIEDTKE W ET AL: "Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 103, October 2000 (2000-10), pages 525-535, XP002182926 ISSN: 0092-8674 cited in the application See Fig 1-2, page 527 and experimental procedures | 1-25 |
| A | HARTENECK C ET AL: "FROM WORM TO MAN: THREE SUBFAMILIES OF TRP CHANNELS" TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 4, April 2000 (2000-04), pages 159-166, XP001012870 ISSN: 0166-2236 cited in the application the whole document | 1-25 |
| A | STERNER O ET AL: "Novel natural vanilloid receptor agonists: new therapeutic targets for drug development." TRENDS IN PHARMACOLOGICAL SCIENCES. ENGLAND NOV 1999, vol. 20, no. 11, November 1999 (1999-11), pages 459-465, XP002242584 ISSN: 0165-6147 the whole document | 17-25 |
| E | GB 2 372 993 A (SMITHKLINE BEECHAM PLC ;SMITHKLINE BEECHAM CORP (US)) 11 September 2002 (2002-09-11) The vanilloid receptor 6 protein shows 99.8% identity with SEQ ID N°2 and 4 over a 604 amino acids overlap | 1-25 |

INTERNATIONAL SEARCH REPORT

Int. application No.
PCT/US 01/45336

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 26
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 26

Present claim 26 relates to compounds defined by reference to a desirable characteristic or property, namely the modulation of the hVR1d biological activity. The claim covers all compounds having this characteristic or property, whereas the application provides disclosure for none such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

A meaningful search could not be carried out because it is not possible to determine if any of the presently known composition/substances is falling under the terms of said claim 26. Besides it is noted, that the inhibitory compounds of claim 26 are not rendered novel just because of the fact that they have been identified by the method of claim 25, e.g. such compounds can already exist. (Apart from this, it is also not possible to establish the scope of this claim without testing all known substances, clearly an undue burden).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 01/45336

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9909140 | A | 25-02-1999 | AU 742391 B2 | 03-01-2002 |
| | | | AU 9115698 A | 08-03-1999 |
| | | | EP 1009804 A1 | 21-06-2000 |
| | | | JP 2001514879 T | 18-09-2001 |
| | | | WO 9909140 A1 | 25-02-1999 |
| | | | US 6335180 B1 | 01-01-2002 |
| | | | AU 2466799 A | 09-08-1999 |
| | | | CA 2309903 A1 | 29-07-1999 |
| | | | EP 1047711 A1 | 02-11-2000 |
| | | | JP 2002503451 T | 05-02-2002 |
| | | | WO 9937675 A1 | 29-07-1999 |
| WO 9900115 | A | 07-01-1999 | WO 9900115 A1 | 07-01-1999 |
| | | | EP 1003491 A1 | 31-05-2000 |
| | | | JP 2002511866 T | 16-04-2002 |
| WO 9937765 | A | 29-07-1999 | WO 9937765 A1 | 29-07-1999 |
| | | | EP 1066381 A1 | 10-01-2001 |
| | | | JP 2002500885 T | 15-01-2002 |
| GB 2372993 | A | 11-09-2002 | US 2003027232 A1 | 06-02-2003 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)